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ABSTRACT 
Background: Although asthma treatments are extensively studied for their physiological effects 
in animal models and their safety and efficacy in humans, their effects on standard testing 
methods and their physiological benefits in asthmatics are often unknown. The result is a gap in 
knowledge on newer therapies such as long-acting muscarinic antagonists (LAMAs) and ultra-
long acting β2 agonists (uLABAs); standardization guidelines for methacholine challenge testing 
(MCT), a common research and clinical technique, remain uninformed as to an appropriate 
abstinence period from these drug classes prior to testing. In addition, the mechanisms through 
which these drugs improve airway hyperresponsiveness, an important factor in asthma, remain 
unknown. These mechanisms can be elucidated through methacholine dose-response curves, 
which illustrate airway hyperresponsiveness in terms of airway sensitivity (position), reactivity 
(slope), and maximal airway narrowing response. 
Methods: Two single dose, double blind, double dummy, randomized clinical trials were 
performed; the first crossover study examined the duration and degree of bronchoprotection 
provided by two LAMAs, tiotropium and glycopyrronium, against methacholine-induced 
bronchoconstriction in mild asthmatics; the second study had a three-way crossover design for 
investigating the effects of glycopyrronium (LAMA) and indacaterol (uLABA), alone and in 
combination, on the methacholine dose-response curve of mild asthmatics. The first study 
entailed baseline MCT, treatment administration, and repeat MCT at 1, 24, 48, 72, 96, and 168 
hours for each treatment, while the second study used a similar protocol but only followed 
participants for 48 hours. 
Results: The first study found that the two LAMAs provided clinically significant and sustained 
bronchoprotection for up to seven days, with the maximal degree of protection (16-fold increase 
in methacholine tolerance) provided at one hour post-treatment. The second study revealed that 
glycopyrronium and combination glycopyrronium/indacaterol each significantly reduced airway 
sensitivity and reactivity. The combination therapy also significantly reduced the maximal 
airway narrowing response to methacholine. Indacaterol alone only produced a mild and short-
lived reduction in airway sensitivity. 
Conclusion: LAMAs should be abstained from for at least seven days prior to undergoing MCT 
to ensure test accuracy. The LAMA glycopyrronium and the combination 
	 	 	 	iii	
glycopyrronium/indacaterol both show promising results in terms of improvements in airway 
sensitivity, reactivity, and maximal response characteristics of airway hyperresponsiveness and 
following further experimentation may become standard therapies for the treatment of poorly 
controlled asthma.  
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1.0 INTRODUCTION AND LITERATURE REVIEW 
1.1 Asthma 
1.1.1 Overview 
Asthma is a common non-communicable respiratory disease that affects approximately 
300 million people worldwide (Global Initiative for Asthma 2016). Although great 
advancements have been made in terms of pharmaceuticals for treating asthma, these 
medications only suppress and do not cure this chronic inflammatory condition (Holgate 2008). 
Asthma is a complex disease to study, as it has a wide range of causes, symptoms, 
severities, and triggers. While environmental and genetic factors have been identified as 
contributing factors, much of the pathophysiology behind this condition still requires further 
elucidation (Akdis & Agache 2013). Asthma can be exhibited by a number of symptoms (e.g. 
difficulty breathing, coughing, wheezing), which develop in response to triggers such as smoke, 
exercise, animals, and pollens (Global Initiative for Asthma 2016). A further complication is the 
existence of subpopulations of asthmatics who exhibit different physiological changes in 
response to their symptom triggers; atopic (i.e. extrinsic) patients experience allergen-induced 
asthma and their airway inflammation is produced by eosinophils, T-helper-2 (Th2)-type cells 
and immunoglobulin E (IgE) antibodies (Amin et al. 2000); the mechanisms underlying non-
atopic (i.e. intrinsic) asthma remain largely unknown, however inflammation in such patients is 
produced predominantly by neutrophils (Amin et al. 2000). For the remainder of this thesis, 
information will be presented on the general asthma population and will not be divided into these 
subpopulations. 
Asthma differs from another common respiratory condition, chronic obstructive 
pulmonary disease (COPD), in that airflow obstruction in asthmatics is typically reversible either 
spontaneously or with therapeutic intervention (Global Initiative for Asthma 2016). However, 
this may not always be the case, particularly in more severe patients (Boulet 2009). A further 
complication when diagnosing patients and choosing an appropriate therapy is the possibility of 
overlap between multiple respiratory conditions, such as between asthma and COPD (Gibson & 
Simpson 2009). Misdiagnosis could lengthen the time required to establish control over 
symptoms and improve patient quality of life and outcome. 
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1.1.2 Pathophysiology 
Asthma is a heterogeneous condition that is characterized by several related phenotypes 
including airway hyperresponsiveness (AHR), airway inflammation, airway remodeling, and 
airflow obstruction. AHR refers to the quick and excessive bronchoconstriction experienced in 
response to stimuli that would not normally cause airway smooth muscle (ASM) contraction. 
Some of the physiological causes of AHR are receptor and/or ion channel dysfunction [e.g. 
elevated muscarinic type-3 (M3) and muscarinic type-1 (M1) receptor expression, muscarinic 
type-2 (M2) receptor dysfunction], abnormal neurotransmitter activity (e.g. increased neuronal 
acetylcholine levels), and altered action potential propagation (Sterk & Bel 1989; Novelli et al. 
2013). Inflammation, remodeling and obstruction of the airways can also influence AHR (Sterk 
& Bel 1989).  
Studies have revealed a wide range of abnormalities in the activity and prevalence of 
inflammatory cells and mediators in diseased airways. Mast cells, macrophages, eosinophils, T-
lymphocytes and neutrophils are among the identified inflammatory cells that influence the 
release of mediators such as leukotrienes and cytokines, all of which produce airway 
inflammation, asthma symptoms (e.g. coughing), airway remodeling, and AHR (Akdis & 
Agache 2013). For example, inflammatory mediators contribute to airway remodeling through 
epithelium shedding, which results in the loss of the barrier important for preventing the 
penetration of bronchoconstrictors through the airway wall (Naylor 1962; Barnes et al. 1985). 
Degradation of the epithelium also likely impedes the regulation of inflammatory mediator 
levels, as protective enzymes such as neutral endopeptidases are not being produced (Barnes 
1996). Inflammatory mediators may also abnormally modulate neurotransmitters such as 
acetylcholine, leading to increased bronchoconstriction and mucus production (Barnes 1996). 
Much remains to be determined with regards to the extent of airway remodeling in 
asthma but it is nonetheless an important factor to consider. It has been shown that airway wall 
remodeling progressively increases with age and/or duration of asthma compared to healthy 
controls through increases in ASM cell volume and number, and decreases in airway lumen 
(Ebina et al. 1993; Bai et al. 2000); these factors together can decrease airway distensibility (i.e. 
impede bronchodilation) and lead to irreversible airflow obstruction. Enhanced airway 
constriction in asthmatics also likely results from increased levels of myosin light-chain kinase 
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(Ammit et al. 2000) and the degradation of the extracellular matrix in ASM (which prevents the 
proper regulation of muscle shortening) (Bramley et al. 1995).  
Despite its higher prevalence and greater severity in COPD patients, mucus 
hypersecretion also poses a problem in asthma. When produced in normal amounts, mucus is 
important for protecting the airway epithelium from harmful inhaled particles (Gosens et al. 
2006). In diseased airways, acetylcholine release is increased and results in overstimulation of 
M3 receptors and, to a lesser extent, M1 receptors (Gosens et al. 2006). This triggers excessive 
mucus production by submucosal glands and goblet cells, which is further augmented by 
synergistic interactions between muscarinic receptors and epidermal growth factor (Gosens et al. 
2006). Inflammatory mediators can contribute to mucus production by enhancing the 
differentiation of cells into goblet cells, thereby increasing the number of mucus-producing cells 
in the airways (Holgate 2008). In addition, these mediators can cause microvascular leakage, 
which leads to an increase in airway secretions, impaired mucociliary clearance, and mucosal 
edema (Holgate 2008). Not only is mucus produced in higher quantities, but its composition is 
also altered; mucin and other components of mucous are secreted at abnormal concentrations, 
yielding more viscous mucus that is not easily cleared from the airways (Alagha et al. 2014).  
1.1.3 Asthma Pharmacotherapy 
The treatment of asthma can be a complicated endeavor due to the wide range of 
respiratory drug classes available and asthma phenotypes expressed. Treatment guidelines for 
physicians follow a step-up format for exploring different medications until that most effective 
for a given patient is found (Global Initiative for Asthma 2016). The first step is short-acting β2 
agonist (SABA; e.g. salbutamol) rescue therapy as needed, which takes effect quickly to treat 
sporadic episodes of airflow obstruction (BouyssouCasarosaet al. 2010). β2 agonists activate β2 
receptors in the airways, which trigger the production of cyclic adenosine monophosphate 
(cAMP) from intracellular adenylyl cyclase; cAMP is key for inducing ASM relaxation and 
bronchodilation (Gibb & Yang 2013).   
If poor symptom control persists, the next treatment step involves inhaled corticosteroids 
(ICS; e.g. budesonide, fluticasone propionate) as controller medication. ICS are well established 
for their improvement of asthma symptom severity and frequency, thereby improving patient 
quality of life with minimal adverse effects and a high safety margin (Pedersen & O’Byrne 
1997). ICS promote the production of anti-inflammatory proteins (e.g. neutral endopeptidases) 
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while suppressing the production of pro-inflammatory proteins (e.g. cytokines) (Pedersen & 
O’Byrne 1997).  
If ICS therapy does not work or is not an option in a particular case, a leukotriene 
receptor antagonist (LTRA; e.g. montelukast) may be prescribed. LTRAs possess some anti-
inflammatory properties that are complementary to that of ICS, as glucocorticoids do not 
attenuate inflammation produced by cysteinyl leukotrienes (CysLTs; e.g. LTC4, LTD4) 
(Lipworth 1999). LTRAs are primarily beneficial for their inhibition of LTC4-induced ASM 
contraction (Lipworth 1999). LTRAs are therefore controller medications with both 
bronchodilator and anti-inflammatory properties.  
Methylxanthines (e.g. theophylline) are another option in place of ICS. This drug class 
provides bronchodilation through the inhibition of phosphodiesterase-4 (PDE-4). Inhibition of 
this enzyme prevents the breakdown of cAMP and subsequently contributes to ASM relaxation. 
PDE-4 inhibition also reduces mucin production and inflammation by reducing the activation of 
monocytes, T cells and neutrophils (Shukla et al. 2009). 
When treatment beyond ICS (or LTRA or methylxanthine) monotherapy is required, 
long-acting β2 agonists (LABAs; e.g. formoterol, salmeterol) are the most common add-on 
therapy. LABAs have similar mechanisms of action to SABAs but they produce significantly 
longer bronchodilation (BouyssouCasarosaet al. 2010; Global Initiative for Asthma 2016); 
LABAs are more potent and have a longer side chain than the short-acting formulations, the 
latter of which allows the anchoring of drug particles near β2 receptors in the airways (Löfdahl & 
Chung 1991). Beyond their bronchodilator activity, LABAs have been suggested to have some 
anti-inflammatory mechanisms, given that β2 receptors are also on inflammatory cells such as 
mast cells where they inhibit the release of histamine, LTC4/LTD4, and PGD2 (Butchers et al. 
1991). A number of safety concerns have been raised regarding the long-term use of LABA 
monotherapy, as patients have been found to develop drug tolerance and experience more severe 
asthma exacerbations, which can prove fatal (Grove & Lipworth 1995; Wijesinghe et al. 2008). 
Attention shifted to the development of once-daily long-acting anti-asthma medications such as 
ultra long-acting β2 agonists (uLABAs), with goals of minimizing side effects and increasing the 
likelihood of patient compliance (i.e. less frequent drug administration) (Matera & Cazzola 
2007). 
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Despite their common use for treating COPD, inhaled long-acting muscarinic antagonists 
(LAMAs; e.g. tiotropium, glycopyrronium) have only recently become incorporated into asthma 
treatment regimens as add-on therapy in cases uncontrolled by ICS or ICS/LABA. At present, 
the only LAMA approved for this use is tiotropium (Peters et al. 2010; Kerstjens et al. 2011; 
Global Initiative for Asthma 2016). LAMAs inhibit cholinergic-induced ASM contraction and 
mucus production by submucosal glands and goblet cells through the blockage of M1 and M3 
receptor activity (Kistemaker et al. 2012; Alagha et al. 2014). LAMAs also exhibit some anti-
inflammatory properties such as the inhibition of acetylcholine-induced chemotactic activity by 
eosinophils, neutrophils, monocytes and macrophages (Kistemaker et al. 2012). Finally, this drug 
class has some anti-remodeling effects, as it reduces ASM cell proliferation, which prevents the 
thickening of ASM (Kistemaker et al. 2012). 
The formulations at the highest step in the treatment guidelines for poorly controlled 
asthma are monoclonal antibodies (e.g. omalizumab, mepolizumab). Various molecules have 
undergone or are undergoing clinical trials, but only three have been approved. One is 
omalizumab, an anti-IgE molecule that inhibits the function of IgE effector cells and prevents the 
activation of the IgE allergic response (i.e. inhibits mast cell and basophil responses) (D’Amato 
et al. 2014). The other approved monoclonal antibodies are mepolizumab and reslizumab, anti-
IL5 molecules that inhibit eosinophil recruitment (Fala 2016).  
Given the heterogeneity of asthma, it is not surprising that several drug classes are 
established for the treatment of this condition. However, the wide availability of so many 
formulations can make it more time-consuming when trying to determine the most effective 
treatment for a given patient. 
1.2 Bronchoprovocation Testing 
A number of testing methods have been developed in an effort to improve accuracy in 
diagnosing or ruling out asthma. These tests are also valuable in research for investigating the 
physiological effects of asthma and of respiratory medications. Direct and indirect 
bronchoprovocation tests each provide benefits and disadvantages. Direct testing refers to the use 
of pharmacological agents (e.g. methacholine, histamine) to “directly” act on receptors in the 
airways to measure airway responses. These tests are more sensitive and so they are most useful 
for ruling out clinically current asthma when the result is negative. On the other hand, indirect 
testing uses stimuli (e.g. exercise, mannitol, hypertonic saline, adenosine monophosphate) to 
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trigger airway narrowing through an “indirect” route, such as via the stimulation of mediator 
release from inflammatory cells. Indirect challenges are more specific and are therefore more 
beneficial for confirming a diagnosis of asthma; however, these tests are also relatively 
insensitive and could therefore produce false negative results in mild or well-controlled 
asthmatics. Direct challenges are relatively safe and quick to perform for investigating new 
therapeutic options while indirect challenges are more appropriate when examining airway 
inflammation (Joos et al. 2003). Both are nonetheless useful for investigating therapeutic 
options. Our study employs the methacholine challenge, which is the most common method used 
for direct bronchoprovocation testing. 
1.2.1 Overview of Methacholine Challenge Testing 
Methacholine challenge testing (MCT) is used to measure direct AHR and to rule out an 
asthma diagnosis. Methacholine is a non-selective muscarinic receptor agonist that mimics the 
effects of acetylcholine on ASM by directly inducing bronchoconstriction when it binds the M1 
and M3 receptors (Cockcroft 2007). A number of protocols for performing MCT have been 
developed over the years; two protocols are commonly used today, the two-minute tidal 
breathing protocol (Cockcroft et al. 1977) and the five-breath dosimeter protocol (modified from 
Chai et al. 1975). A previous study has shown that the latter procedure affects the results through 
deep inhalation-induced bronchoprotection (Cockcroft et al. 2005); the former procedure is used 
in our laboratory.  
The two-minute tidal breathing protocol involves five-minute cycles composed of two 
minutes of inhalation of a concentration of methacholine followed by spirometry at 30 and 90 
seconds post-inhalation. The next inhalation is commenced five minutes after the start of the 
previous inhalation. The cycles are performed with doubling concentrations of methacholine 
with the goal of determining the methacholine PC20 [the provocative concentration of 
methacholine that causes a 20% or greater fall in the forced expiratory volume in one second 
(FEV1)].  
MCT alone is not used to diagnose asthma, as it has greater sensitivity than specificity 
and it represents only one factor of asthma, AHR (Crapo et al. 2000). The sensitivity and 
negative predictive value of MCT (i.e. ability to exclude current asthma) are near 100% in 
patients whose methacholine PC20 is greater than 8-16mg/mL (Cockcroft 2010). However, the 
specificity and positive predictive value of MCT are close to 100% only when a patient’s 
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methacholine PC20 is ≤1mg/mL (Cockcroft 2010). Based on this knowledge, it has been 
established that a methacholine PC20 greater than 16mg/mL is sufficient to exclude a diagnosis of 
current asthma with reasonable certainty (Cockcroft 2010). However, MCT alone is insufficient 
to confirm a case of current asthma unless the methacholine PC20 is ≤1mg/mL, in which case the 
test specificity and positive predictive value are almost 100% (Cockcroft 2010). 
In order to preserve the accuracy of MCT results and to ensure patient safety, the 
American Thoracic Society (ATS) published a set of guidelines to standardize the testing 
procedure and to account for potential confounding factors (Crapo et al. 2000). Different 
medications have been found to influence the test results for varying durations and so, abstinence 
periods from drug classes are recommended. However, not all new medications have been 
examined for their duration of bronchoprotection against methacholine. As a result, some of the 
recommended withdrawal periods may be inaccurate or not indicated at all. In order to ensure 
adequate washout from different medications, studies must examine their duration of effect in 
human models. 
1.2.2 Characteristics of the Methacholine Dose-Response Curve 		
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Figure 1.1. Simulated methacholine dose-response curves illustrating different levels of airway 
responsiveness. 
Although studies typically report MCT results in terms of the PC20, this parameter only 
describes airway sensitivity to methacholine. A less routinely used analytical tool is the 
methacholine dose-response curve (MDRC) of the percent fall in FEV1 per methacholine 
concentration (mg/mL). The MDRC illustrates AHR in terms of airway sensitivity (i.e. 
horizontal position of curve), airway reactivity (i.e. slope of the curve), and maximal airway 
responsiveness (i.e. uppermost vertical placement of the curve). MDRCs can be particularly 
useful during drug development, as they quantify drug-induced changes in airway sensitivity, 
reactivity, and maximal responsiveness. In addition, the investigation of long-term use of a 
respiratory medication through MDRCs allows researchers to observe potentially harmful effects 
that may develop from chronic treatment (e.g. a steeper slope indicates worsening asthma 
exacerbations) (BelZwindermanet al. 1991; Bhagat et al. 1996; Wong et al. 1997).  
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1.2.2.1 Asthmatic Methacholine Dose-Response Curves 
Compared to healthy controls, the MDRC of asthmatics is typically shifted to the left (i.e. 
increased airway sensitivity), has a steeper slope (i.e. increased airway reactivity), and a raised 
plateau or the complete loss of a measurable plateau (i.e. increased maximal constricting 
response) (Sterk & Bel 1989). The mechanisms underlying each of the three characteristic 
features of the MDRC differ with some overlap, hence how a drug can specifically influence 
only one portion of the curve.  
The factors underlying the leftward, or horizontal, shift in the MDRC have been termed 
“prejunctional” mechanisms and consist of anything that enhances the effect of airway narrowing 
stimuli (Sterk & Bel 1989). These include: epithelial damage or malfunction (i.e. greater 
accessibility of stimuli to their receptor sites), abnormal autonomic neural control (i.e. increased 
cholinergic reflex activity), increased inflammatory cell number and activity (e.g. enhanced 
spontaneous mediator release from leukocytes, mast cells, and eosinophils), dysfunctional 
metabolism and/or absorption of inflammatory mediators and neurotransmitters (i.e. persistent 
inflammation and/or bronchoconstriction), and interactions between inflammatory cells, 
mediators, neural control and ASM (i.e. additive effects) (Sterk & Bel 1989).  
“Postjunctional” mechanisms influence the maximal response/plateau of the MDRC and 
refer to anything that causes an increased response by the effector organ (Sterk & Bel 1989). 
Such mechanisms include: increased ASM contractility [from a disruption in receptor regulation, 
propagation of excitation, calcium handling, or increased ASM mass (hypertrophy or 
hyperplasia)], disruptions in viscous and elastic loads (which depends on the balance and 
interdependence of structural elements within the airway wall and lung parenchyma), swelling of 
the airway wall, and excessive intraluminal exudate and secretions (Sterk & Bel 1989). 
The third characteristic of the MDRC is the slope. The steepening of the MDRC slope 
reflects a quicker increase in airflow obstruction following exposure to a constricting stimulus 
(i.e. a more severe exacerbation) (BelZwindermanet al. 1991). The specific physiological 
changes affecting airway reactivity remain unclear. 
With this knowledge of the factors influencing the position and maximal response of the 
MDRC, it is possible to gain a better understanding of the effect of anti-asthma drugs on the 
airways of human models. The MDRC could also potentially serve as a tool for determining the 
best treatment for a patient. 
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1.2.2.2 Non-Asthmatic Methacholine Dose-Response Curves 
The MDRC of non-asthmatics is expected to lie to the right outside the range of a 
positive methacholine challenge (i.e. PC20 >16mg/mL) (Crapo et al. 2000). It is anticipated that 
the curve slope is more flat and that airway narrowing is attenuated at a low percent fall in FEV1 
by forming a response plateau to methacholine (Woolcock et al. 1984). The overall MDRC is 
therefore expected to have a sigmoid shape.  However, given that as high as 14.3% of the 
asymptomatic non-asthmatic population may have AHR (i.e. PC20 ≤16mg/mL), the MDRC of 
this population may not be as uniform as previously described (Jansen et al. 1997).  
1.3 Bronchodilator Mechanisms of Action  
1.3.1 Long-Acting Muscarinic Antagonists 
As previously mentioned, LAMAs inhibit M1 and M3 receptors on ASM, which prevents 
cholinergic-induced effects. M1 receptor blockage also inhibits parasympathetic 
neurotransmission in the ganglia and reduces mucus secretion by preventing electrolyte and 
water secretion by epithelial cells (Alagha et al. 2014). M3 receptor antagonism in turn prevents 
mucus secretion from submucosal glands and inhibits ASM contraction. Unlike their short-acting 
counterparts (SAMAs; e.g. ipratropium) that are regularly prescribed for COPD, LAMAs possess 
receptor selectivity; LAMAs selectively inhibit M1 and M3 receptors while rapidly dissociating 
from M2 receptors.  This selectivity is important, as M2 receptor expression contributes to 
bronchodilation through its negative feedback mechanism in preganglionic nerves and 
parasympathetic nerve terminals where it inhibits the excessive release of acetylcholine (Novelli 
et al. 2013; Alagha et al. 2014). LAMAs also have higher binding affinity and slower 
dissociation from M1 and M3 receptors than do SAMAs, which explains the significantly longer 
duration of effect. 
Tiotropium and glycopyrronium are two potent antimuscarinic quaternary ammonia 
LAMAs that are commonly used as once-daily medications for COPD. The quaternary nitrogen 
in the LAMA structure largely minimizes side effects by preventing the systemic absorption of 
drug particles and the crossing of the blood-brain barrier (Hansel et al. 2005). Unlike tiotropium, 
glycopyrronium does not show kinetic selectivity for binding M3 rather than M2 receptors 
(Lipworth 2014). However, it still shows higher affinity for the M1 and M3 receptor-types than 
M2 receptors. Higher doses of glycopyrronium (50 and 100µg) have shown equivalency to 
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tiotropium (18µg) in terms of degree and duration of bronchodilation in COPD patients with the 
exception that glycopyrronium has a more rapid onset (five minutes post-dose as opposed to 0.5-
1 hour post-dose) (Verkindre et al. 2010). 
Studies investigating the effects of LAMAs in human models have primarily examined 
this drug class for its bronchodilator properties and its ability to reduce the frequency and 
severity of asthma exacerbations (Kerwin et al. 2012). However, physiological investigations in 
humans are relatively rare and experimentation with human tissue is also lacking but crucial. A 
study examining cells obtained through endobronchial biopsies in patients with lung fibrosis 
found that tiotropium prevented airway remodeling by inhibiting acetylcholine-induced 
proliferation of fibroblasts (Pieper et al. 2007). If left unmitigated, fibroblasts contribute to ASM 
cell hyperplasia and alter the normal function of extracellular matrix proteins (Holgate 2008).  
Physiological studies are mainly limited to animal models and not all LAMAs have been 
studied to a great extent in this fashion. When the effects of tiotropium were investigated in 
murine models of asthma challenged with ovalbumin, the acute model did not appear to derive 
any benefit; however, the chronic model showed several improvements in airway remodeling 
following treatment with tiotropium compared to untreated, ovalbumin-challenged mice 
including reduced peribronchial fibrosis, decreased ASM thickness, reduced M3 receptor activity 
and increased M2 activity (Kang et al. 2012). Previous studies in guinea pig models of allergic 
asthma have found that tiotropium partially or completely inhibits increased ASM mass (i.e. 
hyperplasia), contractility, and contractile protein expression, all of which are involved in 
increased acetylcholine-induced ASM remodeling (Gosens et al. 2005; Bos et al. 2007). In 
addition, these studies showed that this LAMA reduces mucus gland hypertrophy and airway 
eosinophilia (Gosens et al. 2005; Bos et al. 2007). A study in mouse models of asthma found 
similar results; tiotropium inhibited the production of eosinophils and Th2-type cytokines [e.g. 
interleukin (IL)-4, IL-5, and IL-13], prevented acute and chronic inflammation, and inhibited the 
thickening of ASM (Ohta et al. 2010). LAMAs have yet to be studied in human participants 
through traditional research techniques such as MCT and allergen challenge testing. 
Glycopyrronium has also been shown to have several anti-inflammatory properties in 
studies with animal models. For example, pre-treatment with glycopyrronium has prevented the 
accumulation of inflammatory mediators [e.g. IL-1β, tumor necrosis factor-α (TNFα)] in the 
bronchoalveolar lavage fluid of mice that had been exposed to cigarette smoke (Shen et al. 
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2014). Shen et al also found that glycopyrronium prevents some airway remodeling by inhibiting 
the cigarette smoke-induced production of matrix metalloproteinase-9, a major enzyme involved 
in the degradation of the extracellular matrix (Shen et al. 2014).  
These findings together suggest that LAMAs have the potential to benefit asthmatics in 
several ways, from reducing airway inflammation and remodeling to preventing 
bronchoconstriction. 
1.3.2 Ultra-Long Acting β2 Agonists 
Physiological data on once-daily ultra long-acting β2 agonists (uLABAs; e.g. indacaterol, 
olodaterol) in humans remain limited, as these add-on medications are relatively new for the 
treatment of COPD and are currently being investigating for use in asthmatics. These longer-
acting β2 agonists were designed to provide the optimal bronchodilation characteristic of this 
drug class with a good safety profile in a once-daily formulation to improve patient adherence. 
Bronchodilation via β2 receptors seems to be produced through multiple mechanisms: increased 
cAMP and PKA levels triggering ASM relaxation through hyperpolarization of ASM cells, 
inhibition of myosin light-chain kinase, inactivation of contractile enzymes through mitogen-
activated protein kinase phosphatase-1 mechanisms, and phosphorylation of inositol 1,4,5-
triphosphate (IP3) resulting in a reduction in intracellular calcium release from the endoplasmic 
reticulum of ASM cells (Giembycz & Newton 2006). Proposed mechanisms behind the long 
duration of action of uLABAs include: the presence of a long lipophilic side chain that anchors 
the drug near or within the β2 receptor, strong binding of the receptor, low plasma clearance, or 
the lipid solubility of the drug allows its deposition and/or storage in the membrane of the target 
tissue (Beasley & Pearce 1993; Trifilieff et al. 2014). 
ULABAs possess strong selectivity and affinity for only the β2 receptor subtype, which 
results in fewer systemic side effects such as tachycardia (BouyssouCasarosaet al. 2010). These 
formulations also exhibit high intrinsic efficacy, which explains the rapid onset of action and 
behaviour as nearly full β2-agonists (Trifilieff et al. 2014). These are highly desirable 
characteristics for full β2 agonists, as they result in less cross-tolerance to SABA rescue 
medications - partial agonists can behave like antagonists if another agonist of higher efficacy for 
the same receptor is used (Beeh et al. 2007; Trifilieff et al. 2014).  
Human studies on uLABA effects have mainly focused on time of onset and degree of 
bronchodilation in COPD patients. Physiological investigations in animal models are also 
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limited; experiments with mouse and guinea pig models of cigarette smoke-induced airway 
inflammation have shown that treatment with olodaterol significantly reduces TNFα levels and 
inhibits enzymes important for neutrophil function and for remodeling of the extracellular matrix 
of ASM (Wex et al. 2015). Following confirmation of the presence of β2 receptors on human 
lung fibroblasts, a study demonstrated that olodaterol inhibited fibroblast proliferation and 
collagen synthesis, both of which are common airway remodeling factors in asthma (Lamyel et 
al. 2011).  
Although some animal studies have suggested that uLABAs possess capabilities beyond 
bronchodilation, more investigations on this new drug type must be completed to clarify its 
functions in humans. 
1.3.3 Combination LAMA/uLABA  
Like the previously described monotherapies, combination LAMA/uLABA formulations 
have shown promising but limited results in asthmatic animal models. Although LAMAs and 
uLABAs act on different receptors, they both utilize the same pool of G proteins, leading to 
receptor crosstalk (Costa et al. 2014). Studies in animal models have shown this relationship 
clearly; mice deficient in an enzyme important for the cAMP pathway normally triggered by β2 
agonists were found to no longer respond to cholinergic stimulation (Hansen et al. 2000); another 
study found that M3 receptor stimulation in hamster ovary eggs transfected with M3 and β2 
receptors resulted in β2 receptor phosphorylation and subsequent desensitization (Budd et al. 
1999). 
The finding that M2 receptors predominate in fibroblasts where they likely inhibit cAMP 
production (even more so in asthmatic fibroblasts) also points to crosstalk, as treatment with 
tiotropium restored cAMP, the main secondary messenger triggered by β2 receptors, to normal 
levels (Costa et al. 2014). This reflects that temporary inhibition of M2 receptors by a LAMA 
augments β2 agonist activity. Given that M2 receptors trigger inhibitory G proteins while β2 
receptors influence stimulatory G proteins, these receptors clearly have a counteracting 
component (Proskocil & Fryer 2005). As a result, the combination of muscarinic antagonist and 
β2 agonist could potentiate bronchodilation, as inhibition of M2 receptors removes this receptor’s 
inhibitory effect on β2 receptors.  
A study that investigated the combined effect of SABA and SAMA 
(salbutamol/ipratropium) in asthmatics revealed that this combination produced positive albeit 
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modest improvements in pulmonary function, a reduction in risk of future exacerbations, and 
fewer hospital admissions compared to either drug alone (Lanes et al. 1998). This suggests 
strong clinical relevance for the use of muscarinic antagonists and β2 agonists in combination. In 
animal models, glycopyrronium and indacaterol together produced synergistic bronchoprotection 
against cholinergic-induced airway narrowing in guinea pig tracheal preparations (Kume et al. 
2012). In guinea pig models of acute allergic asthma, tiotropium was found to synergistically 
enhance the protective effects of olodaterol against allergen-induced AHR by significantly 
reducing the early and late asthmatic response, and allergen-induced airway inflammation (Smit 
et al. 2014). This suggests that endogenous acetylcholine release considerably attenuates β2 
agonist responsiveness and further suggests that there is crosstalk between the two receptor 
types. Furthermore, in both precision-cut lung splices and beagle dog models that had 
acetylcholine-induced bronchoconstriction, combination LAMA/uLABA therapy provided 
significantly more bronchoprotection against carbachol and acetylcholine, respectively, than 
either drug as monotherapy (BouyssouSchnappet al. 2010; Schlepütz et al. 2013). In medium and 
small human isolated bronchi, glycopyrronium and indacaterol in combination synergistically 
inhibited cholinergic contractility, additively inhibited histamine contractility, reduced 
acetylcholine release from the airway epithelium, and increased cAMP in the bronchi and 
epithelial cells (Cazzola et al. 2016). 
Synergism between muscarinic antagonists and β2 agonists has been shown in clinical 
trials investigating combination LAMA/LABAs in COPD patients. Three studies documented 
synergistic improvements in maximal bronchodilation, pulmonary function during day- and 
night-time, and frequency of rescue therapy use following tiotropium/formoterol or 
tiotropium/salmeterol combination therapy in comparison with the respective monotherapies 
(van Noord et al. 2005, 2010; Di Marco et al. 2006). These findings together suggest that 
LAMA/uLABA combination therapy should produce several synergistic benefits, particularly as 
uLABA mechanisms may be disinhibited by muscarinic receptor blockage. 
1.4 Influence of Different Respiratory Drug Classes on Methacholine Challenge and Dose-
Response Curve Results 
1.4.1 Inhaled Corticosteroids 
The ATS guidelines for MCT recommend not withholding ICS therapy prior to testing, 
but studies have shown a significant shift in PC20 over time when these drugs are taken regularly. 
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Over a 12-week period of treatment with budesonide (800µg twice-daily), 14 atopic asthmatics 
showed a mean increase in PC20 of 1.4 doubling doses (Booms et al. 1997). A similar dose shift 
between one and two doubling doses was found in 51 asthmatics after 12 weeks of therapy with 
both 400µg twice-daily and 800µg twice-daily budesonide (Riccioni et al. 2003). Another 
investigation compared the dose shift in PC20 following four weeks of treatment with fluticasone 
at 250µg or 1000µg per day in 64 asthmatics and found that the mean dose shift was between one 
and two doubling concentrations (no dose-dependency) (Sumino et al. 2014). A longer term 
study followed asthmatic participants (n=16) for 12 months during which time they received 
budesonide therapy (200µg twice daily); after 3 months, participants showed a mean two-fold 
doubling dose shift in methacholine PC20, which increased to a four-fold shift by 12 months 
(Juniper et al. 1990).  
In order to better understand the effects of ICS on the airways, these drugs have been 
repeatedly studied for their influence on the MDRC. As monotherapy, they have been 
documented in several studies to produce a rightward shift and often a lower plateau 
(BelTimmerset al. 1991; Overbeek et al. 1996; Booms et al. 1997; Oga et al. 2001). Fluticasone 
propionate was shown to be very effective for decreasing the MDRC plateau in asthmatics after 
6 weeks of treatment, an effect that was shown to persist after 12 weeks (Overbeek et al. 1996). 
The researchers also found a significant increase in methacholine PC20, resulting in a rightward 
shift in the curve and a slight improvement in reactivity. Based on previous findings with regards 
to the function of ICS, the researchers suggested that this improvement in plateau resulted from a 
reduction in airway wall thickness in response to anti-inflammatory functions preventing 
mucosal swelling and/or plasma exudation. Similar findings were reported with beclomethasone 
dipropionate and it was disclosed that the impact of ICS therapy on airway sensitivity was more 
pronounced than on maximal responsiveness (Oga et al. 2001). 
Previous studies specifically examined the effect of budesonide on reversing unlimited 
airway narrowing through the induction of a plateau on the MDRC. Out of 14 participants who 
did not previously show a plateau on their MDRC, nine (64%) produced a plateau after 12 weeks 
of treatment with ICS (Booms et al. 1997); a slight but insignificant decrease in MDRC slope 
was also reported. Another study took the opposite approach and enrolled 16 mild asthmatics 
with a measurable plateau prior to treatment; it was found that budesonide therapy still 
significantly reduced the maximal response to methacholine (BelTimmerset al. 1991). Both 
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publications suggested that budesonide reduces mucosal thickness and intraluminal exudate, 
which allows for the restoration of interdependence between the airway wall and parenchyma.  
MDRCs have been proven useful for gauging which patients can tolerate a reduction in 
their ICS dosage without losing control of their asthma symptoms. One study found that 96% 
(23/24) of participants who initially showed a plateau on their MDRC did not deteriorate in 
asthma control following a 75% reduction in their ICS dosage (Prieto et al. 1999). In 
comparison, only 55% (12/22) of participants who did not have a baseline measurable plateau 
did not deteriorate. Overall, this suggests that the presence of a measurable plateau on the 
MDRC can be used as an objective indicator for safely reducing ICS dose. The study also 
indicated that the introduction of a plateau on the MDRC with continued ICS treatment is not 
necessary for achieving satisfactory control of asthma symptoms. Asthma symptomology must 
therefore stem from more than simply the loss of protective mechanisms against excessive 
airway narrowing. 
1.4.2 Leukotriene Receptor Antagonists. 
Although the ATS recommends abstaining from LTRAs for at least 24 hours before 
undergoing MCT (Crapo et al. 2000), this may in fact be longer than necessary. In a placebo-
controlled study, 10mg montelukast was found not to significantly change responsiveness to 
methacholine at 1 or 25 hours post-treatment (Davis & Cockcroft 2005). When taken daily for 12 
weeks, this same treatment and dose was found to produce only a dose shift of one doubling 
concentration of methacholine (Riccioni et al. 2003). When montelukast was examined for its 
effect on the MDRC of asthmatics, the results were also of low significance; montelukast was 
first investigated as monotherapy for its potential benefits in reducing the maximal airway 
response to methacholine, which revealed no significant improvement in AHR (Ulrik & Diamant 
2009). The researchers next examined the effect of combination ICS plus montelukast therapy on 
the MDRC and found that the LTRA only produced a modest improvement in the maximal 
response plateau and sensitivity compared to ICS alone (Ulrik & Diamant 2010). It should be 
noted that LTRAs are similar to ICS in that these medications must be taken regularly for a 
number of weeks before reaching optimal anti-inflammatory effectiveness (Lipworth 1999). 
Neither drug type is designed for sporadic use in treating acute symptoms. 
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1.4.3 Methylxanthines 
Given its anti-inflammatory and bronchodilator mechanisms, researchers examined the 
methylxanthine theophylline for its effect on methacholine-induced AHR. Following two months 
of treatment with theophylline (dose range of 250-375mg twice-daily), 28 asthmatics showed 
significant reductions in both airway sensitivity (dose shift of approximately one doubling 
concentration of methacholine compared to parallel placebo arm) and reactivity to methacholine 
(Page et al. 1998). The researchers confirmed that these albeit small effects were not simply the 
result of the drug’s bronchodilator effect, as no significant change in baseline FEV1 was 
observed. While this study demonstrated the modest effects of theophylline in comparison with 
ICS therapy, it also revealed that this drug, unlike β2 agonists, did not worsen airway reactivity 
with long-term use. 
1.4.4 Muscarinic Antagonists 
The ATS guidelines suggest that LAMAs like glycopyrronium only provide significant 
bronchoprotection for up to 48 hours, perhaps one week in the case of tiotropium (Crapo et al. 
2000). However, there are no references to corroborate these suggestions. The guidelines have 
been found to be inaccurate in the past with regards to muscarinic antagonists; although it is 
recommended that ipratropium be abstained from for a minimum of 24 hours, its protective 
effects have been found to subside within 12 hours at the standard dose of 40µg (Illamperuma et 
al. 2009). 
Previous studies have shown that tiotropium and glycopyrronium each provide significant 
bronchoprotection against methacholine-induced bronchoconstriction, but no study has examined 
their complete duration of effect. Tiotropium bromide has been found to provide dose-dependent 
bronchoprotection for at least 48 hours in 12 patients (O’Connor et al. 1996). The doses of 10, 40 
and 80µg tiotropium produced methacholine dose shifts of 5, 7.1 and 7.9 doubling concentrations 
at 2 hours, respectively, and of 2.2, 2.2, and 3.9 doubling concentrations at 48 hours, 
respectively. Four participants from this study also completed MCT at 72 hours post-tiotropium 
and all showed significant persistent bronchoprotection. Glycopyrronium has only been followed 
for 30 hours after treatment administration; in ten mild-to-moderate asthmatics, three doses of 
glycopyrronium (0.5, 1.0 and 2.0 mg) each produced significant, sustained, dose-independent 
bronchoprotection against methacholine for at least 30 hours (Hansel et al. 2005). At 2 hours, 
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each dose produced a shift in methacholine PC20 of approximately five doubling concentrations 
and by 30 hours, each dose produced a shift of at least two doubling concentrations. 
No muscarinic antagonist, long- or short-acting, has been characterized for its impact on 
the MDRC thus far.  
1.4.5 β2 Agonists 
Selective β2 agonists, both short- and long-acting, have been extensively studied for the 
degree of bronchoprotection provided by different dosages against methacholine-induced 
bronchoconstriction. With the SABA salbutamol, 100µg has been found to induce methacholine 
dose shifts of 2.1 doubling doses at 30 minutes and 1.3 at 2 hours post-treatment (Higham et al. 
1997); 200µg salbutamol in one study produced a dose shift of approximately two doubling 
doses at 1 hour, an effect that had dissipated within 12 hours (Derom et al. 1992), while a second 
study recorded a 3.5 doubling dose shift at 30 minutes post-treatment, an effect that had 
dissipated within 4 hours (Ramsdale et al. 1991); the latter finding was confirmed in another 
study when after 200µg salbutamol once daily for 10 days, participants showed a dose shift of 
3.5 when MCT was performed 10 minutes following administration of one last 200µg dose of 
salbutamol (Jokic et al. 2001); 400µg salbutamol provided dose shifts of 3.7 doubling 
concentrations at 30 minutes and 2.3 at 2 hours post-dose (Higham et al. 1997). Salbutamol 
clearly produces dose-dependent bronchoprotection for less than 12 hours.  
The LABA salmeterol has been investigated for its single dose and long-term effects in 
several studies; 25µg salmeterol produced doubling dose shifts of 1.9 at 30 minutes and 2.5 at 2 
hours post-treatment (Derom et al. 1992). A dose of 50µg salmeterol has produced some 
variability in results; one study found a relatively consistent dose shift of approximately 2 
doubling doses from 1 to 12 hours (Derom et al. 1992), two studies found a 3.3 doubling dose 
shift at 1 hour (Cheung et al. 1992; Bhagat et al. 1995), and a fourth reported a dose shift of 1 
doubling concentration at 12 hours post-treatment (Booth et al. 1993). With a dose of 100µg 
salmeterol, the dose shift was approximately three doubling concentrations for the first 2 hours 
and significant bronchoprotection was still apparent at 12 hours with a doubling dose shift of two 
(Derom et al. 1992; Higham et al. 1997). Long-term studies found that twice-daily 25µg 
salmeterol produced a dose shift of one doubling concentration after 4 and 8 weeks of regular 
dosing (Cheung et al. 1992; Booth et al. 1993) while twice-daily 42µg salmeterol produced the 
same dose shift after 4, 12, and 24 weeks of treatment (Rosenthal et al. 1999). When usage was 
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stopped after eight weeks, Cheung et al found that no significant bronchoprotection remained 
two days after the final dose was taken (Cheung et al. 1992). Similarly, Rosenthal and colleagues 
found no rebound bronchoconstriction at three days after having ceased daily dosing (first 
follow-up visit post-treatment) (Rosenthal et al. 1999). Altogether, these findings suggest that 
salmeterol-induced bronchoprotection is dose-dependent and that the drug does not last more 
than 48 hours.  
The LABA formoterol has also been characterized for its bronchoprotective effects in 
asthmatics; one hour after dosing, 24µg formoterol produced a dose shift of more than 3 
doubling concentrations while 12µg and 6µg formoterol each produced a doubling dose shift of 
approximately 2.5. After two weeks of regular treatment, 24µg twice-daily, 12µg once-daily and 
6µg twice-daily of formoterol each produced a dose shift of 0.5-1 doubling concentration of 
methacholine (Lipworth et al. 1998). Another study reported a doubling dose shift greater than 
four in asthmatics at 30 minutes post-dosing with 24µg formoterol, which persisted for at least 
12 hours at which time the dose shift was approximately three doubling concentrations 
(Ramsdale et al. 1991). A dose of 12µg formoterol produced slightly less significant results, with 
dose shifts of three to four doubling concentrations at 30 minutes and of two to three doubling 
concentrations at 12 hours post-treatment (Ramsdale et al. 1991). Formoterol at these doses 
therefore generates similar bronchoprotection to salmeterol, but no study has examined its full 
duration of effect.  
The full duration of bronchoprotection against methacholine provided by uLABAs (e.g. 
indacaterol, olodaterol) is not yet known. Olodaterol has only been followed for 32 hours after a 
single dose, at which time it was shown to provide significant persistent bronchoprotection 
(O’Byrne et al. 2009).  At dosages of 2, 5, 10, and 20µg, olodaterol produced methacholine dose 
shifts ranging from 2.1 to 4.2 doubling concentrations at 0.5 hour post-treatment in a dose-
dependent manner. At 32 hours, the range in dose shift was 1.2 to 2.7 doubling concentrations. 
Based on the current guidelines, it is assumed that uLABAs will provide bronchoprotection for 
up to 48 hours, presumably based on LABA data.  
When examined for their effect on the MDRC of asthmatics, both SABAs and LABAs 
seem only to reduce airway sensitivity to bronchoconstricting stimuli (i.e. a rightward shift in the 
MDRC). No MDRC has been generated for uLABAs such as olodaterol as of yet. When the 
effect of the SABA salbutamol (200µg) was compared with that of the LABA salmeterol (50µg), 
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each taken twice daily for four days, the former produced a larger rightward shift (Wong et al. 
1997). This difference is not surprising given the previously mentioned findings regarding the 
dose shift produced by each treatment as well as the fact that salbutamol has a significantly faster 
onset and MCT was performed 15 minutes after final dosing for both treatment arms. Neither 
drug influenced the maximal response to methacholine, but each produced an increase in slope. 
Two similar studies confirmed that regular use of salbutamol steepens the MDRC slope 
(BelZwindermanet al. 1991; Bhagat et al. 1996), one of which corroborated that salbutamol 
shifts the MDRC to the right but has no effect on the maximal response (BelZwindermanet al. 
1991). Bel, Zwinderman and colleagues found that the rightward shift was not correlated with 
the degree of bronchodilation achieved and that the most sensitive subjects at baseline 
experienced the greatest rightward shift in their MDRC.  
The steepening of the MDRC slope is concerning, as it illustrates that more rapid airway 
obstruction occurs following exposure to a bronchoconstricting stimulus. To explain this 
observation, it was suggested that regular use of β2 agonists increases AHR due to excessive 
release of mediators from persistently stimulated β2 receptors on mast cells (Bhagat et al. 1996). 
It was also suggested that ASM β2 receptors become dysfunctional and no longer efficiently 
promote ASM relaxation, thereby contributing to the loss of protection afforded by β2 agonists 
against methacholine (Bhagat et al. 1996).  
1.5 Introduction Summary 
Asthma is a complex heterogeneous disease for which there is no cure. Despite the 
availability of a number of treatment options, the variability in phenotypes among asthma 
patients can make it a time-consuming process to find the right therapy. Research still lags in 
characterizing the various effects of respiratory medications on diseased airways, particularly in 
human models, which further impedes our ability to treat asthma based on phenotype. Direct 
provocation testing such as MCT can be utilized as a tool in respiratory clinics for assessing 
AHR and in research for determining the physiological effects of anti-asthma drugs on diseased 
airways. However, to maintain test standardization and ensure the accuracy of MCT results, new 
treatments must be characterized for the degree and duration of bronchoprotection that they 
afford in order to establish an appropriate abstinence period prior to testing. The examination of 
each asthma drug class through MDRCs is also important, as these visual representations of 
AHR provide preliminary information on the physiological changes elicited by each drug in 
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humans. Recent pharmaceutical developments that lack MCT data include LAMAs, uLABAs, 
and combinations of LAMA/uLABA, each of which shows promise in addressing certain 
pathophysiologies not adequately mitigated by previous treatment regimens. 
1.6 Rationale 
The recent addition of the LAMA tiotropium to the standard treatment hierarchy for 
asthma preceded certain investigations in human models that are important for ensuring accuracy 
in diagnostic and research techniques in asthmatics. For continued standardization of the 
commonly performed MCT procedure, all respiratory medications should be assessed for their 
duration of bronchoprotection against methacholine in order to deduce suitable washout periods. 
This information is not yet known for LAMAs and so the first project of this thesis examined the 
duration and degree of bronchoprotection provided by two LAMAs, tiotropium and 
glycopyrronium.  
Newer respiratory medications, such as LAMAs and uLABAs, have yet to be 
characterized for their effects on the MDRC of asthmatics. This information is beneficial for 
quantifying the effects, if any, of the treatments on airway reactivity and maximal responsiveness 
while supplementing data on airway sensitivity, which may have been previously investigated 
through methacholine PC20 measurements. Results from a study of this nature could inform 
future physiological studies and may eventually help to shape clinical decision making. Despite 
the fact that LAMAs and uLABAs are not intended for monotherapeutic use, it is worthwhile to 
characterize both their individual and combined effects to determine what changes each produces 
on the asthmatic MDRC and whether synergism is in fact observed as has been found in animal 
models. The second study of this thesis investigated the effects of the LAMA glycopyrronium 
and the uLABA indacaterol, alone and in combination, on the MDRC of mild asthmatics. 
2.0 DURATION OF BRONCHOPROTECTION OF THE LONG-ACTING 
MUSCARINIC ANTAGONISTS TIOTROPIUM AND GLYCOPYRRONIUM IN MILD 
ASTHMATICS 
2.1 Objective 
The purpose of this study was to determine the duration and degree of bronchoprotection 
provided by two LAMAs, tiotropium and glycopyrronium, against methacholine-induced 
bronchoconstriction in mild asthmatics. This information could then be incorporated into MCT 
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standardization guidelines, which currently provide a recommended abstinence period from 
LAMAs that has not been scientifically validated. 
2.2 Hypothesis 
The two LAMAs will provide equivalent and significant bronchoprotection against 
methacholine-induced bronchoconstriction for more than 48 hours.  
2.3 Relationship to Thesis 
This chapter describes the first study investigating the complete duration of 
bronchoprotection provided by the LAMAs tiotropium and glycopyrronium against inhaled 
methacholine. This work was published in Respiratory Medicine (Appendix A) and has been 
cited in the 2017 MCT guidelines (Coates et al. 2017). 
2.4 Abstract  
Despite the recent recommendation of the LAMA tiotropium for use in poorly controlled 
asthma, the duration of bronchoprotection provided by this drug class and whether the various 
formulations of LAMAs differ remain unknown. The 1999 standardization guidelines for MCT 
suggest that LAMAs should be avoided for 48 hours (perhaps 1 week in the case of tiotropium) 
prior to testing to ensure proper test interpretation. However, these suggestions are based on 
findings with LABAs. Our objectives were to determine and compare the duration and degree of 
protection afforded by a single dose of two different LAMAs, tiotropium and glycopyrronium, 
against methacholine-induced bronchoconstriction. 
Thirteen mild-to-moderate asthmatics [8 male; baseline FEV1 >65% of predicted; 
baseline PC20 ≤8mg/mL] completed this randomized, double blind, double dummy, crossover 
study. Methacholine challenges were performed before treatment administration (5µg tiotropium 
or 50µg glycopyrronium) and at 1, 24, 48, 72, 96 and 168 hours (7 days) post-treatment. 
Treatment administrations were separated by at least 11 days.  
Both drugs provided significant bronchoprotection, each producing an increase in mean 
PC20 that was greater than 16-fold, or four doubling concentration, by one hour post-dose. 
Tiotropium still provided statistically significant protection on day seven (p=0.0282) while 
glycopyrronium provided bronchoprotection until day seven (p=0.0590). Tiotropium provided 
statistically superior bronchoprotection at 24 and 72 hours compared to glycopyrronium. 
To minimize the occurrence of false negatives, MCT guidelines should be updated to 
recommend a minimum one-week abstinence period from all LAMAs. MCT also differentiated 
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between tiotropium and glycopyrronium with respect to the degree and duration of 
bronchoprotection provided by each.  
2.5 Introduction 
Asthma is a respiratory condition that causes either persistent or sporadic airway 
hyperresponsiveness (AHR) in response to a variety of triggers (Lougheed et al. 2012). Although 
the exact cause of asthma remains unknown, it is believed that genetic and environmental factors 
contribute to its development (Kim & Mazza 2011). In order to treat patients with varying 
symptoms and severity of asthma, a range of pharmaceutical agents have been developed. Due to 
increased demand for more effective treatment regimens, research has now begun to examine the 
use of LAMAs (Peters et al. 2010; Kerstjens et al. 2011). LAMAs function by selectively 
inhibiting muscarinic M1 and M3 receptors and slowly dissociating from them, thereby 
generating a long duration of action (Lipworth 2014). Unlike the SAMA ipratropium bromide 
(IB), LAMAs are more selective and do not greatly inhibit M2 receptors, which are key for 
preventing the excessive presynaptic release of the bronchoconstrictor acetylcholine. A number 
of LAMAs such as tiotropium and glycopyrronium have been developed and are approved for 
use in COPD. Currently, the only LAMA included in the Global Initiative for Asthma report 
‘Global Strategy for Asthma Management and Prevention (2016 update)’ is tiotropium (Global 
Initiative for Asthma 2016). 
Given the incorporation of LAMAs into asthma treatment regimens, it is important to 
know the impact of such medications on diagnostic tests. One of the most common diagnostic 
tests used in asthma research and clinical practice is the methacholine challenge. This test is 
typically used for refuting a physician diagnosis of asthma (Crapo et al. 2000). A number of 
factors, including concomitant medications, have been found to influence the accuracy of this 
diagnostic test, thereby contributing to false negative results.  
To establish a standard testing protocol for accuracy and safety purposes, the ATS 
published a set of guidelines for MCT which includes suggested abstinence periods from several 
classes of pharmaceuticals (Crapo et al. 2000). Due to the various durations of pharmacological 
effects, the ATS guidelines suggest withholding long-acting bronchodilators for 48 hours and 
possibly one week for tiotropium (Crapo et al. 2000). However, the references provided to 
support these washout periods pertained to the duration of action of single doses of LABAs 
(Derom et al. 1992; Cockcroft & Swystun 1997). It may be inappropriate to generalize these 
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results to all long-acting bronchodilators, as LABAs and LAMAs have completely different 
mechanisms of action. In addition, few studies have examined the duration of effect of single 
doses of LAMAs in asthmatics and no study has captured the effect in its entirety.  
2.6 Methods 
2.6.1 Participants 
Participants were first recruited through our contact list of previous participants in our 
laboratory. To achieve our target sample size, the remainder of participants was recruited from 
the campus community through a Research Ethics Board (REB)-approved ad posted on the 
online university news portal (PAWS). This study was approved by the University of 
Saskatchewan Biomedical REB (Bio-REB 15-254; Appendix B) and was registered with 
clinicaltrials.gov (NCT02622243). Prior to enrolling in the study, each participant was given the 
opportunity to ask questions before providing written informed consent.  
Eligible participants were at least 19 years of age, had a methacholine PC20 ≤ 8mg/mL, 
had a baseline % predicted FEV1 ≥65%, and were either nonsmokers or ex-smokers with less 
than ten pack-years history. Individuals were ineligible if they had taken any anticholinergic 
agent within 30 days or if they had suffered an upper respiratory tract infection within 4 weeks of 
study entry. ICS monotherapy was permitted as long as it was taken regularly at a stable dose for 
at least 30 days prior to study enrollment. Salbutamol rescue therapy was allowed but was 
abstained from for six hours before all lab visits. Due to known contraindications for MCT and 
for the study treatments, the following were excluded: pregnant or nursing women, and those 
suffering from cardiovascular or prostate or kidney or urinary retention problems, or glaucoma.  
2.6.2 Methacholine Challenge Test 
The two-minute tidal breathing protocol for MCT was performed as outlined in the ATS 
guidelines for MCT (Crapo et al. 2000): 
1. The following methacholine concentrations in mg/mL were prepared in advance by 
diluting either 1600mg or 1280mg Provocholine® (Methapharm, Inc., Brantford, ON, CA) 
powder with 0.9% saline: 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128.  
2. Baseline spirometry was performed to obtain three reproducible FEV1 measurements. 
3. 2mL of saline diluent (0.9%) was inserted into a Bennett-Twin jet nebulizer (Puritan 
Bennett Corporation, Carlsbad, CA) that had been calibrated to give an output volume of 
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0.13mL/min prior to beginning the study. A participant used the same nebulizer for all of 
their testing. 
4. The participant calmly breathed in nebulized aerosol for two minutes via a facemask while 
their nose was clipped. 
5. At 30 seconds and 90 seconds post-inhalation, the participant’s FEV1 was measured. A 
third FEV1 measurement was obtained at 150 seconds post-inhalation if the FEV1 value at 
90 seconds was >5% less than the value measured at 30 seconds.  
6. At 5 minutes after the start of the previous inhalation cycle, the next cycle was started with 
2mL of the lowest concentration of methacholine and steps 4-5 were repeated. A 
participant received the same starting concentration of methacholine for each 
methacholine challenge. 
7. Steps 4-6 were repeated with doubling concentrations of methacholine until the PC20 was 
attained (i.e. after ≥20% fall in FEV1), until the highest methacholine concentration 
(256mg/mL*) had been administered, or if the participant wished to stop. *To administer 
the 256mg/mL concentration of methacholine, 2mL of 128mg/mL methacholine was 
inhaled for four minutes. 
8. Following a baseline methacholine challenge, participants were given their randomized 
study treatment. Following post-treatment MCT, participants were offered 200µg 
salbutamol to quickly reverse the methacholine-induced bronchoconstriction. 
2.6.3 Study Design 
This was a randomized, double blind, double dummy, crossover study. For each 
treatment arm, participants underwent baseline MCT followed by treatment administration and 
MCT at 1, 24, 48, 72, and 96 hours post-treatment. Each methacholine challenge was performed 
at the same time of day (± two hours). It was subsequently identified that the treatments could 
last longer than 96 hours. It was also found that the first participant developed a response plateau 
(i.e. three data points within 5%) around a 20% fall in FEV1. As a result, a study amendment was 
drafted and approved (Appendix C) to allow for MCT at 7 days (or 168 hours) post-treatment. 
The amendment also allowed for the administration of one additional concentration of 
methacholine if a participant showed signs of developing a plateau (i.e. two data points within 
5% when a 20% fall in FEV1 was reached). Initially, testing on day 7 was only performed in 
participants who showed persistent bronchoprotection at 96 hours. It was soon recognized 
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however, that statistical analysis would be weakened if a participant had data until day 7 on one 
drug, but only data until 96 hours post-treatment on the other study drug. Following this, all 
remaining participants underwent MCT on day seven for both treatments. The treatment 
administrations were separated by a minimum 11-day washout. 
2.6.4 Study Drugs and Blinding 
Inhalers were pre-loaded with active and placebo capsules (Breezhaler®) or canisters 
(Respimat®); participants and the administering investigator were blinded to the treatment and 
randomization scheme.  For each treatment, participants took two inhalations from a Respimat® 
and two inhalations (from the same capsule) from a Breezhaler®; one device contained an active 
treatment and the other a placebo. Participants were advised to hold their breath for five seconds 
after each inhalation.  The glycopyrronium treatment arm consisted of a dose of 50µg and the 
tiotropium treatment arm consisted of a dose of 5µg.  
2.6.5 Statistical Analysis 
A sample size of 13 participants provided a 99% study power for detecting a half 
concentration difference in methacholine PC20. The methacholine PC20 data were calculated with 
Formula 2.1 (Cockcroft et al. 1983):  
Methacholine PC20 = antilog [log C1 + 
!"# !!!!"#!! !"!!!!!!!! ] 
C1 = Next-to-last concentration of methacholine administered; 
C2 = Last concentration of methacholine administered (the concentration producing a 
20% or greater fall in FEV1); 
R1 = Percent fall in FEV1 post-C1; 
R2 = Percent fall in FEV1 post-C2; 
If the maximum methacholine concentration was administered and the fall in FEV1 was 
only between 10-20%, the PC20 was extrapolated using Formula 2.2 (Jokic et al. 1998): 
Methacholine PC20 = [20 /last percent fall in FEV1] x final concentration administered; 
If the FEV1 fell by less than 10% at the maximum methacholine concentration (256 
mg/mL), the methacholine PC20 was arbitrarily set at 1024mg/mL. The PC20 values were then 
log-transformed and used to assess bronchoprotection by calculating the dose shift in 
methacholine PC20 with Formula 2.3 (O’Connor et al. 1992): 
PC20 dose shift = (Δlog methacholine PC20)/0.3; 
	 	 	 	27	
Using Statistix 9 (Analytical Software, Tallahassee, FL, USA), paired t-tests were 
performed to compare treatment differences in PC20 dose shift and in baseline FEV1 (using the 
highest of the three baseline FEV1 measurements). Repeated measures analysis of variance 
(ANOVA) was performed with Statistix 9 to compare dose shift and pre-challenge FEV1 data 
between the two drugs. A dose shift from baseline of at least one doubling concentration was 
considered clinically significant (Dehaut et al. 1983). Graphs were generated with SigmaPlot 10 
(Systat Software, Inc., Richmond, CA, USA). Significance was two-sided and set at 0.05. 
Results are reported as mean data ± standard error of mean (SEM), unless otherwise stated. 
2.7 Results 
2.7.1 Participants 
Table 2.1. Participant demographics 
Participant Gender Age 
(yrs.) 
 
Height 
(cm) 
 
Pre-GLY 
FEV1 (% 
Predicted) 
Pre-TIO 
FEV1 (% 
Predicted) 
PC20 Pre-
GLY 
(mg/mL) 
PC20 Pre-
TIO 
(mg/mL) 
1 M 69 168 72 77 1.0 1.4 
2 M 39 178 88 85 1.2 0.64 
3 M 22 183 83 82 6.4 7.2 
4 F 22 173 96 96 0.98 1.2 
5 M 31 196 99 96 1.1 3.4 
6 F 27 168 102 96 1.5 2.4 
7 M 24 178 100 99 1.1 1.1 
8 M 29 185 105 105 10.0 7.0 
9 M 44 175 95 95 7.1 7.6 
10 F 28 160 89 91 1.4 3.4 
11 M 20 185 76 94 0.78 0.73 
12 F 21 170 79 80 0.66 1.5 
13 F 24 147 68 76 0.36 0.16 
Mean: 62% M 31 [13] 174 [12] 89 [12] 90 [10] 1.5* 1.8* 
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*, geometric mean; [ ], standard deviation; GLY, glycopyrronium; TIO, tiotropium; FEV1, 
forced expiratory volume in one second; PC20, provocative concentration of methacholine 
causing a 20% fall in FEV1 
 
A total of 18 participants enrolled in the study and 13 followed it to completion (see 
Table 2.1). Five participants were excluded; four did not have a positive methacholine challenge 
and one did not have an adequate baseline FEV1. No unexpected serious adverse effects 
occurred. Reported side effects were mild and included topical dryness, shortness of breath, chest 
tightness, muscle stiffness, and headaches. All were known side effects of either drug or of MCT 
and subsided without the need for intervention. No participants were taking ICS as a 
monotherapy and all were nonsmokers. 
2.7.2 Bronchoprotection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Mean dose shift and standard error at various time points following treatment with 
tiotropium (TIO) and glycopyrronium (GLY). The sample size was 13 except for TIO at 96 hours 
(n=12), TIO at 168 hours (n=10) and GLY at 168 hours (n=9). P values represent the difference 
between the treatment arms at the given time points. 
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Table 2.2. Methacholine PC20 data 
 Methacholine PC20 (mg/mL) at: 
Baseline 1 
hour 
24 
hours 
48 
hours 
72 
hours 
96 
hours 
168 
hours 
Tiotropium  1.8 33 15 11 9.1 7.0 3.8 
Glycopyrronium  1.5 30 5.4 5.6 3.5 3.2 2.4 
Baseline and post-treatment PC20 data presented as geometric means  
PC20, provocative concentration of methacholine causing a 20% fall in FEV1 
Figure 2.2. Individual methacholine PC20 values pre-treatment and at 96 hours post-dose for 
each drug. Single data points represent geometric mean and SEM values. P values represent the 
difference between the PC20 values at 96 hours versus those values at baseline within the same 
treatment arm. 
 
Dose shift data and methacholine PC20 values for both treatments are shown in Figure 2.1 
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and Table 2.2, respectively. Both treatments significantly increased the amount of methacholine 
required to achieve a 20% fall in FEV1 by more than 16-fold at one hour. Tiotropium and 
glycopyrronium each continued to provide clinically significant bronchoprotection at 96 hours 
(p-0.001 and p=0.012, respectively), as shown in Figure 2.2. At 168 hours, tiotropium provided 
statistically significant bronchoprotection (p=0.028; dose shift=0.84; n=10) while 
glycopyrronium did not (p=0.059; dose shift=0.52; n=9).  
Tiotropium appears to be superior to glycopyrronium until the 168-hour time-point. 
Tiotropium provided significantly more bronchoprotection than glycopyrronium at 24 hours 
(p=0.006) and 72 hours (p=0.008), and approached statistical significance at 48 hours (p=0.050) 
and 96 hours (p=0.057). Paired t-tests of the dose shift produced by each drug at 1 and 168 hours 
post-treatment showed no statistical difference between the two treatments (p=0.865 and 
p=0.212 respectively).  
2.7.3 Bronchodilation 
Table 2.3. Mean peak FEV1 data 
 Mean peak FEV1 values at: 
Baseline 1  
hour 
24  
hours 
48 
hours 
72 
hours 
96 
hours 
168 
hours 
Tiotropium 3.70 
 
3.70 
(0.976) 
3.82 
(0.058) 
3.71 
(0.931) 
3.66 
(0.506) 
3.75 
(0.817) 
n=12 
3.36 
(0.158) 
n=10 
Glycopyrronium 3.65 3.75 
(0.053) 
3.74 
(0.005*) 
3.70 
(0.174) 
3.65 
(0.880) 
3.66 
(0.671) 
3.40 
(0.697) 
n=9 
( ), P values; *, statistical significance; FEV1, forced expiratory volume in one second 
Sample sizes are specified if different from n=13 
 
Mean peak FEV1 data only differed significantly from baseline at 24 hours post-
glycopyrronium, as shown in Table 2.3. In terms of mean shift in peak FEV1 [95% confidence 
interval], glycopyrronium provided an average increase in lung volume of 90 mL, from 3.65L 
[3.00, 4.29] at baseline to 3.74L [3.12, 4.37] at 24 hours. Borderline statistically significant shifts 
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in mean peak FEV1 from baseline were observed with glycopyrronium at 1 hour (p=0.053) and 
with tiotropium at 24 hours (p=0.058). No significant difference in mean FEV1 was observed 
between the two treatments at any time-point. 
2.7.4 Post hoc analysis of methacholine dose-response curves 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Comparison of the mean MDRCs pre-treatment versus one hour post-treatment with 
tiotropium and glycopyrronium, respectively. Zero was set as the methacholine concentration 
that caused the minimum 20% fall in FEV1 at baseline. Any lower concentrations administered 
were plotted as negative x-values and any higher concentrations were plotted as positive x-
values. Best-fit curves were then generated. Data points with a sample size less than six were 
excluded. 
 
Figure 2.3 shows that the mean baseline MDRC prior to each treatment arm was 
exponential-shaped and did not appear to plateau. At one hour post-treatment, both drugs shifted 
the curve to the right, reduced the slope, and produced a response plateau between a 10-15% fall 
in FEV1. 
2.8 Discussion 
The gap in knowledge regarding the duration of bronchoprotection provided by LAMAs 
against methacholine in asthmatics necessitated that a study of this nature be performed to 
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inform MCT standardization guidelines; this is particularly important now that a LAMA 
(tiotropium) is recommended for use in this patient population (Global Initiative for Asthma 
2016). Previously, O’Connor et al found that different dosages of tiotropium provided 
bronchodilation for up to 24 hours and dose-dependent bronchoprotection for at least 48 hours in 
12 mild-to-moderate asthmatics (O’Connor et al. 1996). With a reduced sample size of four, they 
also found persistent bronchoprotection at 72 hours post-treatment. Hansel et al performed a 
similar study comparing bronchoprotection provided by IB versus three different dosages of 
glycopyrronium in ten mild-to-moderate asthmatics (Hansel et al. 2005). They found that while 
IB provides more bronchoprotection at 2 hours post-treatment, bronchoprotection by 
glycopyrronium is greater at 12, 24 and 30 hours. Unfortunately, neither of these studies 
followed their participants until the treatments had completely worn off and so, the complete 
duration of bronchoprotection provided by each drug remained unknown.  
Our findings show that bronchoprotection provided by glycopyrronium lasts up to seven 
days while tiotropium still provides statistically significant bronchoprotection at seven days. 
However, the dose shift in methacholine PC20 at seven days after each treatment was not 
clinically significant, as it was less than one doubling concentration in both cases. Initially, 
participants only completed day 7 of testing if they still showed significant bronchoprotection at 
96 hours. This resulted in reduced sample sizes on day seven for both treatments and it is 
possible that neither drug may have been found to be significant one week after drug 
administration had all participants completed day seven testing. Nonetheless, these findings 
suggest that current guidelines for MCT need to be updated to account for the significantly 
longer duration of bronchoprotection provided by LAMAs than the currently suggested 48 hours 
and “perhaps 1 wk. for tiotropium” (Crapo et al. 2000).  
The secondary objective of this study was to compare the two LAMAs in order to 
determine if there is any difference in bronchoprotection between the two treatments. Since the 
two study drugs are typically used in COPD patients, more data has been collected on their 
treatment effects in that patient population. Glycopyrronium has been found to provide a dose-
dependent bronchodilator effect, with higher doses (i.e. 50-115.2µg) producing comparable 
effects to the recommended tiotropium dosage of 18µg in COPD patients (Verkindre et al. 2010; 
Kerwin et al. 2012; Rennard et al. 2014). The main difference observed between the two 
treatments was that glycopyrronium provides more rapid and significant bronchodilation from 
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five minutes to four hours post-treatment (Verkindre et al. 2010; Kerwin et al. 2012). This 
presented the hypothesis that these two drugs would exert similar durations of bronchoprotection 
and bronchodilation in asthmatics undergoing MCT.  
Our results reflect that while their overall duration is similar in terms of clinical 
significance, tiotropium provides superior bronchoprotection at almost all time points, and its 
superiority reached statistical significance at 24 and 72 hours post-treatment. Reasons for this 
difference may be that the dosage of tiotropium administered was that recommended for 
asthmatics while glycopyrronium was administered per guidelines for COPD patients. Although 
glycopyrronium is somewhat more selective for M3 receptors than for M1 and M2 types, only 
tiotropium has kinetic selectivity for M3 over M2 receptors, which could lead to a significant 
difference in perceived bronchoprotection between the two treatments (Moulton & Fryer 2011). 
If glycopyrronium binds M2 receptors for a longer period of time, this could produce prolonged 
inhibition of this receptor-type’s normal function as a moderator of acetylcholine in the airways. 
The result could be a reduction in overall bronchoprotection, as elevated acetylcholine levels 
could promote some bronchoconstriction.  
It has also been suggested that differences in receptor binding kinetics between 
tiotropium and glycopyrronium only explain some of the variation seen in their respective 
durations of action (Fogarty et al. 2011). Drug rebinding may prolong the duration of action of 
pharmaceuticals, as freshly dissociated drug molecules could rebind to receptors further down 
the target tissue rather than being immediately metabolized (Sykes et al. 2012). Given that some 
drug molecules would be lost to metabolism with each dissociation and rebinding event, 
glycopyrronium could lose effect more quickly, as it dissociates more rapidly than tiotropium. 
Traditional pharmacokinetic data with these LAMAs are not applicable given the present study 
context of single dose, inhaled treatment in the airways of a live human model. As such, we can 
only speculate regarding the influence of receptor binding kinetics in distinguishing tiotropium 
from glycopyrronium. Another potential factor contributing to the different effects of each drug 
could be their respective delivery methods. It has been argued that soft mist inhalers deliver 
pharmaceuticals more efficiently than do dry powder inhalers, leading to more drug deposition in 
the airways even in the event of poor inhalation technique (Brand et al. 2008). 
Neither drug produced a strong bronchodilator effect, which is contradictory to results 
obtained in previous studies in mild asthmatics (O’Connor et al. 1996; Hansel et al. 2005). Only 
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glycopyrronium provided statistically significant bronchodilation at one time-point, 24 hours 
post-treatment. However, this effect was not clinically significant and only represented an 
increase in volume of 97mL while the ATS guideline for significant post-bronchodilator FEV1 is 
a 200mL increase (and 12%) (American Thoracic Society 1995). This lack of significant 
bronchodilation in the current study may be explained by the much greater dosages of the 
treatments administered in previous studies. It should also be noted that the participants were 
mildly asthmatic and so, they likely had relatively low airway constriction at rest. Therefore, the 
airways may not have had much capacity to dilate further. Nonetheless, while this study’s 
findings do not suggest that the two LAMAs are effective bronchodilators in mild asthmatics, 
they both provide significant bronchoprotection, particularly at one hour post-treatment where 
both drugs produced a dose shift of four doubling concentrations of methacholine (or a 16-fold 
increase in mean PC20). This is comparable to the duration of bronchoprotection provided by 
other drug types; at 30 minutes post-dose, the LABA formoterol (24µg) provides 20-fold 
bronchoprotection and the uLABA olodaterol (20µg) provides 19-fold protection (Ramsdale et 
al. 1991; O’Byrne et al. 2009).  
In addition to the anticipated shift of the MDRC to the right compared to the pre-
treatment curve, both LAMAs unexpectedly produced a reduced maximal response to 
methacholine. The reduction in maximal response reflects a decrease in what appeared at 
baseline to be unlimited AHR (Sterk & Bel 1989). The rightward shift reflects a reduction in 
airway sensitivity to methacholine, which is unsurprising given the binding of LAMAs to M1 and 
M3 receptors, thereby preventing the binding of bronchoconstrictors (Sterk & Bel 1989; Beasley 
et al. 2009). Potential mechanisms behind the decrease in maximal response to methacholine 
include reduced ASM contractility and inhibition of mucus secretion responsible for airway wall 
swelling (Sterk & Bel 1989). Tiotropium has also been found to trigger anti-inflammatory 
mechanisms in COPD patients (Holownia et al. 2010). This function may contribute to both the 
rightward shift and plateau in the MDRC, as the airways are less sensitive to stimuli (i.e. lower 
release of inflammatory mediators) and swelling is reduced. In comparison, ICS also produce a 
lower maximal response and a rightward shift in the MDRC while β2 agonists simply produce a 
rightward shift (Wong et al. 1997; Oga et al. 2001). Further investigation into the impact of 
LAMAs on the MDRC of asthmatics could expand our current knowledge on the physiological 
effects of these medications and could have implications for clinical decision-making. 
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Overall, the results from this study provide objective data indicating that the current 
guidelines underestimated the complete duration of clinically significant bronchoprotection by 
LAMAs, although the undocumented caveat for one week for tiotropium did prove accurate. The 
remaining question is whether all LAMAs act roughly equivalently to tiotropium or 
glycopyrronium and so, in order to better account for the length and degree of bronchoprotection 
of this drug class, it would be recommended that all LAMAs be abstained from for a minimum 
of one week prior to undergoing MCT to avoid false negative or difficult-to-interpret test results.  
3.0 THE EFFECT OF GLYCOPYRRONIUM AND INDACATEROL, AS 
MONOTHERAPY AND IN COMBINATION, ON THE METHACHOLINE DOSE-
RESPONSE CURVE 
3.1 Objectives 
The purpose of this study was to characterize the physiological effects of a LAMA 
(glycopyrronium) and a uLABA (indacaterol), as monotherapy and in combination, based on the 
changes each elicited on the MDRCs of mild asthmatics. A secondary objective was to compare 
these asthmatic MDRCs with a non-asthmatic control MDRC to better visualize how the study 
drugs may (or may not) improve airway function towards a “normal” level of responsiveness. 
3.2 Hypotheses 
The LAMA (glycopyrronium) will significantly reduce airway sensitivity (i.e. rightward 
shift), reactivity (i.e. smaller slope), and maximal responsiveness (i.e. low response plateau) to 
methacholine, as found post hoc in the previous study. The uLABA (indacaterol) will only 
produce a rightward shift, as has been found with both SABAs and LABAs. The combination 
therapy will produce synergistic improvements in airway sensitivity, reactivity, and maximal 
responsiveness, based on current knowledge of synergistic interactions in animal models and in 
clinical trials of LAMA/LABA combinations in COPD patients.  
3.3 Relationship to Thesis 
This chapter discusses the second study undertaken for this Master of Science thesis, 
which sought to confirm the previous findings with glycopyrronium while also investigating two 
other treatments: indacaterol, and combination glycopyrronium/indacaterol. This study focused 
on the use of MDRCs to distinguish the bronchoprotective mechanisms of the two drug classes 
administered as monotherapy and in combination. 
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3.4 Abstract 
MDRCs can be useful for illustrating pharmacologic bronchoprotection against 
methacholine-induced AHR by quantitating changes in airway sensitivity (position), reactivity 
(slope), and maximal responsiveness. Our objective was to determine the influence of single-
dose glycopyrronium (LAMA) and indacaterol (uLABA), as monotherapy and in combination, 
on the MDRC of mild asthmatics and to compare these findings with a non-asthmatic control 
curve. 
This was a randomized, double blind, double dummy, three-way crossover study. For 
asthmatic participants (n=14), each treatment arm included a baseline methacholine challenge, 
drug administration, and repeat methacholine challenges at 1, 24, and 48 hours. Non-asthmatic 
control participants (n=22) underwent a single methacholine challenge and did not receive any 
study treatment.  
Treatment effects on the MDRCs were first explored as mean data. Compared to 
baseline, indacaterol produced a slight reduction in sensitivity to methacholine at one hour; 
glycopyrronium significantly reduced airway sensitivity and reactivity as well as slightly 
decreased maximal responsiveness at all time-points. The control and one-hour glycopyrronium 
curves are nearly identical. Only combination therapy appeared to generate a true response 
plateau. Combination therapy also decreased airway sensitivity for at least 48 hours and reduced 
airway reactivity for 24 hours. 
When graphed individually, the asthmatic participants’ one-hour curves varied not only 
with respect to which drug provided the more favourable response but also with respect to how a 
specific drug altered the characteristics of the MDRC. 
Among the non-asthmatic participants, 32% (7/22) were found to be hyperresponsive to 
methacholine or saline and were not included as controls.  
MDRCs differentiate the bronchoprotective mechanisms triggered by different classes of 
asthma medications. In general, the only effect following indacaterol treatment was decreased 
sensitivity. On the other hand, glycopyrronium and combination therapy provided significant 
persistent bronchoprotection against methacholine, but only the latter protected against excessive 
airway narrowing (i.e. maximal responsiveness). Assessment of bronchoprotection using 
MDRCs may be useful during treatment development when performing superiority, equivalence, 
and/or non-inferiority trials.  
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3.5 Introduction 
As a heterogeneous condition with multiple phenotypes, asthma is a complicated disease 
to research. Although pharmaceutical agents are thoroughly studied for their safety and efficacy 
in animal models and clinical trials, investigations into their physiological effects in human in 
vivo models are often lacking. For example, new therapeutic interventions are often unknown for 
their influence on common diagnostic tests such as MCT for AHR. 
MCT is a common research technique that can be used to assess pharmacologic 
bronchoprotection against cholinergic-induced AHR. Such effects can be evaluated based on the 
resulting improvement in methacholine sensitivity through an increase, or dose shift, in 
methacholine PC20. Drug effects can also be studied through the generation of MDRCs, which 
illustrate not only airway sensitivity (i.e. position), but also airway reactivity (i.e. slope) and 
maximal responsiveness. Compared to that of a healthy airway, the typical asthmatic MDRC is 
shifted to the left (i.e. increased sensitivity), has a steeper slope (i.e. increased reactivity) and 
shows a higher maximal constricting response (i.e. excessive airway narrowing) (Sterk & Bel 
1989; Wong et al. 1997).  
Underlying physiology causing increased airway sensitivity includes epithelial damage 
and dysfunction, increased cholinergic neural activity, and airway inflammation (Sterk & Bel 
1989). Greater maximal airway responsiveness can result from increased ASM contractility, 
swelling of the airways, airway remodeling, and/or excessive mucus secretion (Sterk & Bel 
1989). With this knowledge, it is possible to elucidate the mechanisms of action of drugs based 
on the changes they produce on the MDRC.  
Three new or emerging therapies for poorly controlled asthma include LAMAs, 
uLABAs, and combination LAMA/uLABA. The previous study found that a single dose of each 
of the LAMAs tiotropium and glycopyrronium produced not only a rightward shift but also, post 
hoc, a low response plateau on the MDRC (Blais et al. 2016). Contrastingly, use of SABAs and 
LABAs have only been shown to improve airway sensitivity through a rightward shift on the 
MDRC (BelZwindermanet al. 1991; Wong et al. 1997). Whether uLABAs such as indacaterol 
produce the same result is unknown. While combination LAMA/uLABA therapy has generated 
promising results in animal models of asthma (BouyssouSchnappet al. 2010; Schlepütz et al. 
2013; Costa et al. 2014; Smit et al. 2014), its influence on MCT and, more specifically, on the 
MDRC in humans is still unclear. 
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3.6 Methods 
3.6.1 Participants 
Participants were either recruited through our contact list of previous participants in the 
Asthma Research Lab or were recruited from the University of Saskatchewan community via an 
REB-approved ad posted on the online university news portal (PAWS). This study was approved 
by the University of Saskatchewan Biomedical REB (Bio REB 16-205; Appendix D) and was 
registered with clinicaltrials.gov (NCT02953041). Prior to beginning the study, each participant 
was given the opportunity to ask questions before providing written informed consent.  
3.6.1.1 Asthmatic Participants 
Eligible asthmatic participants were 18 years of age or older, had a methacholine PC20 ≤ 
8mg/mL, and had a baseline % predicted FEV1 of 65% or greater. In addition, eligible 
participants could not have suffered from an upper respiratory tract infection or from allergy-
induced asthma symptoms within four weeks prior to the study. Exsmokers or current smokers 
could participate as long as they had less than ten pack-year history. Current smokers abstained 
from smoking completely on each test day prior to their study visit. An individual was ineligible 
to participate if they had taken any cholinergic agent or LABA within ten days prior to beginning 
the study. Participants taking regular ICS (monotherapy) were allowed to participate provided 
they had been taking their medication in the same dose regularly for at least 30 days. Salbutamol 
was allowed as rescue therapy but was withheld for six hours prior to all study visits. Due to 
known contraindications for MCT and the study treatments, the following were excluded: 
pregnant or nursing mothers, those with cardiovascular, kidney, prostate or urinary retention 
problems and those with hypokalemia, diabetes, or glaucoma.  
3.6.1.2 Non-Asthmatic Participants 
Eligible non-asthmatic participants were 18 years of age or older, were nonsmokers (or 
former smokers with less than ten pack-years history) and had a negative methacholine PC20 
(>16mg/mL). An individual could not participate if they were pregnant or nursing, if they had 
cardiovascular problems or if they had suffered an upper respiratory tract infection within four 
weeks of the study. Individuals were also excluded if they had a personal or first-degree family 
history of respiratory illness.  
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3.6.2 Methacholine Challenge Testing 
The two-minute tidal breathing protocol for MCT was performed as outlined in the 
previous chapter (section 2.6.2) with the following changes to the protocol steps: 
Step  1: The maximum concentration prepared was 64mg/mL. 
Step 7: Doubling concentrations of methacholine were administered until the highest 
concentration (128mg/mL*) had been administered, when a plateau response was 
achieved (three data points within 5%, provided that a minimum 10% fall in FEV1 had 
been attained), when a participant’s FEV1 dropped by 40% from the lowest FEV1 post-
saline, or if the participant wished to stop. *To administer the 128mg/mL concentration, 
2mL of 64mg/mL concentration was inhaled for four minutes. 
Step 8: For non-asthmatic participants, following their methacholine challenge, they 
were given the option of relieving any methacholine-induced bronchoconstriction with 
200µg salbutamol. 
3.6.3 Study Design 
This was a randomized, double blind, double dummy, three-way crossover study. A non-
asthmatic group was recruited to serve as a control for “normal” methacholine responsiveness 
and did not receive any study medications. On test day, all participants avoided exercise prior to 
each scheduled study visit. 
3.6.3.1 Protocol for Asthmatic Participants 
Asthmatic participants underwent three treatment arms, each consisting of four 
methacholine challenges (Table 3.1). Each treatment arm entailed three study visits at the same 
time of day (± two hours) on three consecutive days. The first day of each treatment arm took 
approximately three hours; first, a baseline methacholine challenge was performed to establish 
the participant’s methacholine PC20 at rest. While under observation, participants then self-
administered one of the blinded study treatments. Participants were instructed to hold their breath 
for five seconds after each inhalation of the study medication to ensure drug deposition.  A note 
was made if the participant coughed following drug inhalation and the specific inhaler causing 
the cough was marked to take into account the possibility of the drug particles being coughed 
out. Participants then underwent MCT at 1, 24, and 48 hours post-treatment. Testing at 24 and 48 
hours took approximately 1 hour. Following a minimum ten-day washout between treatment 
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administrations, the same procedure was repeated with the second study treatment. Following a 
second ten-day washout, the procedure was again repeated with the third study treatment.  
Table 3.1. Treatment visit schedule for asthmatic participants 
Visit 1  
(≈3 hours) 
§ Breakdown of study procedure and requirements 
§ Signing of the consent form 
§ Baseline methacholine challenge 
§ Treatment 1 inhalation (provided participant meets eligibility 
            criteria) 
§ Methacholine challenge at 1 hour post-treatment 
Visit 2 
(≈1-1.5 hours) 
§ Methacholine challenge at 24 hours post-treatment 
Visit 3 
(≈1-1.5 hours) 
§ Methacholine challenge at 48 hours post-treatment 
Washout (minimum 10 days between treatment administrations) 	
3.6.3.2 Protocol for Non-Asthmatic Participants 
Each participant underwent a single methacholine challenge, which took approximately 
one hour.  
3.6.4 Study Drugs and Blinding 
Active treatments and matching placebos were pre-loaded into Breezhaler® inhalers; 
both participants and the administering investigator were blinded to the treatment and 
randomization.   Each treatment involved administering the contents of two inhalers; for the 
LAMA monotherapy, one inhaler contained a glycopyrronium capsule (Seebri®) and the other 
contained a placebo capsule. For the uLABA monotherapy, one device contained an indacaterol 
(Onbrez®) capsule and the other contained a placebo capsule. For the combination therapy, one 
inhaler contained a glycopyrronium capsule and the other contained an indacaterol capsule. Each 
glycopyrronium capsule contained a 50µg dose and each indacaterol capsule contained a 75µg 
dose.  
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3.6.5 Statistical Analysis 
With a sample size of 15 asthmatic participants, the power of this study was 99% for 
detecting a half concentration difference in methacholine responsiveness. MDRCs were graphed 
with SigmaPlot 10 as the percent fall in FEV1 per methacholine concentration administered. 
Best-fit curves were then generated.  Mean control MDRC slopes as well as mean asthmatic 
MDRC slopes after each treatment and at each time-point were calculated through linear 
regression analysis using Excel® 2011 (Microsoft Corp., Redmond, WA, USA); the data points 
included were those from the two concentrations of methacholine that at baseline had been 
administered prior to achieving a minimum 20% fall in FEV1, plus all subsequent data points. If 
a response plateau formed, the data points up to the first of three plateau points were included for 
slope calculation. Slope values were then compared with paired t-tests using Excel® 2011. 
Slopes are presented with the units percent fall in FEV1/methacholine concentration. 
Methacholine PC20 data were calculated by algebraic formula (see Formula 2.1). If a 
participant’s FEV1 fell between 10-20% after the last concentration of methacholine (128 
mg/mL), their PC20 was extrapolated (see Formula 2.2). If a participant’s FEV1 fell less than 
10% from baseline after the final methacholine concentration, their PC20 was arbitrarily set at 
256mg/mL. Methacholine PC20 data were log-transformed and used to assess bronchoprotection 
through the dose shift in methacholine PC20 from baseline (see Formula 2.3). Bronchoprotection 
was deemed to be clinically significant if the dose shift was at least one doubling concentration 
of methacholine greater than the baseline PC20 (Dehaut et al. 1983). Baseline FEV1 
measurements for each treatment and time-point were averaged within each participant. Using 
Statistix 9, a two-way ANOVA (subject/treatment) and all pairwise comparisons [least 
significant difference (LSD)] were performed to determine the differences in dose shift and 
baseline spirometry data. Significance was two-sided and set at 0.05. Results are presented with 
95% confidence intervals, unless otherwise stated. 
The non-asthmatic data were analyzed separately from the asthmatic results. Non-
asthmatic participants with a negative methacholine challenge (i.e. PC20 >16mg/mL) were 
classified as non-hyperresponsive. Non-asthmatic participants with a positive test (i.e. PC20 
≤16mg/mL) or with a high degree of responsiveness to the saline control inhalation (i.e. >20% 
fall in FEV1) were classified as hyperresponsive. When possible, methacholine PC20 data were 
calculated as described earlier. Individual slopes were calculated as described previously with 
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some modifications; if no plateau developed, all data points were included, and the methacholine 
concentrations were log-transformed. Slopes are presented with the units % fall in FEV1/(log 
mg/mL). 
3.7 Results 
3.7.1 Participants 
3.7.1.1 Asthmatic Participants 
Table 3.2. Asthmatic participant demographics 
Participant Gender Age 
(years) 
Height 
(cm) 
Mean 
Baseline 
FEV1 (L) 
Mean 
Baseline 
FEV1 (% 
Predicted) 
Mean Baseline 
Methacholine 
PC20 (mg/mL) 
01 F 24 157 2.24 74 0.24 
02 M 40 178 3.49 83 0.92 
03 M 20 169 3.61 84 3.6 
04 F 28 168 3.32 97 3.8 
05 M 27 173 3.14 73 0.22 
06 F 23 173 3.55 95 2.0 
07 F 21 163 3.70 111 2.4 
08 F 21 173 3.65 98 3.7 
09 F 29 160 2.62 84 2.0 
10 M 32 185 3.41 72 1.8 
11 M 70 168 2.14 78 1.7 
12 M 22 173 4.17 95 3.1 
13 F 18 130 1.62 73 1.3 
14 M 25 172 4.23 99 2.1 
15 F 30 160 2.98 96 3.2 
16 M 23 180 4.29 90 2.4 
Mean: 50% Male 28 [12] 168 [12] 3.26 [0.77] 88 [12] 2.2*  
[ ], standard deviation;*, geometric mean; FEV1, forced expiratory volume in one second; PC20, 
provocative concentration of methacholine causing a 20% fall in FEV1 
	 	 	 	43	
Mean Baseline MCh PC20 – determined by averaging the pre-treatment baseline PC20’s 
 
A total of 16 asthmatics were recruited (Table 3.2) and 14 completed the study; one 
participant was withdrawn prior to the second randomized treatment due to significant 
improvement in their baseline PC20 in the non-hyperresponsive range (i.e. PC20 >16mg/mL). 
Another participant was withdrawn prior to the third randomized treatment due to worsening 
asthma symptoms. Reported side effects were mild and all subsided without need for 
intervention. Reported side effects included tremors, cold-like symptoms, headaches, fatigue, 
dizziness, flushing, and throat irritation. These adverse effects are known to sometimes occur 
with MCT or with the study treatments. Upon treatment inhalation, eight participants coughed 
immediately after inhaling the uLABA monotherapy, one coughed after the LAMA monotherapy 
and two coughed after the uLABA-containing inhaler of the combination therapy. 
3.7.1.2 Non-Asthmatic Participants 
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Table 3.3. Non-hyperresponsive non-asthmatic participant demographics 
Participant Gender Age 
(years) 
Height 
(cm) 
Mean Baseline 
FEV1 (L) 
Mean Baseline FEV1 
(% Predicted) 
H01 F 25 163 3.64 112 
H02 F 22 168 3.10 88 
H03 F 18 180 3.31 82 
H04 F 36 163 2.57 83 
H05 M 26 180 4.83 103 
H06 M 20 170 3.33 77 
H07 M 20 170 3.77 88 
H08 M 27 170 4.78 115 
H09 M 29 164 3.43 90 
H10 M 34 175 4.15 98 
H11 F 47 173 3.30 101 
H12 F 20 170 4.00 111 
H13 F 22 168 3.44 99 
H14 F 35 157 3.30 113 
H15 M 64 178 2.90 84 
Mean: 47% Male 30 [12] 170 [7] 3.59 [0.63] 96 [13] 
[ ], standard deviation; FEV1, forced expiratory volume in one second 
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Table 3.4. Hyperresponsive non-asthmatic participant demographics (n=7) 
Subject Age 
(yrs.) 
Gender Height 
(cm) 
Weight 
(kg) 
Mean 
Baseline 
FEV1 (L) 
Mean 
Baseline 
FEV1 (% 
predicted) 
PC20 
(mg/mL) 
1 20 M 178 73 3.58 76 n/a 
2 20 F 169 59 3.03 84 11 
3 29 M 173 70 3.21 76 15 
4 22 M 185 95 5.86 118 3.0 
5 22 M 180 80 4.40 92 4.2 
6 23 F 172 72 3.58 98 3.1 
7 20 F 173 59 3.47 93 6.4 
Mean: 22 [3] 4 M 
(57%) 
176 [6] 73 [12] 3.88 
[0.98] 
91 [15] 7.1 [4.9] 
[ ], standard deviation; FEV1, forced expiratory volume in one second; PC20, provocative 
concentration of methacholine causing a 20% fall in FEV1 
 
Twenty-two participants enrolled in the study; fifteen were non-hyperresponsive (Table 
3.3) and were used to generate the control MDRC. Seven participants (32%) were 
hyperresponsive (Table 3.4), with six having a positive methacholine challenge and one 
experiencing a significant response to the saline control (i.e. 27% fall in FEV1). If a participant’s 
methacholine challenge result was positive (PC20<16mg/mL), they were not included in the 
control group for comparison with the asthmatic results. Both groups of non-asthmatics reported 
some allergies; of the non-hyperresponsive group, one had an allergy to penicillin and one to cats 
(topical – hives); of the hyperresponsive group, one had an allergy to grass (topical – rash), one 
to peanuts (anaphylaxis), and one to spring pollens (disclosed post-MCT - possibly undiagnosed 
allergic rhinitis). Three former smokers were non-hyperresponsive, and no former smokers were 
hyperresponsive.  
3.7.2 Methacholine Dose-Response Curves and Slopes 
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Figure 3.1. Mean non-asthmatic (control), baseline and post-treatment MDRCs at 1 hour (A), 
24 hours (B), and 48 hours (C). The methacholine concentration causing a minimum 20% fall in 
FEV1 at baseline is designated as zero on the x-axis (i.e. corresponds to the final data point on 
baseline curves). Mean responses below (three) and above (five) comprise the post-treatment 
dose-response curves. Only data points with at least n=8 are included. The sample size for each 
curve is: n=15 for LAMA, n=16 for uLABA, and n=14 for combo.  
 
Mean asthmatic MDRCs for baseline, 1, 24, and 48 hours post-treatment for each drug 
and the mean non-asthmatic control MDRC are depicted in Figure 3.1 A-C. The mean non-
asthmatic control MDRC and the mean combo MDRC at one hour post-dose meet the study 
definition of a plateau (i.e. last three data points within 5%); both MDRCs formed a plateau 
between a 10-15% fall in FEV1. 
In terms of mean slopes (m), the uLABA (m=5.5, 6.0, and 6.6 at 1, 24, and 48 hours, 
respectively) did not differ significantly from baseline (m=10.4) at any time-point. Only the one-
hour LAMA slope (m=1.7) was statistically similar to the control slope (m=2.0; p=0.514). The 
LAMA at 1, 24 (m=4.2), and 48 hours (m=3.8) differed significantly from baseline (p=0.003, 
0.027, and 0.016, respectively). The combo differed significantly from baseline at 1 (m=3.0; 
p=0.021) and 24 hours (m=3.3; p=0.039), but not at 48 hours (m=4.4; p=0.067).  
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3.7.2.1 Individual Asthmatic Methacholine Dose-Response Curves 
 
Figure 3.2. Comparison of the mean asthmatic baseline MDRC with the one-hour post-treatment 
curves, graphed separately for each participant. The methacholine concentration causing a 
minimum 20% fall in FEV1 at baseline is designated as zero on the x-axis (i.e. corresponds to the 
final data point on baseline curves). Higher and lower methacholine concentrations 
administered are plotted as positive and negative x-values, respectively. Red = mean baseline; 
yellow = uLABA; orange = LAMA; green = combo  
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Individual asthmatic participants differed in terms of both the drug(s) producing the more 
favourable response and the changes in characteristics on the MDRC elicited by each treatment 
(Figure 3.2). Some participants did not reach a response plateau (i.e. three consecutive data 
points within 5%) with any treatment (i.e. A, G, J, M), while others developed a response plateau 
after one (i.e. B, F, H, I, K, L, O, P), two (i.e. N) or all three (i.e. D) treatments. The uLABA did 
not always appear to be the least beneficial medication (i.e. D, H, O). In the same fashion, the 
combo did not always appear to be the more beneficial treatment (i.e. A, B, I, J, M). 
3.7.2.2 Individual Non-Asthmatic Methacholine Dose-Response Curves 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Individual MDRCs of 15 non-hyperresponsive (A) and 6 hyperresponsive (B) non-
asthmatic participants.  
 
The non-asthmatic response to cholinergic stimulation could be divided into four 
subgroups; non-hyperresponsive participants (Figure 3.3.A) could be subdivided into a plateau 
group (n=8; mean slope=4.4 ±1.1), a near-plateau group that was one data point shy of a plateau 
(n=3; mean slope=11.6 ±2.9), and a non-plateau group (n=3; mean	 slope=15.1	 ±6.6); the 
hyperresponsive participants (Figure 3.3.B) could be grouped together (n=7; mean slope=24.6 
±2.5).  
A B 
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3.7.3 Methacholine Dose Shifts 
 
Figure 3.4. Mean methacholine dose shifts and their respective 95% confidence intervals for 
each treatment arm at 1, 24, and 48 hours post-dosing. The sample size for each treatment is: 
n=15 for LAMA, n=16 for uLABA, and n=14 for combo 
 
Table 3.5. Proportion of participants with a dose shift ≥ 1 doubling concentration post-treatment  
Time Post-Dose LAMA, n=15 uLABA, n=16 Combo, n=14 
1 hour 100% (15/15) 62.5% (10/16) 100% (14/14) 
24 hours 73.3% (11/15) 37.5% (6/16) 64.3% (9/14) 
48 hours 80% (12/15) 18.8% (3/16) 64.3% (9/14) 
LAMA; long-acting muscarinic antagonist; uLABA, ultra-long acting β2 agonist; Combo, 
combination LAMA/uLABA 
 
Mean methacholine dose shifts from baseline at 1, 24, and 48 hours post-treatment are 
illustrated in Figure 3.4. Geometric mean baseline PC20’s are 2.13 [1.32-2.95] for the LAMA, 
2.47 [1.83-3.11] for the uLABA, and 1.78 [1.21-2.34] for the combo therapy. The uLABA and 
combo were statistically different (p=0.024) from each other. 
The LAMA and combo treatments provided clinically significant protection against 
methacholine-induced bronchoconstriction at 1, 24 and 48 hours through dose shifts of 
approximately five, two, and two doubling concentrations, respectively. The uLABA only 
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provided clinically significant bronchoprotection at one hour with a dose shift of approximately 
1.5 doubling concentrations. All dose shifts post-LAMA and post-combo are equivalent. Both 
treatments differ significantly from the uLABA at 1 (p<0.00001) and 48 hours (p=0.012). The 
LAMA and uLABA differ significantly at 24 hours (p=0.049). Table 3.5 describes the proportion 
of participants receiving clinically significant bronchoprotection from each treatment over 48 
hours. 
3.7.4 Bronchodilation 
Table 3.6. Mean baseline and post-dose shifts in FEV1  
Treatment: Baseline FEV1 (L) FEV1 1 hour (L) FEV1 24 hours (L) FEV1 48 hours (L) 
LAMA 3.25 
[2.77-3.73] 
3.31 
[2.86-3.76] 
3.33 
[2.87-3.79] 
3.26 
[2.82-3.71] 
uLABA 3.32 
[2.91-3.72] 
3.31 
[2.91-3.72] 
3.34 
[2.94-3.73] 
3.29 
[2.89-3.69] 
Combo 3.16 
[2.70-3.62] 
3.25 
[2.77-3.72] 
3.26 
[2.78-3.74] 
3.32 
[2.83-3.81] 
[ ], 95% confidence intervals; FEV1, forced expiratory volume in one second; LAMA, long-
acting muscarinic antagonist; uLABA, ultra-long acting β2 agonist; Combo, combination 
LAMA/uLABA 
 
Baseline and post-treatment FEV1 data are described in Table 3.6. Mean baseline FEV1 
results for the LAMA, uLABA and combo did not differ significantly (p=0.060). No treatment 
produced significant bronchodilation; the combo produced the greatest improvement in FEV1 
(160mL increase from baseline at 48 hours post-treatment).  
3.8 Discussion 
The investigation of drug effects through changes on MDRCs provides interesting 
information on the bronchoprotective mechanisms while also differentiating individual 
responses. Beginning with the examination of the mean data, each treatment provided a distinct 
set of changes to the mean asthmatic MDRC. The LAMA glycopyrronium significantly reduced 
airway sensitivity and reactivity for at least 48 hours, and mildly reduced maximal 
responsiveness at 1 hour. The large degree of bronchoprotection and the lack of significant 
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bronchodilation observed post-LAMA confirm the findings of the first study and reinforce the 
fact that LAMA therapy could be clinically beneficial for some asthmatics (Blais et al. 2016). 
The minimal improvement in FEV1 capacity was again unsurprising given the mild (if any) 
airway constriction at rest in the study population. Interestingly, the one-hour post-LAMA 
MDRC is nearly identical to the non-asthmatic control curve in terms of position and slope, but 
lacks a response plateau. Combination therapy does not appear to act synergistically or additively 
with respect to airway sensitivity and reactivity, as LAMA monotherapy produced the largest 
rightward shift (i.e. a doubling dose shift of approximately five) and reduction in slope. The shift 
in methacholine PC20 following LAMA treatment was not surprising as this drug is reported to 
be a competitive inhibitor of cholinergic activity. However, the shape of the one-hour LAMA 
curve indicates both non-competitive (decrease in maximal response) and competitive (rightward 
shift) antagonism may be occurring and that various mechanisms may be involved. 
Several potential mechanisms may explain the MDRC changes observed post-LAMA. A 
study investigating the effects of glycopyrronium in guinea pig trachea preparations observed the 
blockage of calcium release and signaling, which resulted in the inhibition of ASM contractility 
(Fukunaga et al. 2016). This may have been a factor in the small reduction in maximal 
responsiveness observed at one hour. Although the study timeline may have been too short for 
anti-airway remodeling mechanisms to have a significant impact, it is possible that the LAMA 
prevented airway remodeling to some degree, which would again reduce the maximal response 
attained; in guinea pig trachea preparations, tiotropium was observed to inhibit airway wall 
thickening and the hypertrophy of mucous glands (Bos et al. 2007).  
In terms of the significant improvement in airway sensitivity post-LAMA, competitive 
receptor binding and anti-inflammatory properties may be involved. The prevention of 
cholinergic binding to M1 and M3 receptors in particular could inhibit any abnormal autonomic 
cholinergic control (i.e. excessive bronchoconstriction). Anti-inflammatory effects may be less 
likely given the single dose, short follow-up study design. However, it is possible that 
glycopyrronium is inhibiting the release and activity of various inflammatory mediators. In 
mouse models of COPD, this LAMA prevented the accumulation of IL-1β and TNFα that 
normally occurs after cigarette smoke exposure (Shen et al. 2014). Tiotropium has also been 
shown to possess anti-inflammatory properties; in mouse models of asthma that had been acutely 
or chronically challenged with ovalbumin (used to induce AHR and airway remodeling), pre-
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treatment with tiotropium inhibited the production of eosinophils and Th2 cytokines, which are 
common inflammatory mediators involved in the allergic response during an asthma 
exacerbation (Ohta et al. 2010). 
With regards to reduced airway reactivity, only the LAMA at one hour produced a slope 
that was statistically similar to the control curve slope. This is a desirable feature of a respiratory 
medication, as reactivity represents the speed of onset of asthma symptoms during an 
exacerbation, also referred to as “breakthrough” bronchoconstriction (Löfdahl & Chung 1991; 
Wong et al. 1997; Lipworth et al. 1998). The LAMA-induced improvement in airway reactivity 
is likely the result of a combination of mechanisms involved in airway sensitivity and maximal 
responsiveness. Altogether, the significant and persistent bronchoprotective mechanisms 
triggered by LAMA therapy merit further investigation to inform clinical decision-making as 
LAMAs become more commonly used for asthma. 
The effects produced by the uLABA indacaterol draw a sharp contrast to those observed 
post-LAMA; the uLABA only produces a mild reduction in airway sensitivity (i.e. a 1.5 
doubling dose shift) at 1 hour and loses clinical significance by 24 hours. This low degree of 
bronchoprotection was unexpected given that the uLABA olodaterol has been shown to produce 
at least 32 hours of significant bronchoprotection against methacholine (O’Byrne et al. 2009). 
SABAs (e.g. salbutamol) and LABAs (e.g. formoterol, salmeterol) have also been shown to 
reduce airway sensitivity more significantly than was found with indacaterol; at 1 hour post-
dose, 200µg salbutamol produced a dose shift of 2 (Derom et al. 1992), 50µg salmeterol 
produced a dose shift of 2-3.3 (Cheung et al. 1992; Derom et al. 1992; Bhagat et al. 1996), and 
24µg formoterol produced a dose shift of 4 doubling concentrations of methacholine (Ramsdale 
et al. 1991). The uLABA indacaterol did not appear capable of outcompeting methacholine-
induced bronchoconstriction for long. It is possible that coughing soon after treatment inhalation 
may have led to the exhalation of a significant amount of the drug particles. Coughing occurred 
in half of the study sample during the uLABA monotherapy arm and was rare in the other two 
treatment arms. This observation has been made previously, where a large clinical trial of n=416 
reported that 17.8% of participants coughed within 15 seconds of having inhaled indacaterol 
(Feldman et al. 2010).  
A physiological theory for the rapid loss of any uLABA-induced effects may be the result 
of receptor desensitization; when activated for a prolonged period of time, β2 receptors 
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eventually trigger their own desensitization. β2 receptors initiate an intracellular pathway that 
leads to protein kinase A (PKA) production. As PKA accumulates, it activates G-protein-coupled 
receptor kinases (GRKs) that phosphorylate and uncouple activated β2 receptors by triggering the 
recruitment of β-arrestin, a molecule that deactivates Gs proteins (Shenoy & Lefkowitz 2003). 
Unimpeded M3 receptor activity also desensitizes β2 receptors, as M3 receptor activation 
promotes the Gq protein-mediated production of protein kinase C (PKC); PKC has a similar 
influence on β2 receptors as PKA, and additionally reverses the β2 agonist-induced inhibition of 
myosin light-chain kinase, an important enzyme for triggering ASM contraction (Barisione et al. 
2010). 
Despite the lack of any apparent synergistic effects on airway sensitivity and airway 
reactivity, combination therapy did alter maximal responsiveness. Both LAMA monotherapy and 
LAMA/uLABA combination therapy produced virtually identical dose shifts in methacholine 
responsiveness at all time-points, but only the combination produced a response plateau similar 
to that observed with the control group. Perhaps no further significant reduction in airway 
sensitivity and reactivity is possible beyond that produced by the LAMA therapy. 
A theory for the synergistic development of a response plateau relies on the increased 
activity of β2 receptors as a result of M2 and M3 inhibition by the LAMA. M2 receptors, when 
activated, inhibit cAMP formation and stimulate the opposite G protein (Gi) to that triggered by 
β2 receptor activity. Therefore, through the concomitant use of a muscarinic antagonist with a β2 
agonist, the latter’s stimulation of cAMP production could be unimpeded, and M3 receptors are 
unable to trigger β2 receptor desensitization as discussed previously. With full, unobstructed β2 
receptor activity, it is possible that the uLABA and LAMA initiate complimentary inhibition of 
calcium signalling, which results in a stronger block on ASM contractility. The uLABA is 
anticipated to block calcium through its stimulation of the production of PKA, which deactivates 
IP3 and consequently inhibits calcium release from the sarcoplasmic reticulum (SR) (Barisione et 
al. 2010). PKA also promotes calcium/sodium exchange, which depletes cells of intracellular 
calcium, and stimulates both sodium/potassium ATPase and calcium-activated potassium 
channels (Gunst & Stropp 1988; Twort & van Breemen 1989; Kume et al. 1992). These 
mechanisms together result in the hyperpolarization of ASM cells and the inhibition of airway 
contractility. LAMAs in turn prevent IP3 production through their blockage of M3 receptor 
activity, which then prevents intracellular calcium levels from increasing sufficiently to trigger 
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contractile mechanisms (Meurs et al. 1988; Buels & Fryer 2012). LAMA blockage of M2 
receptors also reduces ASM contractility, as the inhibition of M2-stimulated Gi protein activation 
prevents cyclic ADP-ribose from mediating calcium release via the ryanodine receptor channels 
in the SR (Jude et al. 2008). These known mechanisms of action for uLABAs and LAMAs 
should together block airway contractility and consequently excessive airway narrowing to a 
greater degree than either monotherapy.  
It is interesting to note that while the LAMA and combo therapies produced equivalent 
mean dose shifts at all time-points, the LAMA shifted the MDRC further to the right (i.e. larger 
reduction in airway sensitivity) than did the combo. A potential explanation for this difference 
could be that a uLABA-induced increase in airway cilia beat frequency coupled with the LAMA-
induced block on further mucus production temporarily leads to some airflow obstruction 
(Bennett 2002); the airways may be temporarily obstructed by the mucus layer that is being 
moved by the airway cilia up the airways towards the oesophagus to be swallowed.  
One last potential observation of synergism may be the bronchodilation found post-
combination therapy. Of the three treatment arms, the combo produced the largest increase in 
FEV1, which improved by 160mL at 48 hours post-combo. This is not clinically significant in 
this study population, as published guidelines for significant post-bronchodilator FEV1 
improvement is a minimum of 200mL (American Thoracic Society 1995). Despite not being 
clinically significant, this bronchodilation may be the product of either boosted β2 receptor 
activity due to concomitant LAMA use or perhaps due to the mean baseline FEV1 pre-combo 
being lower (albeit not significantly) than that prior to the other two treatments. 
Although the mean data present interesting findings that allow for the differentiation 
between each treatment, the individual data shown in Figure 3.2 reflect how variable individual 
responses to treatments can be. This variability may be related to the various asthma phenotypes 
and could be the result of several factors such as the specific pathophysiologies involved and 
their severity as well as potential long-term effects from previous treatments used. These 
findings illustrate the relevance of modernizing health care to personalized medicine, as asthma 
treatments are not one-size-fits-all. Future research should aim to identify a set of feasible 
procedures to perform in patients in order to more accurately determine which drug will be of 
most benefit for them. The ideal drug is particularly effective at minimizing excessive airway 
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narrowing (i.e. reducing maximal responsiveness), as this symptom if unmitigated causes 
asthma-related deaths. 
Finally, with regards to the non-asthmatic participants recruited, it was unexpected that so 
many (32%) of these asymptomatic individuals would demonstrate AHR. The variability in 
MDRC shape within the non-asthmatic non-hyperresponsive group was also worth noting. For 
example, not all non-hyperresponsive individuals developed a response plateau, and the closer a 
participant’s PC20 was to 16mg/mL, the more likely their MDRC would be exponential in shape. 
Unfortunately, the sample size of non-asthmatics precluded any statistical analyses, such as a 
comparison of the MDRC slopes of each subgroup (i.e. plateau vs. near-plateau vs. non-plateau 
vs. hyperresponsive group).  
The characteristic of the MDRC that is typically described as the most serious problem 
for hyperresponsive individuals is the loss of protective mechanisms that minimize airway 
narrowing, resulting in an exponential curve (Woolcock et al. 1984; Moore et al. 1996). This is 
an oversimplification, as AHR is a dynamic process and as such MDRC shapes can change; for 
example, studies have shown the reversal of hyperresponsiveness over time in previously 
hyperresponsive non-asthmatics (Rijcken et al. 1993; Van Den Nieuwenhof et al. 2008). AHR 
also appears to result from several mechanisms, especially since the recruited sample of non-
hyperresponsive non-asthmatics did not all show a response plateau.  
Interestingly, past studies have linked AHR to factors such as smoking and a family 
history of respiratory illness (Burney et al. 1987; Woolcock et al. 1987; Gray et al. 2000) and yet 
neither was present in the hyperresponsive sample. While AHR does not necessarily correlate 
with asthma development, evidence has shown that atopy is strongly correlated with the 
condition, which was present in some of the hyperresponsive sample (but only one produced 
asthma-related symptoms) (Van Den Nieuwenhof et al. 2008). Several suggestions have been put 
forth to explain asymptomatic AHR, but studies have been largely divided on the issue 
(Woolcock et al. 1987; Pin et al. 1993; Laprise & Boulet 1997; Salome et al. 1997; Laprise et al. 
1999; Boulet 2003; Boulet et al. 2006; Yoshikawa & Kanazawa 2011). We are left wondering if 
these individuals have a higher risk of developing asthma or if they simply have a “nonnegative” 
methacholine challenge due to high test sensitivity (Cockcroft & Davis 2010). It is worth noting 
that the MDRCs of hyperresponsive asymptomatic non-asthmatics resembled those of asthmatics 
in terms of seemingly excessive airway narrowing. The significant response post-diluent in one 
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participant and the PC20 <8mg/mL in four hyperresponsive non-asthmatics also closely 
resembles responsiveness observed in mild asthmatics.  
Our findings provide important preliminary information on the usefulness of 
glycopyrronium and indacaterol alone and in combination in mild asthmatics based on their 
effects on the MDRC. While indacaterol produced little benefit, glycopyrronium and 
combination therapy both provided significant bronchoprotection with regards to reduced airway 
sensitivity and reactivity to cholinergic stimuli. Only combination therapy significantly protected 
against excessive airway narrowing through the formation of a response plateau. This 
physiological benefit is important for preventing asthma-related deaths. Future studies examining 
the physiological effects of the study drugs in human in vivo models would be beneficial for 
informing clinical decision-making, particularly given that asthma patients exhibit a wide range 
of phenotypes.  
4.0 GENERAL DISCUSSION 
As we move forward in drug development research for the treatment of asthma, it is 
important that studies maintain pace and explore these new medications for their influence on 
current research and clinical practices. Knowledge on the duration, degree, and characteristics of 
bronchoprotection provided by various treatments against methacholine-induced 
bronchoconstriction is important not only for ensuring continued MCT data accuracy but also for 
guiding future physiological research.  
We focused particularly on LAMAs and uLABAs, both of which are the subjects of 
ongoing research exploring their use in asthmatics. We first wished to inform MCT 
standardization guidelines of an appropriate, scientifically confirmed abstinence period from 
LAMAs. We succeeded in identifying that a single administration of the recommended dose of 
glycopyrronium or tiotropium each only provides clinically significant bronchoprotection for up 
to seven days. We were therefore able to make the recommendation that LAMAs should be 
avoided for at least seven days prior to undergoing MCT.  
The first study was not without its limitations. For example, our findings after a single 
dose of each LAMA may not be equivalent to that found with regular daily dosing. Future 
studies could thus investigate long-term daily-use of LAMAs to determine if such a regimen 
significantly influences perceived drug effects through MCT. An inherent limitation to this type 
of study is the severity of asthma that can be tested through MCT – perhaps the drug effects may 
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be significantly shorter (or longer) in more severe asthmatics who are more likely to be taking 
such medications, but MCT is not advisable in that patient population given their more severe 
airway constriction at rest and their need for daily therapy. To gain a better appreciation of the 
bronchoprotection provided by LAMAs against real-world constricting stimuli (cholinergic 
stimuli are highly unlikely in one’s every day environment), studies could explore these 
medications through allergen or indirect bronchoprovocation testing.  
Following the unexpected MDRC results from the first study, we sought in the second 
study to confirm our findings and to explore the newly developed uLABA drug class. The well 
established drug classes of ICS, SABAs, and LABAs have each been thoroughly studied for their 
influence on the MDRC of asthmatics through which important information about 
bronchoprotective mechanisms and long-terms effects has been elucidated. Our study was the 
first to explore a LAMA and a uLABA for their individual and combined effects on the MDRC 
of mild asthmatics. With regards to the mean data, we were able to distinguish the LAMA and 
combination therapies from the uLABA, as the former two produced comparable and significant 
improvements in airway sensitivity and reactivity while the latter afforded only a mild 
improvement in airway sensitivity. Interestingly, only the mean combination MDRC at one hour 
produced a response plateau like the non-asthmatic control MDRC; however, the one-hour 
LAMA curve most resembled that of the control despite not producing a response plateau. 
Altogether, the mean data suggest that LAMAs and combination LAMA/uLABAs are 
worthwhile to consider for use in asthmatics and merit further investigation to identify the 
asthma phenotypes most likely to benefit from their use. 
The individual asthmatic results present more complex findings that reflect how mean 
data can oversimplify study findings. The high variability in response to each treatment is not 
surprising, considering how different the study participants can be from each other in terms of 
pathophysiology, genetics, and environment. The movement towards the practice of more 
personalized medicine seems highly appropriate for this respiratory condition given our findings. 
The non-asthmatic group presented a variety of MDRC shapes and raised questions as to 
long-standing assumptions regarding “normal” responsiveness to methacholine.  The absence of 
a measurable plateau in some non-hyperresponsive participants agrees with previous findings 
that a plateau is not necessary in asthmatics for attaining satisfactory control of asthma 
symptoms (Prieto et al. 1999). AHR and accompanying asthma stem from a combination of 
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factors, which likely cannot be differentiated fully through MDRCs. Nonetheless, the majority of 
non-hyperresponsive participants achieved or almost achieved the expected response plateau at a 
low percent fall in FEV1 (<15% fall). These data were valuable as control references to better 
visualize the improvements in lung function provided by the study treatments in the asthmatic 
participants. The unexpected high prevalence of asymptomatic AHR in the study population 
presents this phenomenon as a worthy subject for further investigation of its long-term 
implications, especially since these study participants were devoid of most known causative 
factors of AHR (e.g. family history of respiratory illness, respiratory symptoms, smoking).  
As with the first study, the MDRC investigation possessed several limitations. Although 
inferences could be made regarding each treatment’s physiological mechanisms based on current 
knowledge of MDRCs, these remain speculative until further studies are performed, preferably in 
human models. Again, investigations of drug effects after a single dose may not accurately 
reflect what would be observed with long-term treatment; however, such studies do help in 
establishing the initial treatment response and are not biased by patient adherence (only one 
dose). The range of methacholine concentrations available and the safety rules used for 
determining when to stop a methacholine challenge also limit the extent to which plateau 
development and overall responsiveness can be examined on the MDRC. Such limitations are 
difficult to overcome considering the high cost and available doses of methacholine as well as 
the need to maintain patient comfort and safety during testing. Insufficient information on 
individual participants’ phenotypes and history of asthma was gathered, which precluded any 
correlation analyses between phenotypes and resulting responses to the treatments.  
With the non-asthmatic data, we did not foresee the large percentage of participants with 
AHR and so, our protocol did not incorporate specific questions for these participants to better 
understand their past and whether they have in fact experienced similar symptoms as those 
induced by methacholine. In addition, retrospective statistical analyses of the non-asthmatic 
slope data could not be performed due to the small sample size. Finally, in the hyperresponsive 
non-asthmatic participants, MCT was stopped at a 20% fall in FEV1 per our protocol, which 
prevented the accurate determination of the maximal response plateau or lack thereof; regardless, 
this is the typical stopping criterion for MCT and so, asthmatic responsiveness to methacholine is 
usually affected by the same limitation.  
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The ideal system for the personalized treatment of asthma would feature a set of objective 
tests for determining which treatment option is most appropriate for a given patient. Future 
studies could therefore focus on developing one such system perhaps through the identification 
and differentiation of different markers of inflammation and/or airway remodelling by phenotype 
in addition to MCT. Further research into asymptomatic AHR could also prove beneficial, 
particularly if we were able to distinguish transient AHR from potentially asthma-causing AHR. 
Whether all uLABAs behave like indacaterol on the MDRC could be an interesting investigation, 
considering the small degree of bronchoprotection observed in this study in comparison with the 
significant finding with olodaterol found in a previous study (O’Byrne et al. 2009). LAMAs and 
LAMA/uLABA combinations could also be examined with ICS co-therapy, given that these 
combinations are recommended for poorly controlled asthma. 
In summary, the LAMAs tiotropium and glycopyrronium were found to produce 
significant and persistent bronchoprotection against methacholine-induced bronchoconstriction 
for seven days, which reinforces the importance of such studies considering that standardization 
guidelines originally recommended only a 48-hour abstinence period from LAMAs (except 
tiotropium). Glycopyrronium also provided significant reductions in airway sensitivity and 
reactivity, both of which are important characteristics of AHR. In addition to significant 
reductions in airway sensitivity and reactivity, combination glycopyrronium/indacaterol was the 
only study treatment to produce a mean response plateau, an important feature for preventing 
asthma related deaths through excessive airway closure. With further experimentation, LAMAs 
and combination LAMA/uLABA therapies may prove to be valuable for the effective and long-
term treatment of asthma symptoms and progression. 
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a b s t r a c t
The duration of bronchoprotection against methacholine-induced bronchoconstriction by long-acting
muscarinic antagonists (LAMA's) in asthmatics and whether these drugs differ in their pharmacody-
namic properties remain to be determined. The most recent published guidelines for methacholine
challenge testing (MCT) suggest that LAMA's should be abstained from for 48 h prior to testing, perhaps
one week in the case of tiotropium.
The objectives were to determine and compare the duration of protection of a single dose of two
different LAMA's, tiotropium and glycopyrronium, against methacholine-induced bronchoconstriction.
Thirteen mild-to-moderate asthmatics [with a forced expiratory volume in 1 s (FEV1) > 65% of pre-
dicted and a baseline methacholine provocation concentration causing a 20% reduction in FEV1
(PC20) ! 8 mg/mL] completed this double-blind, double-dummy, crossover study. Methacholine chal-
lenges were performed before treatment (5 mg tiotropium or 50 mg glycopyrronium) and at 1, 24, 48, 72,
96 and 168 h post-treatment. The minimum duration between treatment administration was 11 days.
Both drugs provided significant bronchoprotection, each producing greater than a 16-fold increase in
mean PC20 by 1 h. Tiotropium still provided statistically significant protection at 7 days (p ¼ 0.0282)
while glycopyrronium provided bronchoprotection until day 7 (p ¼ 0.0590). Tiotropium provided sta-
tistically superior bronchoprotection at 24 and 72 h compared to glycopyrronium.
To minimize the occurrence of false negatives, MCT guidelines should be updated to recommend a
minimum one-week abstinence period from all LAMA's. MCT was also able to statistically differentiate
between tiotropium and glycopyrronium with respect to the degree and duration of bronchoprotection
provided by each.
Clinical trial registration number: NCT02622243.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Asthma is a respiratory condition that causes either persistent or
sporadic airway hyperresponsiveness (AHR) in response to a vari-
ety of triggers [1]. Although the exact cause of asthma remains
unknown, it is believed that genetic and environmental factors
contribute to its development [2]. In order to treat patients with
varying symptoms and severity of asthma, a range of pharmaceu-
tical agents have been developed. Short-acting bronchodilators
(e.g. salbutamol) are used to alleviate symptoms in the event of an
acute exacerbation. For more severe asthmatics, common drug
regimens include inhaled corticosteroids (ICS) for reducing airway
inflammation taken as amonotherapy or in combinationwith long-
acting beta agonists (LABA's). Recently, the safety of long-term use
of LABA's as a monotherapy has been questioned, as they appear to
significantly reduce beta agonist efficacy and may lead to more
severe asthma exacerbations [3,4].
Due to increased demand for more effective treatment regi-
mens, research has now begun to examine the use of long-acting
* Corresponding author. Division of Respirology, Critical Care and Sleep Medicine,
Department of Medicine, University of Saskatchewan, 103 Hospital Drive, Ellis Hall,
5th Floor, Saskatoon, SK S7N 0W8, Canada.
E-mail address: don.cockcroft@usask.ca (D.W. Cockcroft).
Contents lists available at ScienceDirect
Respiratory Medicine
journal homepage: www.elsevier .com/locate/rmed
http://dx.doi.org/10.1016/j.rmed.2016.07.017
0954-6111/© 2016 Elsevier Ltd. All rights reserved.
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muscarinic antagonists (LAMA's) in combination with ICS, and as
triple therapy with ICS plus LABA [5,6]. LAMA's function by selec-
tively inhibiting muscarinic M1 and M3 receptors and slowly
dissociating from them, thereby generating a long duration of ac-
tion [7]. Unlike the short-acting muscarinic antagonist ipratropium
bromide (IB), LAMA's are more selective and do not greatly inhibit
M2 receptors, which are key for preventing the excessive presyn-
aptic release of the bronchoconstrictor acetylcholine. A number of
LAMA's such as tiotropium and glycopyrronium have been devel-
oped and are approved for use in chronic obstructive pulmonary
disease (COPD). Currently, the only LAMA included in the Global
Initiative for Asthma (GINA) report ‘Global Strategy for Asthma
Management and Prevention (2016 update)’ is tiotropium [8].
Given incorporation of LAMA's into asthma treatment regimens,
it is important to know the impact of such medications on diag-
nostic tests. One of the most common diagnostic tests used in
asthma research and clinical practice is the methacholine (MCh)
challenge. This test is typically used for confirming or refuting a
physician diagnosis of asthma [9]. A number of factors, including
concomitant medications, have been found to influence the accu-
racy of this diagnostic test, thereby contributing to false negative
results. To establish a standard testing protocol for accuracy and
safety purposes, the American Thoracic Society (ATS) published a
set of guidelines for MCT which includes suggested abstinence
periods from several classes of pharmaceuticals [9]. Due to the
various durations of pharmacological effects, the ATS guidelines
suggest withholding long-acting bronchodilators for 48 h and
possibly one week for tiotropium [9]. However, the references
provided to support these washout periods only investigated the
duration of action of single doses of LABA's [10,11]. It may be
inappropriate to generalize these results to all long-acting bron-
chodilators, as LABA's and LAMA's have completely different
mechanisms of action.
The two LAMA's examined in this study, tiotropium and glyco-
pyrronium, are both potent antimuscarinic quaternary ammoniums
that are widely used, once-daily medications for COPD [12,13].
These treatments are generally well tolerated with a good safety
profile [12,14]. The most common side effect reported for both
drugs is xerostomia, which is caused by the inhibition of acetyl-
choline signaling, the neurotransmitter responsible for saliva pro-
duction via M1 and M3 receptor activation [12].
Few studies have examined the duration of effect of single doses
of LAMA's in asthmatics and no study has captured the effect in its
entirety. We hypothesized that these two drugs would have similar
efficacy against methacholine-induced bronchoprotection in
asthma and that the duration protection would be greater than
48 h.
2. Methods
2.1. Participants
Eligible participants were at least 19 years of age, had a MCh
PC20 ! 8 mg/mL and had baseline lung function (% predicted FEV1)
of 65% or greater. None had taken any anticholinergic agent within
30 days nor had they suffered a respiratory tract infection within 4
weeks of study entry. No participants were taking inhaled corti-
costeroids as a monotherapy. Known contraindications for MCT
include pregnant or nursing women, and those suffering from
cardiovascular or prostate problems, kidney or urinary retention
problems, or glaucoma. Such participants were excluded. Consent
was obtained from all participants prior to commencing the study.
The study was approved by the University of Saskatchewan
Biomedical Research Ethics Board (Bio-REB 15e254).
2.2. Methacholine challenge test
The MCT method used was the 2-min tidal breathing dosing
protocol outlined in the ATS guidelines for MCT [9]. The protocol
was completed with the Bennett Twin jet nebuliser (Puritan Ben-
nett Corporation, Carlsbad, CA), which was calibrated to produce an
output of 0.13 mg/mL prior to beginning the study. For each testing
session, spirometry was first performed to obtain a baseline FEV1
with the highest (peak) FEV1 being used for further analysis. For the
tidal breathing protocol [9], the participant wore nose clips and
calmly inhaled nebulised aerosol through a loose-fitting facemask
for 2 min. Spirometry was then performed at 30 and 90 s post-
inhalation to determine the resulting change in FEV1. The next
inhalation was started 5 min following the start of the previous
inhalation. Aerosolized saline (0.9%) was administered first and
subsequent inhalations consisted of doubling concentrations of
MCh. This procedure was repeated until a fall in FEV1 of 20% or
more occurred. Post-dose, a maximum MCh concentration of
256 mg/mL could be administered to achieve a 20% fall in FEV1,
thereby allowing for interpolation or extrapolation to determine
the MCh PC20. If the maximum MCh concentration was adminis-
tered and the fall in FEV1 was only between 10 and 20%, the PC20
was extrapolated from the log dose vs. response curve algebraically.
If the FEV1 fell by less than 10% at the maximum MCh concentra-
tion, the MCh PC20 was arbitrarily set at 1024 mg/mL.
2.3. Study design
This was a randomised, double-blind, double-dummy, crossover
study. For each treatment arm, participants underwent baseline
MCT followed by treatment inhalation and MCT at 1, 24, 48, 72, and
96 h post-treatment. Each MCT was performed at the same time of
day and a minimum of 11 days elapsed between doses. Initially,
testing on day 7 was only performed in participants who showed
persistent bronchoprotection at 96 h. It was subsequently recog-
nized however, that statistical analysis would be weakened if a
participant had data until day 7 on one drug, but only data until
96 h post-treatment on the other study drug. Following this, all
remaining participants underwent 168 h post-dose MCT for both
treatments.
2.4. Study drugs and blinding
Inhalers were pre-loaded with active and placebo capsules
(Breezhaler®) or canisters (Respimat®); both participants and the
administering investigator were blinded to the treatment. For each
treatment, participants took two inhalations from a Respimat and
two inhalations (from the same capsule) from a Breezhaler (one
active and one placebo), holding their breath for 5 s after each
inhalation. The glycopyrronium treatment arm consisted of a dose
of 50 mg and the tiotropium treatment arm consisted of a dose of
5 mg. The treatments were administered in random order.
2.5. Statistical analysis
With a sample size of thirteen participants, the power of this
study was greater than 85% for detecting a half concentration dif-
ference in MCh PC20. PC20 data was log-transformed before further
analysis. Bronchoprotection was assessed as the dose shift in MCh
PC20 [dose shift ¼ (DlogMCh PC20)/0.3]. Paired t-tests were used to
compare treatment differences in PC20 dose shift and in baseline
FEV1. Repeated measures analysis of variance was performed to
compare dose shifts and baseline FEV1 data between the two drugs.
Results are reported as mean data ± standard error of mean (SEM),
unless otherwise stated. Significance was set at 0.05.
C.M. Blais et al. / Respiratory Medicine 118 (2016) 96e101 97
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3. Results
3.1. Participants
Eighteen non-smoking subjects with physician-diagnosed mild-
to-moderate asthma were recruited from the local community and
thirteen of them (8 males, 5 females) completed the study (see
Table 1). Five participants were excluded; four did not have a
positive MCh challenge and one did not have an adequate baseline
FEV1. No unexpected serious adverse effects occurred. Reported
side effects were mild and included topical dryness, shortness of
breath, chest tightness, muscle stiffness, and headaches. All were
known side effects of either drug or of MCT, and subsided without
the need for intervention.
3.2. Bronchoprotection
Dose shift data and MCh PC20 values for both treatments are
shown in Fig. 1 and Table 2 respectively. Both treatments signifi-
cantly increased the amount of MCh required to cause a 20%
decrease in FEV1 by more than 16-fold at 1 h. Tiotropium and gly-
copyrronium each continued to provide clinically significant
bronchoprotection at 96 h (p-0.0010 and p ¼ 0.0122, respectively),
as shown in Fig. 2. At 168 h, tiotropium provided statistically sig-
nificant bronchoprotection (p ¼ 0.0282, n ¼ 10) while glyco-
pyrronium did not (p ¼ 0.0590, n ¼ 9).
Tiotropium appears to be superior to glycopyrronium until the
168 h time-point. Tiotropium provided significantly more bron-
choprotection than glycopyrronium at 24 h (p ¼ 0.0058) and 72 h
(p ¼ 0.0082) post-treatment, and approached statistical signifi-
cance at 48 h (p ¼ 0.0503) and 96 h (p ¼ 0.0568). Paired t-tests of
the dose shift produced by each drug at 1 h and at 7 days post-
treatment showed no statistical difference between the two
treatments (p ¼ 0.8651 and p ¼ 0.2123 respectively).
3.3. Bronchodilation
Overall, mean peak FEV1 data only differed significantly from
baseline at 24 h post-glycopyrronium, as shown in Table 3. In terms
of mean shift in peak FEV1 and the 95% confidence intervals, gly-
copyrronium provided an average increase in volume of 90 mL,
from 3.65 L [3.00, 4.29] at baseline to 3.74 L [3.12, 4.37] at 24 h post-
treatment. Borderline statistically significant shifts in mean peak
FEV1 from baselinewere observedwith glycopyrronium at 1 h post-
treatment and with tiotropium at 24 h post-treatment. No
significant difference in mean FEV1 was observed between the two
treatment arms at any point.
3.4. Post hoc analysis of MCh dose-response curves
Fig. 3 shows that the mean MCh dose-response curves prior to
each treatment arm did not appear to plateau (i.e. produce a
maximal response to MCh). At 1 h post-treatment, both drugs
shifted the curve to the right and produced a plateau.
4. Discussion
Given the gap of knowledge in current literature on LAMA use in
asthmatics, the primary objective of this study was to determine
the duration of bronchoprotection provided by tiotropium and
glycopyrronium against methacholine-induced bronchocon-
striction. Previously, O'Connor et al. found that different dosages of
tiotropium provide bronchodilation for up to 24 h and dose-
dependent bronchoprotection for at least 48 h in twelve mild-to-
moderate asthmatics [15]. With a reduced sample size of four,
they also found persistent bronchoprotection at 72 h post-
Table 1
Participant demographics.
Participant Gender Age (yrs.) Height (cm) Pre-GLY FEV1 (% predicted) Pre-TIO FEV1 (% predicted) PC20 Pre-GLY (mg/mL) PC20 Pre-TIO (mg/mL)
1 M 69 168 72 77 1.0 1.4
2 M 39 178 88 85 1.2 0.64
3 M 22 183 83 82 6.4 7.2
4 F 22 173 96 96 0.98 1.2
5 M 31 196 99 96 1.1 3.4
6 F 27 168 102 96 1.5 2.4
7 M 24 178 100 99 1.1 1.1
8 M 29 185 105 105 10.0 7.0
9 M 44 175 95 95 7.1 7.6
10 F 28 160 89 91 1.4 3.4
11 M 20 185 76 94 0.78 0.73
12 F 21 170 79 80 0.66 1.5
13 F 24 147 68 76 0.36 0.16
Mean: 62% M 31 [13] 174 [12] 89 [12] 90 [10] 2.6a 2.9a
Standard deviation.
GLY; glycopyrronium, TIO; tiotropium.
a Geometric mean.
Fig. 1. Mean dose shift and standard error at various time points following treatment
with tiotropium (TIO) and glycopyrronium (GLY). The sample size was 13 except for
TIO at 96 h (n ¼ 12), TIO at 168 h (n ¼ 10) and GLY at 168 h (n ¼ 9). P values represent
the difference between the treatment arms at the given time points.
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treatment. Hansel et al. performed a similar study comparing
bronchoprotection provided by IB versus three different dosages of
glycopyrronium in ten mild-to-moderate asthmatics [16]. They
found that while IB provides more bronchoprotection at 2 h post-
treatment, bronchoprotection by glycopyrronium is greater at 12,
24 and 30 h post-dose. Unfortunately, in both of these studies,
participants were not followed until the drugs had lost all effect and
so, the complete duration of bronchoprotection provided by each
treatment remains unknown.
The results from this study reflect that bronchoprotection pro-
vided by glycopyrronium lasts up to 7 days while tiotropium still
provides statistically significant bronchoprotection at 7 days.
However, it should be noted that clinically significant broncho-
protection is defined as a shift in MCh PC20 that is greater than one
doubling concentration of MCh. Therefore, while tiotropium did
provide statistically significant bronchoprotection at 7 days
compared to pre-treatment, neither tiotropium nor glyco-
pyrronium provided clinically significant bronchoprotection at 7
days. Initially, participants only completed day 7 of testing if they
still showed significant bronchoprotection at 96 h. This resulted in
reduced sample sizes on day 7 for both treatments and it is possible
that neither drug may have been found to be significant at 7 days
Table 2
MCh PC20 data.
MCh PC20 (mg/mL) at:
Baseline 1 h 24 h 48 h 72 h 96 h 168 h
Tiotropium treatment arm: 2.9 (0.74) 199 (104) 74 (35) 57 (38) 97 (78) 44 (31) 9.6 (4.4)
Glycopyrronium treatment arm: 2.6 (0.86) 202 (104) 29 (14) 25 (13) 11 (5.3) 17 (10) 4.7 (1.6)
Baseline and post-treatment PC20 data presented as geometric means (SEM).
Fig. 2. Individual MCh PC20 values at pre-treatment and at 96 h post-dose for each drug. Single data points represent geometric mean and SEM values. P values represent the
difference between the PC20 values at 96 h versus those values at baseline within the same treatment arm.
Table 3
Mean peak FEV1 at each time point during both treatment arms.
Mean peak FEV1 values at:
0 h 1 h 24 h 48 h 72 h 96 h 168 h
Tiotropium 3.70 3.70 (0.091) 3.82 (0.058) 3.71 (0.931) 3.66 (0.506) 3.75 (0.817) n ¼ 12 3.36 (0.158) n ¼ 10
Glycopyrronium 3.65 3.75 (0.053) 3.74 (0.005*) 3.70 (0.174) 3.65 (0.880) 3.66 (0.671) 3.40 (0.697) n ¼ 9
P values in brackets.
Sample sizes are specified if different from n ¼ 13.
*p < 0.05.
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had all participants completed day 7 testing. Nonetheless, these
findings suggest that current guidelines for MCT need to be upda-
ted to account for the significantly longer duration of broncho-
protection provided by LAMA's than the currently suggested 48 h
and “perhaps 1 wk for tiotropium” [9].
The secondary objective of this study was to compare the two
LAMA's in order to determine if there is any difference in broncho-
protection between the two treatments. As previously mentioned,
the two drugs investigated in this study are typically used in COPD
patients and as such have more research data in that patient popu-
lation. Glycopyrronium has been found to provide a dose-dependent
bronchodilator effect, with higher doses (i.e. 50e115.2 mg) producing
comparable effects to the recommended tiotropium dosage of 18 mg
in COPD patients [17e19]. Themain difference observed between the
two treatments was that glycopyrronium provides more rapid and
significant bronchodilation from 5min to 4 h post-treatment [18,19].
This presented the hypothesis that these two drugs would exert
similar durations of bronchoprotection and bronchodilation in
asthmatics undergoing MCT.
Our findings show that while their overall duration is similar in
terms of clinical significance, tiotropium provides superior bron-
choprotection at almost all time points, and its superiority reached
statistical significance at 24 and 72 h post-treatment. Reasons for
this difference may be that the dosage of tiotropium administered
was that recommended for asthmatics while glycopyrronium was
administered per guidelines for COPD patients. Although glyco-
pyrronium is somewhat more selective for M3 receptors than for
M1 andM2 types, only tiotropium has kinetic selectivity for M3 over
M2 receptors, which could lead to a significant difference in
perceived bronchoprotection between the two treatments [20]. If
glycopyrronium binds M2 receptors for a longer period of time, this
could produce prolonged inhibition of this receptor-type's normal
function as a moderator of acetylcholine in the airways. The result
could be a reduction in overall bronchoprotection, as elevated
acetylcholine levels would promote some bronchoconstriction.
It has also been suggested that differences in receptor binding
kinetics between tiotropium and glycopyrronium only explain
some of the variation seen in their respective durations of action
[21]. Drug rebinding may prolong the duration of action of
pharmaceuticals, as freshly dissociated drug molecules could
rebind to receptors further down the target tissue rather than being
immediately metabolized [22]. Given that some drug molecules
would be lost to metabolism with each dissociation and rebinding
event, glycopyrronium could lose effect more quickly, as it disso-
ciates more rapidly than tiotropium. Another potential factor
contributing to the different effects of each drug could be their
respective delivery methods. It has been argued that soft mist in-
halers deliver pharmaceuticals more efficiently than do dry powder
inhalers, leading to more drug deposition in the airways even in the
event of poor inhalation technique [23].
Neither drug produced a strong bronchodilator effect, which is
contradictory to results obtained in previous studies in mild asth-
matics [15,16]. Only glycopyrronium provided statistically signifi-
cant bronchodilation at one time point, 24 h post-treatment.
However, this effect was not clinically significant and only repre-
sented an increase in volume of 97 mL while the ATS guideline for
significant postbronchodilator FEV1 is a 200 mL increase (or 12%)
[24] This lack of significant bronchodilation in the current study
may be explained by the much greater dosages of the treatments
administered in previous studies. It should also be noted that the
participants weremildly asthmatic and so, they likely had relatively
lowairway constriction at rest. Therefore, the airways may not have
had much capacity to dilate further. Nonetheless, while this study's
findings do not suggest that the two LAMA's are effective bron-
chodilators in mild asthmatics, they both provide significant
bronchoprotection, particularly at 1 h post-treatment where both
drugs produced a dose shift of 4 doubling concentrations of MCh
(or a 16-fold increase in mean PC20). This is comparable to the
duration of bronchoprotection provided by other drug types; at
30 min post-dose, the long acting beta agonist formoterol (24 mg)
provides 20-fold bronchoprotection and the ultra long-acting beta
agonist olodaterol (20 mg) provides 19-fold protection [25,26].
An unanticipated finding was that both LAMA's produced a
reduced maximal response to MCh and shifted the MCh dose-
response curve to the right compared to the pre-treatment curve.
The reduction in maximal response reflects a decrease in what
appeared at baseline to be unlimited airway hyperresponsiveness
[27]. The rightward shift reflects a reduction in sensitivity to MCh,
which is unsurprising given LAMA's function of binding to M1 and
M3 receptors, thereby preventing the binding of bronchocon-
strictors [3,27]. Potential mechanisms behind the decrease in
maximal response to MCh include reduced airway smooth muscle
contraction and inhibition of mucus secretion responsible for
airwaywall swelling [27]. Tiotropium has also been found to trigger
anti-inflammatory mechanisms in COPD patients [28]. This func-
tion may contribute to both the rightward shift and plateau in the
MCh dose-response curve, as the airways are less sensitive to
stimuli (i.e. lower release of inflammatory mediators) and swelling
is reduced. In comparison, ICS also produce a lower maximal
response and a rightward shift in the MCh dose-response curve
while beta agonists simply produce a rightward shift [29,30].
Overall, the results from this study suggest that, in the absence
of objective data, the current guidelines have underestimated the
complete duration of clinically significant bronchoprotection by
LAMA's and yet still accurately predicted that tiotropium would
have a longer duration of effect. It is now questionable whether all
LAMA's act roughly equivalently to tiotropium or to glyco-
pyrronium and so, in order to better account for the length and
degree of bronchoprotection of this drug class, it would be rec-
ommended that all LAMA's be abstained from for a minimum of
one week prior to undergoing MCT to avoid false negative or
difficult to interpret test results.
Future studies in this area could compare other LAMA's to those
tested in this study. In addition, potential reasons for the
Fig. 3. Comparison of mean MCh dose-response curve pre-treatment versus 1 h. post-
treatment with tiotropium and glycopyrronium, respectively. 0 was set as the MCh
concentration that caused participants' FEV1 pre-treatment to drop by !20%. Any
lower concentrations administered were plotted as negative and any higher concen-
trations were plotted as positive. Best-fit curves were then generated. Any MCh con-
centration numbers with less than n ¼ 6 were excluded.
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differences in effects between tiotropium and glycopyrronium
could be further elucidated in order to then determine which may
be more suitable as add-on therapy in the treatment of poorly
controlled asthma. Studies could also investigate whether long-
term, daily use of LAMA's influences the overall duration and de-
gree of bronchoprotection provided by these drugs, as we only
investigated single dose effects. An additional aspect of this study
to ponder is the dosage of each drug, as the dose of glycopyrronium
administered was based on indications for COPD patients. Perhaps
a different dosagewould be more advisable for asthmatics and may
therefore impact the duration of bronchoprotection provided.
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Application	for	Biomedical	Research	Ethics	Review	
	
PART	1:	Identification	1.1	 Project	Title		Duration	of	bronchoprotection	of	the	long-acting	muscarinic	antagonists	tiotropium	&	glycopyrronium	against	methacholine-induced	bronchoconstriction	Protocol	Number	(if	applicable):	Bio-15-254	1.2	 Principal	Investigator		Full	Name:	Dr.	Donald	W.	Cockcroft		Mailing	Address:	Division	of	Respirology,	Critical	Care	and	Sleep	Medicine,	Department	of	Medicine																								5th	Floor	Ellis	Hall																							103	Hospital	Drive																							Saskatoon,	SK	S7N	0W8	Email:	don.cockcroft@usask.ca	Phone:	306-844-1446	NSID	number	(U	of	S	faculty	only):	dwc614	1.3	 University/Institutional	Affiliation	of	Principal	Investigator		Position:	Professor	Department:	Medicine	Division:	Respirology,	Critical	Care	and	Sleep	Medicine	1.4	 Project	Personnel	(including	graduates/post	graduates/residents)		Full	Name:	Dr.	Beth	Davis	Project	Position/Role:		Sub-Investigator	University/Institutional	Affiliation:	Research	Scientist	for	the	U	of	S	Department	of	Medicine,	Division	of	Respirology,	Critical	Care	and	Sleep	Medicine	
Full	Name:	
	
	Project	Position/Role:		 	University/Institutional	Affiliation:	 	
Email:	 		Phone:		 Email:	 		 Phone:	 	
For administrative use only 
File Number:   Date received: 
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beth.davis@usask.ca		 		306-844-1444		Full	Name:	
	
	Project	Position/Role:		 	University/Institutional	Affiliation:	 	 Full	Name:	 	Project	Position/Role:		 	University/Institutional	Affiliation:	 	Email:	 		 Phone:	 		 Email:	 		 Phone:	 	
If	this	is	a	student/graduate/resident	project,	please	provide	the	following	information:	a)	Student	Name:	Christianne	Blais	 b)	Supervisor	Name:	Dr.	Cockcroft	&	Dr.	Davis	1.5	 Primary	Contact	Person	for	Correspondence	(if	different	than	Section	1.2)		Full	Name:	Dr.	Beth	Davis		Mailing	Address:	Same	as	Principal	Investigator	Email:	beth.davis@usask.ca	Phone:	306-844-1444	1.6	 Research	Site(s)	where	project	will	be	carried	out:	Room	346	Ellis	Hall,	University	of	Saskatchewan	1.7	 Proposed	Project	Period:	From	(MM/DD/YY)	10/01/2015	To	(MM/DD/YY)	04/01/2016	
Specify	any	time	considerations	the	REB	should	be	aware	of	(e.g.	short	enrolment	
period):	Student	Honour’s	project	for	the	2015-16	academic	year	1.8	 Has	this	project	applied	for/received	ethical	approval	from	any	other	Saskatchewan	REB?			Yes	 	No	If	yes,	specify	where:	 	
Has	this	project	applied	for/received	ethical	approval	from	another	Research	Ethics	
Board	outside	of	Saskatchewan?			Yes	 	No	If	yes,	specify	where	(if	known):	 	1.9	 Do	you	consider	this	project	to	involve:			Minimal	Risk	 	More	than	Minimal	Risk	1.10	 Provide	name	of	funding	source:	 	Source	of	Funds:		 	Industry	 	 	 	National	Institute	of	Health	(NIH)			 	 	 	Not-for-Profit	Foundation	 	Cooperative	Group	(NCIC,	COG,	RTOG)		 		 	 	 	Tri-Council	Grant		 	Internally	funded		 	 	 	Grant-in-aid	
Status	of	Funds:		 	Awarded	 	Pending	1.11	 Name	of	Sponsor	if	different	from	above	funding	source:	 		
PART	2:	REGULATORY	REQUIREMENTS	2.1	 If	the	project	involves	an	investigational	drug,	natural	product,	medical	device	or	
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marketed	drug/device	being	used	outside	of	the	approved	indication,	check	whether	or	
not	the	No	Objection	Letter	(NOL)	or	the	Investigational	Testing	Authorization	(for	
devices)	has	been	obtained	from	the	appropriate	Health	Canada	regulatory	agency.	GN	2.1		 	N/A	–	Proceed	to	Question	2.2		
	 Yes	 Pending	 N/A	
Therapeutic	Products	Directorate	(TPD)	 	 	 	
Natural	Health	Products	Directorate	
(NHPD)	 	 	 	
Biologics	and	Genetics	Therapies	
Directorate	(BGTD)	 	 	 	
Investigational	Testing	Authorization	
(ITA)	 	 	 		Date	of	approval	(MM/DD/YY):	
	
	Please	forward	the	NOL	and/or	ITA	to	the	Research	Ethics	Office	when	available.	2.2	 Is	there	a	requirement	for	this	research	to	comply	with	United	States	(OHRP/FDA)	
regulations	for	research	ethics?			Yes	 	No	2.3	 Clinical	trials	are	required	to	be	registered	with	clinicaltrials.gov.	Please	submit	confirmation	of	registration	when	available.		2.4	 Peer	Review		For	research	with	more	than	minimal	risk,	the	REB	must	be	satisfied	about	both	the	value	and	the	scientific	validity	of	the	project.	Under	some	circumstances	and	depending	on	the	level	of	risk,	the	REB	may	request	that	a	peer	review	be	conducted	as	a	condition	of	approval.	Research	that	poses	minimal	risk	will	not	usually	require	peer	review.			Has	this	research	proposal	received	any	independent	scientific	review?		 	Yes	(please	attach)			No			 	Not	applicable	2.5	 According	to	Good	Clinical	Practices	Section	3.1.2,	the	Principal	Investigator	should	submit	a	current	curriculum	vitae	(CV)	providing	evidence	of	qualifications	to	conduct	the	project.	If	a	CV	has	not	been	submitted	within	last	5	years,	please	attach.			Is	the	PI’s	CV	attached?					 	Yes		 	Not	applicable		
PART	3:	BRIEF	OVERVIEW	OF	RESEARCH	PROJECT	(two	page	maximum)	3.1	 Research	Question/Hypothesis		Specify	the	research	question(s)	being	evaluated	in	the	project.	What	is	the	duration	of	bronchoprotection	of	the	long-acting	muscarinic	antagonists	(LAMA’s)	tiotropium	and	glycopyrronium	against	methacholine-induced	bronchoconstriction?	How	do	they	compare	to	each	other?	How	do	they	compare	to	the	time	lines	suggested	in	the	American	Thoracic	Society	Guidelines	for	Methacholine	Challenge	Testing?	
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3.2	 Academic	Validity		Provide	evidence	(scientific	literature,	pilot	projects,	etc.)	that	the	scientific	reasoning	and	design	of	the	project	are	sufficiently	sound	to	meet	the	objectives	of	this	project.	Methacholine	challenge	testing	(MCT)	has	long	served	as	a	common	and	reliable	procedure	for	measuring	airway	responsiveness.	As	such,	it	can	be	utilized	to	determine	the	extent	and	duration	of	bronchoprotection	provided	by	various	drugs.	The	ATS’s	guidelines	for	MCT	are	quite	vague	as	to	the	duration	for	which	LAMA’s	should	be	withheld	before	the	implementation	of	this	testing	method.	As	they	stand,	the	guidelines	indicate	that	such	medications	must	be	abstained	from	for	a	minimum	period	of	48	hours,	one	week	in	the	case	of	tiotropium,	prior	to	testing.	Data	to	support	these	time	frames	is	lacking	and	no	reference	data	is	provided	that	pertains	specifically	to	the	two	drugs	in	question.	3.3	 Research	Design/Methods		Provide	a	description	of	research	design	(e.g.	parallel	group	or	cross-over	design)	and	methods	to	be	used.	Include	a	justification	for	the	use	of	a	placebo,	if	applicable.	Please	note	that	if	the	analysis	or	the	interpretation	of	the	research	results	refers	to	Aboriginal	people,	language,	culture	or	history	as	a	primary	focus	of	the	project,	consultation	with	the	appropriate	community	is	required.	Please	outline	the	process	to	be	followed.	This	will	be	a	randomized,	double	blind,	double	dummy	study.	The	MCT	method	used	will	be	the	two-minute	tidal	breathing	dosing	protocol.	Twelve	to	fifteen	subjects	will	participate,	each	of	which	will	undergo	a	total	of	twelve	methacholine	(MCh)	challenges.	Each	MCh	challenge	will	be	stopped	when	the	subject’s	FEV1	drops	by	20%,	or	if	the	concentration	of	MCh	reaches	256	mg/mL.	On	the	first	day	of	testing,	subjects	will	undergo	a	MCh	challenge	to	determine	their	baseline	MCh	PC20.	They	will	then	self-administer	the	study	treatment	from	two	different	inhalation	devices.	One	device	will	contain	active	LAMA	treatment	and	the	other	a	placebo.	The	standard	dose	of	tiotropium	is	two	puffs	(5μg)	from	the	Respimat®	inhaler	and	that	of	glycopyrronium	is	one	tablet	(50	μg)	inhaled	from	the	Breezehaler®	dry	powder	inhaler.	The	identity	of	the	active	drug	inhaled	will	be	unknown	to	the	participants	and	to	the	study	staff.	One	hour	following	drug	inhalation,	the	subjects	will	undergo	a	second	MCh	challenge	to	determine	the	initial	physiological	response	to	the	drug	through	a	variation	in	their	MCh	PC20	compared	to	their	baseline	result.	The	subjects	will	then	each	return	to	the	lab	at	the	same	time	of	day	for	four	consecutive	days	to	undergo	MCh	challenge	testing	at	24hrs,	48hrs,	72hrs,	and	96hrs	post-antimuscarinic.	After	a	rest	period	of	one	week	to	allow	for	drug	washout,	the	same	procedure	will	be	followed	with	the	second	treatment.		3.4	 Statistical	Analysis		Include	a	summary	of	the	primary	and	secondary	end-points/outcomes,	the	planned	sample	size	(with	justification)	and	planned	statistical	and	interim	analyses.	MCh	PC20	data	will	first	be	log-transformed.	Comparison	of	the	shift	in	dose	of	MCh	required	to	produce	the	MCh	PC20	within	and	between	treatments	will	be	done	using	Student’s	t-test	with	the	significance	set	at	0.05.	The	sample	size	of	12-15	participants	will	power	the	test	by	over	80%	for	detecting	a	half	concentration	difference	in	PC20	values.	3.5	 Potential	Significance/Justification		Explain	the	significance	of	the	project	in	order	to	support	the	ethical	tenet	that	the	proposed	research	has	value	(i.e.,	what	are	the	anticipated	public	and	scientific	benefits	of	the	project?).	The	results	of	this	study	will	provide	data	to	either	confirm	or	update	the	current	guidelines	on	
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MCT	with	regards	to	the	appropriate	period	of	abstinence	from	LAMA’s	required	before	the	performance	of	a	MCh	challenge.	This	study	will	also	provide	data	on	the	difference	in	duration	of	bronchoprotection	between	two	different	medications	with	the	same	mechanism	of	action.	
	
PART	4:	PARTICIPANT	RECRUITMENT	4.1	 How	many	participants	will	be	enrolled	in	the	project:					Globally?	0		Locally?	12-15	4.2	 Describe	who	will	be	selected	(target	population)	and	the	criteria	for	their	inclusion.	Individuals	19	years	of	age	or	older	who	have	been	diagnosed	with	asthma	with	a	MCh	PC20	≤	4mg/mL	(+10%)	and	who	have	a	baseline	lung	function	(%	predicted	FEV1)	≥65%	may	participate.	4.3	 Describe	who	will	be	excluded	from	participation.	No	individual	may	participate	in	this	study	if	they	have	taken	any	anticholinergic	agent	within	30	days	prior	to	the	beginning	of	the	study.	Several	contraindications	for	MCT	are	known,	such	as	pregnancy	and	nursing	mothers,	and	cardiovascular	problems.	Such	individuals	will	therefore	be	excluded	from	this	study.	In	addition,	individuals	with	a	prostate,	kidney	or	urinary	retention	problem,	or	with	glaucoma	will	also	be	excluded,	as	these	are	contraindications	for	the	two	LAMAs	being	administered.	4.4	 Provide	a	detailed	description	of	the	method	of	recruitment.		a) How	will	prospective	participants	be	identified?	We	will	offer	the	study	to	individuals	who	have	previously	participated	in	research	in	our	lab	and	who	have	indicated	their	willingness	to	consider	participation	in	future	studies	where	their	asthma	diagnosis	and	demographics	match	the	inclusion	criteria.	b) Who	will	contact	prospective	participants?	Any	of	the	named	study	staff/student	c) How	will	this	be	done?	(Ensure	that	any	letters	of	initial	contact	or	other	recruitment	materials	are	attached	to	this	submission	(e.g.	advertisements,	flyers,	verbal	or	telephone	script,	etc.).		Communication	will	most	likely	occur	by	email	and	if	not,	then	phone	contact	will	be	made.	If	recruitment	is	slow,	an	REB-approved	ad	will	be	placed	on	PAWS	
	
PART	5:	CONSENT	PROCESS	5.1	 Describe	the	consent	process.		a) Who	will	ask	for	consent?	Dr.	Cockcroft	or	Dr.	Davis.	The	student	researcher	may	explain	and	obtain	consent	provided	either	Dr.	Cockcroft	or	Dr.	Davis	is	present.	b) Where,	and	under	what	circumstances?	Signing	of	the	consent	form	will	occur	in	Room	346	Ellis	Hall.	c) Describe	any	situation	in	which	the	renewal	of	consent	for	this	research	might	be	appropriate	and	how	this	would	take	place	(e.g.	Participant	turns	18	or	emergency	situation).		No	such	situation	is	anticipated.	It	is	understood	that	re-consent	will	be	required	if	such	a	situation	presents	itself.		5.2	 How	long	will	the	participant	have	to	decide	whether	or	not	to	participate?	If	less	than	twenty-four	hours,	provide	an	explanation.	At	least	24	hours	will	be	given.	5.3	 Will	all	participants	be	able	to	consent	on	their	own	behalf?			Yes	 	No	
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If	No,	explain	why:	
	
	a) 				If	a	participant	is	unable	to	consent,	who	will	consent	on	his/her	behalf?	 	b) 				Will	the	participant	be	able	to	assent	to	participate?		Yes	 	No	If	yes,	explain	how	assent	will	be	sought:	 	5.4	 If	monetary	compensation	or	reimbursements	for	expenses	will	be	offered	to	the	
participants	please	provide	the	details.	The	participants	will	be	reimbursed	$25	per	MCh	challenge	performed.	5.5	 Describe	your	plans	for	providing	project	results	to	the	participant?		Participants	are	welcome	to	contact	the	lab	following	the	completion	of	the	study	and	the	breaking	of	the	randomization	code	to	obtain	personal	results.	They	may	request	a	summary	of	the	results	and/or	provision	of	any	research	article	regarding	the	study	when	(if)	available.		
PART	6:		PROCEDURES	AND	RISKS	6.1	 Identify	those	procedures	that	are	different	from	the	current	standard	of	care	(i.e.	unique	
to	the	research	project).	MCT	is	a	commonly	used	testing	method	in	clinical	practice	and	as	such	is	a	standard	procedure	in	our	lab.	This	is	not	an	everyday	procedure	and	in	that	sense,	it	is	specific	to	this	study.	6.2	 What	are	the	known	risks	associated	with	the	procedures	outlined	in	Section	6.1?	Also	
include	any	risks	associated	with	the	placebo	or	wash	out	periods,	if	applicable.	MCT	may	cause	wheezing,	coughing,	mild	shortness	of	breath,	chest	tightness,	dizziness,	and/or	headaches.	However,	most	people	do	not	experience	any	symptoms.	There	are	no	known	risks	with	the	placebo,	and	the	washout	period	(at	least	four	days)	is	sufficient	in	duration	to	prevent	any	reaction	between	test	drugs.	6.3	 What	strategies	will	be	put	in	place	to	minimize	and/or	manage	the	potential	risk(s)	to	
participants	and	other	affected	individuals?	The	lab	has	standard	procedures	to	help	minimize/manage	risks	(e.g.	Ventolin	is	kept	on	hand	to	counteract	MCh	if	the	need	arises).	The	student	researcher	will	have	expert	guidance	available	at	all	times.		6.4	 For	double	blind	projects,	describe	the	provisions	made	to	break	the	code	in	an	
emergency	situation	[24	hour	availability],	and	indicate	who	has	the	code.		If	it	is	clearly	articulated	in	the	clinical	protocol,	it	is	acceptable	to	append	the	information	or	provide	the	protocol	page	reference.	The	randomization	code	will	be	maintained	in	a	sealed	envelope	in	the	lab	until	all	testing	is	complete.	Should	an	emergency	occur	where	the	code	must	be	broken,	the	envelope	will	be	opened	and	the	treatment	administered	identified.			N/A,	not	a	double	blind	project		
PART	7:	DATA	SECURITY	AND	STORAGE			
The	Saskatchewan	Health	Information	Protection	Act	(HIPA)	requires	an	assessment	of	the	
risks	to	privacy	and	how	the	risks	will	be	minimized.		Accessing	existing	patient	information,	
such	as	Health	Records,	requires	consent	of	the	individual	which	must	be	addressed	in	the	
consent	form.	
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7.1	 Indicate	from	which	sources	personal	and	health	information	data	will	be	collected:			Participant	data	collected	prospectively	for	the	purpose	of	this	project	(e.g.	case	report	form)		Family	physician	record		Heath	Region	–	please	specify	Region,	Site	&	Dept.	if	applicable:		
	
	 		SK	Ministry	of	Health		SK	Cancer	Agency		Other	–	please	specify:	 		Not	applicable	(No	personal	or	health	information	to	be	collected).		Proceed	to	Section	8.	7.2	 How	will	the	confidentiality	of	participants	and	their	health	information	be	protected?	Subject	data	will	be	de-identified	by	use	of	study	code	and	initials.	7.3	 Describe	the	storage	arrangements	and	final	disposition	of	the	project	data	collected.	All	data	will	be	stored	in	Room	346	Ellis	Hall,	which	has	keyed	entry.	7.4	 List	the	project	personnel	who	have	access	to	any	identifiable	personal	health	
information	and	who	will	have	access	to	any	list	that	links	participant	names	to	their	
project	ID	number,	consent	form,	enrolment	log,	etc.		Principal	Investigator,	Sub-Investigator	and	Student	Researcher	7.5	 Check	all	applicable	boxes	below	to	provide	an	assessment	of	the	potential	privacy	risks	
and	the	safeguards/solutions	that	you	will	put	in	place	to	mitigate	the	risks.		
Potential	Privacy	Risks	 Possible	Safeguards/Solutions	(check	all	that	you	will	use)		Unauthorized	external	or	internal	access	to	identifying						information	through	active	use	or	transmission		
	Project	personnel	screening/agreements		 		Access	authorization	procedures			 		Designated	systems	administrator			 		Passwords/screen	timeouts		 		 		System	access	audits/disclosure	logs			 		Secure	mail/transport		 	 	 		Firewall/virus	protect		 	 	 		Encrypted	transmission		Identification	through	publication	or	release	 	Aggregation	levels		 	 		 		Alternate	identifiers		 		Identification	through	data-matching	 	Use	of	non-linkable	elements	or	identifiers		Loss	of	data	control	outside	jurisdiction	 	Confidentiality	and	security	agreements	for	out-of-						province	recipients	or	storage	providers		
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PART	8:	CONFLICT	OF	INTEREST	8.0	 Is	there	any	real	or	perceived	conflict	of	interest	(any	personal	or	financial	interest	in	the	
conduct	or	outcome	of	this	project)?		Will	any	of	the	researcher(s),	members	of	the	
research	team	and/or	their	immediate	family	members:	
• Receive	personal	benefits	in	connection	with	this	project	over	and	above	the	direct	costs	of	conducting	the	project,	such	as	remuneration	or	employment?		Yes	 	No	
• Receive	significant	payments	of	other	sorts	from	the	sponsor	such	as	grants,	compensation	in	the	form	of	equipment	or	supplies	or	retainers	for	ongoing	consultation	and	honoraria?		Yes	 	No	
• Have	a	non-financial	relationship	with	a	sponsor	(such	as	unpaid	consultant,	board	membership,	advisor	or	other	non-financial	interest?		Yes	 	No	
• Have	any	direct	involvement	with	the	sponsor	such	as	stock	ownership,	stock	options	or	board	membership?		Yes	 	No	
• Hold	patents,	trademarks,	copyrights,	licensing	agreements	or	intellectual	property	rights	linked	in	any	way	to	this	project	or	the	sponsor?		Yes	 	No	
• Have	any	other	relationship,	financial	or	non-financial,	that	if	not	disclosed,	could	be	construed	as	a	conflict	of	interest?		Yes	 	No	If	yes,	please	describe	the	personal	benefits	or	relationship.	
	
	 		
PART	9:	Declaration	by	Principal	Investigator		
(or	Supervisor	for	student	projects)	
Project	Title:	Duration	of	bronchoprotection	of	the	long-acting	muscarinic	antagonists	tiotropium	&	glycopyrronium	against	methacholine-induced	bronchoconstriction	
• I	confirm	that	the	information	provided	in	this	application	is	complete	and	correct.	
• I	accept	responsibility	for	the	ethical	conduct	of	this	project	and	for	the	protection	of	the	rights	and	welfare	of	the	human	participants	who	are	directly	or	indirectly	involved	in	this	project.		
• I	will	comply	with	all	policies	and	guidelines	of	the	University	and	Health	Region/affiliated	institutions	where	this	project	will	be	conducted,	as	well	as	with	all	applicable	federal	and	provincial	laws	regarding	the	protection	of	human	participants	in	research.		
• I	will	ensure	that	project	personnel	are	qualified,	appropriately	trained	and	will	adhere	to	the	provisions	of	the	REB-approved	application.		
• I	will	ensure	that	any	significant	changes	to	the	project,	including	the	proposed	method,	consent	process	or	recruitment	procedures,	will	be	reported	to	the	Research	Ethics	Board	for	consideration	in	advance	of	its	implementation.		
• I	will	ensure	that	a	status	report	will	be	submitted	to	the	Research	Ethics	Board	for	consideration	within	one	month	of	the	current	expiry	date	each	year	the	project	remains	open,	
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and	upon	project	completion.		
• If	personal	health	information	is	requested,	I	assure	that	it	is	the	minimum	necessary	to	meet	the	research	objective	and	will	not	be	reused	or	disclosed	to	any	parties	other	than	those	described	in	the	REB-approved	application,	except	as	required	by	law.		
• I	confirm	that	adequate	resources	to	protect	participants	(i.e.,	personnel,	funding,	time,	equipment	and	space)	are	in	place	before	implementing	the	research	project,	and	that	the	research	will	stop	if	adequate	resources	become	unavailable.	
• I	understand	that	if	the	contract	or	grant	related	to	this	research	project	is	being	reviewed	by	the	University	or	Health	Region,	a	copy	of	the	ethics	application	inclusive	of	the	consent	document(s),	may	be	forwarded	to	the	person	responsible	for	the	review	of	the	contract	or	grant.	
• I	understand	that	if	the	project	involves	Health	Region	resources	or	facilities,	a	copy	of	the	ethics	application	may	be	forwarded	to	the	Health	Region	research	coordinator	to	facilitate	operational	approval.				_______________________________	 	 	
	
																																																	 	 	Signature	of	Principal	Investigator	 	 	 Printed	Name	of	Principal	Investigator		 Date	(MM/DD/YY)		
Department	Head	(or	supervisor	for	student	projects:		The	signature/approval	of	the	Department/Administrative	Unit	acknowledges	that	he/she	is	aware	of	and	supports	the	research	activity	described	in	the	proposal.				_______________________________	 	 	 																																																	 	 	Signature	of	Department	Head	 	 	 	 Printed	Name	of	Department	Head			 Date	(MM/DD/YY)		 						
PART	11:	ATTACHMENTS		
Provide	a	full	and	accurate	listing	of	all	documents	submitted	with	this	application.		All	projects	requiring	the	use	of	RQHR	resources	must	complete	this	section.		
Document	 Included?	 Comments	Certificate	of	Approval	from	another	REB	 	Yes	 	N/A	 	
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Peer	Review	reports	 	Yes	 	N/A	
	
	
Participant	Consent	Form	 	Yes	 	N/A	 	
Control	Participant	Consent	Form	 	Yes	 	N/A	 	
Assent	Form	 	Yes	 	N/A	 	
Tissue/Blood	Banking	Consent	Form	 	Yes	 	N/A	 	
Letter	of	Initial	Contact	 	Yes	 	N/A	 	
Advertisement	to	Recruit	Participants	 	Yes	 	N/A	 	
Questionnaires,	tests,	interview	scripts,	etc.	 	Yes	 	N/A	 	
Other-	please	specify:		 	 	Yes	 	N/A	 	
Other-	please	specify:		 	 	Yes	 	N/A	 	
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6.5 Appendix E: LAMA Study Participant Consent Form 
	
PARTICIPANT INFORMATION AND CONSENT FORM 
 
Title of Study: Duration of bronchoprotection of the long-acting muscarinic antagonists 
tiotropium & glycopyrronium against methacholine-induced bronchoconstriction 
 
Principal Investigator: Dr. D.W. Cockcroft, 
 Department of Medicine 
 Division of Respirology, Critical Care and Sleep Medicine 
 University of Saskatchewan 
 306-844-1446  don.cockcroft@usask.ca 
Sub-Investigator: Dr. Beth Davis,   
 Department of Medicine 
 Division of Respirology, Critical Care and Sleep Medicine 
 University of Saskatchewan 
 306-844-1444  beth.davis@usask.ca 
Student Researcher: Christianne Blais (PHPY 432 Student) 
 Department of Physiology 
 University of Saskatchewan 
 306-480-8983  cmb831@mail.usask.ca 
    
 Supervised by the Principal Investigator and Sub- 
 Investigator 
 24 hour contact: Dr. Beth Davis 306-229-8709 
 
Introduction: You are invited to participate in this research study, as your asthma diagnosis, age 
and health status make you a suitable representative of the population of interest.  
Your participation is entirely voluntary and you may withdraw from the study at any time 
without providing a reason for doing so. If you do not wish to participate or if you choose to 
withdraw from the study, your current health care and/or academic status (if you are a student at 
the U of S) will not be impacted. 
Please take time to read the following information carefully. You may direct any questions or 
concerns to the study staff prior to and throughout the duration of the study.  
 
Agencies Contributing Funds, Resources, and Drugs to the Study: The study will be 
internally funded. Novartis Pharmaceuticals Canada Inc. will be providing the active drug 
Seebri®, placebos, and Breezehaler® inhalation devices. Boehringer Ingelheim Pharmaceuticals 
Inc. will be providing the active drug Spiriva®, placebos, and Respimat® inhalation devices. The 
researchers and the University of Saskatchewan are not being paid to conduct this study. 
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Purpose of Study: Bronchodilators are medications that can improve breathing in those who are 
experiencing difficulty (e.g. an individual with asthma). Ventolin® is an example of a 
bronchodilator/inhaler that is commonly used. There are other bronchodilator drugs, including 
drugs that can block muscarinic receptors. When these receptors are activated, the airway smooth 
muscle contracts. This results in bronchoconstriction and difficulty breathing. Therefore, by 
blocking these receptors, breathing is improved. Treatments called “long-acting muscarinic 
antagonists” (LAMA’s), including Spiriva®(tiotropium bromide monohydrate) and 
Seebri®(glycopyrronium bromide) are two such medications. The main purpose of this study is to 
determine how long each medication will block the effect of inhaled methacholine (MCh), a 
known bronchoconstrictor. Methacholine challenge testing is a common procedure performed in 
clinical practice to confirm or refute an asthma diagnosis. Currently, the American Thoracic 
Society’s (ATS’s) Guidelines for Methacholine and Exercise Challenge Testing do not contain 
data on the duration of bronchoprotection provided by LAMA’s, such as tiotropium and 
glyropyrronium. The guidelines simply recommend 48 hours of abstinence from LAMA’s, one 
week in the case of tiotropium, prior to MCh challenge testing. Our results will provide objective 
data that may influence the recommended guidelines for conducting MCh challenges. We plan to 
recruit twelve to fifteen participants. 
 
Eligible Participants: To be eligible to participate in this study, you must be 19 years of age or 
older. You must also have been diagnosed with asthma and have a current MCh PC20 
[concentration of MCh causing a 20% reduction in forced expiratory volume in one second 
(FEV1)] ≤ 4mg/mL (+10%) (explained in more detail on the next page). You must also have 
sufficient baseline lung function. For this study, the amount of air you can forcefully exhale 
during the first second of exhalation (FEV1) must be at least 65% of what is predicted for your 
age, height and gender. You may not participate in this study if you have taken any 
anticholinergic agent within 30 days prior to the beginning of the study. If you are taking 
corticosteroids on a daily basis, you may participate in the study provided you continue to take 
your usual dose. Bronchodilator therapy (e.g. Ventolin®, bricanyl) is allowed but must be 
withheld for at least six hours prior to all visits. Use of longer-acting beta agonist bronchodilators 
will not be allowed. Due to contraindications for the two LAMA’s and for the testing method, 
you may not participate in this study if you are pregnant or nursing, if you have cardiovascular, 
prostate, kidney or urinary retention problems, and/or if you have glaucoma. 
 
Study Overview/Visit Schedule: You will be required to attend the laboratory on twelve 
occasions, six for each treatment period. For example, on a Monday, you will be required to 
undergo MCh challenge testing (the procedure described below), following which you will be 
provided with two inhalers (one Respimat® and one Breezehaler®). One inhaler will contain an 
active LAMA (either Spiriva® or Seebri®) and the other will contain a placebo. Neither you nor 
the study staff will know which inhaler contains the active treatment, although this information 
will be available if necessary. You will inhale two puffs from the Respimat® inhaler and one puff 
from the Breezehaler®. You will then wait for one hour before undergoing a second MCh 
challenge. This visit will take between 2.5 and 3 hours. You will then be required to return to the 
lab at the same time once a day for four consecutive days (days 2-5). On each day you will 
undergo a single MCh challenge, which will take between 1 and 2 hours. You will then return to 
the lab on Monday (day 7 post-treatment) for a final methacholine challenge. During each MCh 
challenge, we will also ask you to rate your perceived level of airway constriction/discomfort on 
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a scale of 0-10 (0 being no feeling of constriction and 10 being level of constriction is extremely 
uncomfortable).  
Following one week of rest to allow medication washout, you will be required to follow the same 
schedule with the other treatment. The order in which you receive the treatments will be random. 
The data collected will then allow for comparison of the duration of action of each drug in 
relation to the ATS guidelines. 
 
MCh Challenge: MCh challenge testing involves the inhalation of aerosolized MCh through a 
loose-fitting mask for a period of two minutes. During this time, your nose will be plugged with 
a noseclip and you will be asked to breathe normally. MCh is a bronchoconstrictor and may 
cause your airways to constrict. Following the inhalation of MCh, you will be required to inhale 
deeply and exhale as forcefully as you can into a spirometer, which is a handheld device 
connected to a computer that allows for the measurement of your lung capacity. This is referred 
to as spirometry or lung function testing. We will repeat this procedure with increasing 
concentrations of MCh until the amount of air you can forcefully exhale is decreased by 30% or 
the maximal concentration of methacholine (256mg/mL) is inhaled. Ventolin® (albuterol) will 
be kept on hand in the case of an emergency. 
 
Responsibilities of The Participant: As a participant of this study, you will be expected to (1) 
follow the directions of the investigators and researchers, and (2) report all medications 
(prescribed, over-the-counter, and herbal products) being used or that you plan on taking prior to 
and throughout the duration of the study. This step is important both for your own safety as well 
for accurate interpretation of the test results. If a situation arises where you must use a 
medication that will interfere with the study, we ask that you take the medication and contact us 
to reschedule your appointment. 
 
Benefits of Participating in This Study: If you choose to participate in this study, know there 
will be no benefit for you personally. However, your participation will help increase knowledge 
on the effective use of MCT as an asthma diagnostic tool, where current data is lacking.  
 
Honorarium: If you choose to participate in this study, you will not be charged for the study 
drugs or any research-related procedures. Although you will not be paid for your participation, 
you will be provided with an honorarium in the amount of $25 per MCh challenge ($350 total) to 
cover your time and out-of-pocket expenses (e.g. parking, meals). Should you choose to 
withdraw early from this study, you will be compensated according to the number of MCh 
challenge tests to which you participated. The University of Saskatchewan will require your 
social insurance number and will send you a T4A slip at the appropriate time. 
 
Potential Risks and Discomforts: MCh challenge testing may cause the following symptoms: 
wheezing, coughing, mild shortness of breath, chest tightness, dizziness, and/or headaches. The 
effects of MCh can be treated with inhaled salbutamol or will subside untreated. 
Some common side effects (>1% of patients) of Spiriva® (tiotropium bromide monohydrate) 
include: dry mouth (4.1%), cold symptoms (2.7-15.9%), and headaches (3.8%). Less common 
(0.5-1% of patients) include stomach aches, muscle pain, and constipation. 
Some side effects of Seebri® (glycopyrronium bromide) experienced in 1-10% of patients 
include dry mouth, headaches, insomnia, cold symptoms and stomach pains. 
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Voluntary Withdrawal: Your participation in this study is voluntary and as such, you may 
withdraw from the study at any time. No reason needs to be given for your withdrawal, and your 
current health care and/or academic status will not be impacted in any way. The data collected 
about you until the point of withdrawal will be retained for analysis. 
You will be notified if new information regarding the drugs or procedure involved becomes 
available during the course of the study that may affect your willingness to continue to 
participate. 
 
Study-Related Injury: In the case of a medical emergency related to the study, you should seek 
immediate care and, as soon as possible, notify the study staff. Inform the medical staff you are 
participating in a clinical study. Necessary medical treatment will be made available at no cost to 
you. By signing this document, you do not waive any of your legal rights against the 
investigators or anyone else. 
 
Confidentiality: In Saskatchewan, the Health Information Protection Act (HIPA) defines how 
the privacy of your personal health information must be maintained so that your privacy will be 
respected. Your name will not be attached to any information, nor mentioned in any study report, 
nor be made available to anyone except the research team. However, no guarantee can be made 
for complete confidentiality. It is the intention of the research team to publish results of this 
research in scientific journals and to present the findings at related conferences and workshops, 
but your identity will not be revealed.  
Your study records will be kept for at least 5 years in a secured area (Room 346 Ellis Hall). This 
is a locked room when unattended. After storage, your study records will be shredded in a 
confidential manner. 
 
Contact Regarding Any Questions/Concerns About The Study: If you have any questions or 
concerns regarding this study before or during participation, you may contact Dr. Cockcroft at 
306-844-1446 or Dr. Davis at 306-844-1444. 
If you have any concerns about your rights as a research participant and/or your experiences 
while participating in this study, contact the Chair of the University of Saskatchewan Research 
Ethics Board at 306-966-2975. This study has been reviewed and approved on ethical grounds by 
the University of Saskatchewan Research Ethics Board. 
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Consent 
o I have read the information in this consent form. 
o I understand the purpose, procedure and possible risks of the study. 
o I have had the opportunity to ask questions and have received satisfactory answers. 
o I am free to withdraw from this study at any time for any reason and the decision to stop 
taking part will not affect my future medical care or academic status. 
o I give permission for the use and disclosure of my de-identified personal health 
information collected for the research purposes described in this form.  
o I understand that by signing this document I do not waive any of my legal rights. 
o I will be given a signed and dated copy of this consent form. 
I agree to participate in this study: 
 
 
 
Printed name of participant     Date 
 
 
 
Signature of participant      Phone # 
 
 
 
Printed name of person obtaining consent    Date 
 
 
 
Signature of person obtaining consent 
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6.6 Appendix F: Certificate of Ethics Approval for LAMA/uLABA Study 	
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6.7 Appendix G: Application for Ethics Approval for LAMA/uLABA Study 
		
 
REB Application for Biomedical Research Ethics Review (last updated 03-Mar-2013) 
 
1 
 
   
 
   
Application for Biomedical Research Ethics Review 
 
PART 1: IDENTIFICATION 
1.1 Project Title GN 1.1 
The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-
response curve 
Protocol Number (if applicable): Bio 16-205 
1.2 Principal Investigator GN 1.2 
Full Name: Dr. Donald W. Cockcroft  
Mailing Address: Division of Respirology, Criticial Care and Sleep Medicine, University of Saskatchewan, 546 
Ellis Hall, 103 Hospital Drive, Saskatoon, SK S7N 0W8 
 
Email: don.cockcroft@usask.ca 
Phone: 306-844-1446 
NSID number (U of S faculty only): dwc614 
1.3 University/Institutional Affiliation of Principal Investigator GN 1.3 
Position: Professor 
Department: Medicine 
Division: Respirology, Critical Care and Sleep Medicine 
1.4 Project Personnel (including graduates/post graduates/residents) GN 1.4 
Full Name: Dr. Beth E. Davis 
Project Position/Role:  Research Supervisor/Co-
Investigator 
University/Institutional Affiliation: University of 
Saskatchewan 
Full Name: Christianne Blais 
Project Position/Role:  Master's Student Researcher 
University/Institutional Affiliation: University of 
Saskatchewan 
Email: beth.davis@usask.ca  
Phone: 306-844-1444  
NSID number (U of S only): 
 
 
 Email: cmb831@mail.usask.ca  
Phone: 306-480-8983 
NSID number (U of S only): cmb831 
 
Full Name:  
Project Position/Role:   
University/Institutional Affiliation:  
Full Name:  
Project Position/Role:   
University/Institutional Affiliation:  
Email:   
Phone:  
NSID number (U of S only): 
 Email:   
Phone:  
NSID number (U of S only):  
 
For administrative use only 
File Number:   Date received: 
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2 
 
 
If this is a student/graduate/resident project, please provide the following information: 
a) Student Name: Christianne Blais 
NSID number (U of S only): cmb831 
b) Supervisor Name: Dr. Cockcroft and Dr. Davis 
1.5 Primary Contact Person for Correspondence (if different than Section 1.2) GN 1.5 
Full Name: Christianne Blais 
Mailing Address: Room 346 Ellis Hall, University of Saskatchewan, 103 Hospital Drive, Saskatoon SK. S7N 0W8 
Email: cmb831@mail.usask.ca 
Phone: 306-480-8983 
1.6 Research Site(s) where project will be carried out: GN 1.6 Room 346 Ellis Hall, University of Saskatchewan 
1.7 Proposed Project Period: GN 1.7 From (MM/DD/YY) 08/01/2016 To (MM/DD/YY) 08/31/2017 
Specify any time considerations the REB should be aware of (e.g. short enrolment period): Student One-Year 
Master's Project (must be completed by Summer 2017) 
1.8 Has this project applied for/received ethical approval from any other Saskatchewan REB? GN 1.8 
 Yes  No 
If yes, specify where:  
Has this project applied for/received ethical approval from another Research Ethics Board outside of Saskatchewan?  
 Yes  No 
If yes, specify where (if known):  
1.9 Do you consider this project to involve: GN 1.9 
 Minimal Risk  More than Minimal Risk 
1.10 Provide name of funding source: GN 1.10 Internal Funds 
Source of Funds:   Industry    National Institute of Health (NIH)  
    Not-for-Profit Foundation  Cooperative Group (NCIC, COG, RTOG)   
    Tri-Council Grant   Internally funded 
    Grant-in-aid 
Status of Funds: GN 1.11  Awarded  Pending 
1.11 Name of Sponsor if different from above funding source: GN 1. 12   
 
PART 2: REGULATORY REQUIREMENTS 
2.1 If the project involves an investigational drug, natural product, medical device or marketed drug/device being used 
outside of the approved indication, check whether or not the No Objection Letter (NOL) or the Investigational 
Testing Authorization (for devices) has been obtained from the appropriate Health Canada regulatory agency. GN 2.1 
 
 N/A – Proceed to Question 2.2 
 
 Yes Pending N/A 
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Therapeutic Products Directorate (TPD)    
Natural Health Products Directorate (NHPD)    
Biologics and Genetics Therapies Directorate (BGTD)    
Investigational Testing Authorization (ITA)    
 
Date of approval (MM/DD/YY): 
 
 
Please forward the NOL and/or ITA to the Research Ethics Office when available. 
2.2 Is there a requirement for this research to comply with United States (OHRP/FDA) regulations for research ethics? 
GN 2.2 
 Yes  No 
2.3 Clinical trials are required to be registered with clinicaltrials.gov. Please submit confirmation of registration when 
available. GN 2.3 
2.4 Academic Validity GN 2.4 
For research with more than minimal risk, the REB must be satisfied about both the value and the scientific validity of the 
project. Under some circumstances and depending on the level of risk, the REB may request that a peer review be 
conducted as a condition of approval. Research that poses minimal risk will not usually require peer review.  
 
Has this research proposal received any independent scientific review?   Yes (please attach)   No    Not applicable 
2.5 According to Good Clinical Practices Section 3.1.2, the Principal Investigator should submit a current curriculum vitae (CV) 
providing evidence of qualifications to conduct the project. If a CV has not been submitted within last 5 years, please attach. 
GN 2.5                        Is the PI’s CV attached?      Yes   Not applicable 
 
PART 3: BRIEF OVERVIEW OF RESEARCH PROJECT (two page maximum) 
3.1 Research Question/Hypothesis GN 3.1  
Specify the research question(s) being evaluated in the project. 
How do glycopyrronium and indacaterol, as monotherapy and in combination, shift the methacholine (MCh) 
dose-response curve (DRC)? What is the duration and degree of bronchoprotection provided by each 
treatment?  
3.2 Academic Validity GN 3.2 
Provide evidence (scientific literature, pilot projects, etc.) that the scientific reasoning and design of the project are 
sufficiently sound to meet the objectives of this project. 
Methacholine challenge testing (MCT) is a common and reliable procedure for measuring airway 
responsiveness. The airway hyperresponsiveness component of asthma has been shown to result from 
increased sensitivity to bronchoconstrictors and an increased maximal constricting response to said stimuli. 
These effects can be visualized on a MCh DRC; a leftward shift symbolizes increased sensitivity (i.e. less 
stimuli needed to generate a constricting response due to factors like epithelial damage, increased 
inflammatory cell activity and abnormal autonomic activity); the loss or elevation of a plateau represents a 
heightened maximal response (i.e. excessive hyperresponsiveness due to factors like increased smooth 
muscle contractility, a reduction in mechanical loads, intraluminal secretions or swelling of the airways); a 
steeper slope results from increased reactivity (i.e. increased risk of severe exacerbation in response to a 
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stimulus).  
The representation of a drug’s effect on the MCh DRC could not only help to characterize the impact of the 
drug on the airways, but could also potentially serve as a tool for determining the best treatment for a 
patient based on a comparison of their baseline MCh DRC to that of a non-asthmatic. So far, it has been 
shown that inhaled corticosteroids (ICS) produce a righward shift and often a lower plateau (i.e. reduced 
maximal response). Beta-2 agonists typically only shift the curve rightward. In one of our previous studies, 
it was found that long-acting muscarinic antagonists (LAMAs) such as glycopyrronium and tiotropium seem 
to produce a rightward shift and lower plateau. No MCh DRC has been generated for ultra long-acting beta 
agonists (uLABAs) such as indacaterol as of yet. 
Given the widespread use of MCT in clinics and in research, it is important that its accuracy be maintained 
in order to minimize the likelihood of generating false negative results. The determination of the degree and 
duration of bronchoprotection against MCh provided by each drug will inform standardization guidelines on 
the required washout timeframes for these treatments prior to undergoing pulmonary function and MCT.    
3.3 Research Design/Methods GN 3.3   
Provide a description of research design (e.g. parallel group or cross-over design) and methods to be used. Include a 
justification for the use of a placebo, if applicable. Please note that if the analysis or the interpretation of the research results 
refers to Aboriginal people, language, culture or history as a primary focus of the project, consultation with the appropriate 
community is required. Please outline the process to be followed. 
This will be a randomized, double-blind, three-way crossover study testing glycopyrronium (Seebri®) vs. 
indacaterol (Onbrez®) vs. glycopyrronium and indacaterol. The MCT method used will be the two-minute 
tidal breathing dosing protocol. We plan to enroll 30 participants, 15 asthmatic and 15 non-asthmatic 
participants.  
Asthmatic Participants Procedure: Each participant will undergo a total of 12 MCh challenges. Each MCh 
challenge will be stopped when a plateau is reached, when the subject’s forced expiratory volume in one 
second (FEV1) drops 40% from baseline, when post-treatment the concentration of MCh administered 
reaches 128mg/mL, or if the participant wishes to stop for any reason (e.g. discomfort). For the purpose of 
this study, a plateau will be defined as the last 3 consecutive data points falling within 5% of each other. 
The first day of testing will take approx. 3hrs. and will entail participants undergoing a MCh challenge to 
determine their baseline MCh provocative concentration causing a 20% fall in FEV1 (PC20). They will then 
inhale the contents of two Breezhaler® devices. For each monotherapy treatment arm, one inhaler will 
contain one of the two active drugs while the other device will contain a placebo capsule (i.e. inhalation of 
50µg glycopyrronium and a placebo, or 75µg indacaterol and a placebo). For the combination therapy arm, 
each device will contain active treatment (i.e. inhalation of 50µg glycopyrronium and 75µg indacaterol)*.  
The identity and order of the treatments administered will be unknown to the participants and to the study 
staff.  The blinding of the study treatments will be completed by the local pharmacy. Participants will then 
undergo MCT at 1 hr., 24 hrs., and 48 hrs. post-treatment. Testing at 24 and 48 hrs. should take approx. 1-
1.5 hrs. Therefore, participants must attend the lab at roughly the same time of day (±1 hr.) for 3 
consecutive days for each treatment arm. Following a minimum 10-day washout between treatment 
administrations, the same procedure will be repeated with the second study treatment. Following a second 
10-day washout, the procedure will be repeated with the third study treatment. A table summarizing the 
study schedule for asthmatic participants can be found in the consent form. 
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*Protocol in the event of coughing post-dosing: The participant will be advised to cough before undergoing 
drug inhalation to relieve any potential mucus blockage. It will be noted if the participant coughs following 
drug inhalation, as this could lead to exhalation of some of the medication. 
Non-Asthmatic Participant Procedure: Each non-asthmatic participant will undergo a single MCh challenge, 
which should take approx. 1 hr. This will allow for the generation of a "normal" MCh DRC to compare with 
the asthmatic data. The MCh challenge will be stopped when the response to MCh reaches a plateau, when 
the participant's FEV1 drops by 40% from baseline, when the highest concentration of MCh (128mg/mL) 
has been administered, or if the participant wishes to stop for whatever reason. 
Methacholine Challenge: MCT involves the inhalation of aerosolized MCh, a known bronchoconstrictor that 
may cause the airway to constrict. The participant will inhale MCh through a loose-fitting mask for a period 
of two minutes. During the inhalation period, their nose will be plugged with a nose clip and they will be 
asked to breathe normally. Following inhalation of MCh, they will be required to inhale sharply and exhale 
as forcefully as they can into a spirometer in order to measure their lung capacity (i.e. spirometry). We will 
then repeat this procedure with increasing concentrations of MCh until one of the pre-defined stops is 
reached (i.e. plateau, 40% reduction in FEV1, max MCh administered, or participant choice). Asthmatic 
participants will be given salbutamol following each MCh challenge, except after the “baseline” or un-
medicated MCh challenge prior to each treatment; following these challenges, they will be given one of the 
study medications instead. If non-asthmatic participants show a response to MCh, they will be given the 
option of taking salbutamol for quick reversal of the effects of MCh.  
3.4 Statistical Analysis GN 3.4   
Include a summary of the primary and secondary end-points/outcomes, the planned sample size (with justification) and 
planned statistical and interim analyses. 
MCh PC20 data will be log-transformed. Bronchoprotection will be assessed as the shift in MCh PC20 from 
baseline [dose shift= (ΔlogMCh PC20)/0.3]. Comparison of the shift in dose of MCh required to produce the 
PC20 within and between treatments will be done using Student’s t-test and will be illustrated in the form of 
MCh DRCs. Significance will be set at 0.05. The sample size of 15 participants will power the test by over 
95% for detecting a half concentration difference in PC20 values. (The 15 non-asthmatics are only being 
used to generate a "normal" MCh DRC, no statistical analysis) 
3.5 Potential Significance/Justification GN 3.5   
Explain the significance of the project in order to support the ethical tenet that the proposed research has value (i.e., what 
are the anticipated public and scientific benefits of the project?). 
The results from this study will allow for a better understanding of the mechanisms behind asthma and how 
a uLABA, a LAMA, and a combo uLABA+LAMA influence the airways of asthmatics. The data will also either 
confirm or update the current guidelines on MCT with regards to the appropriate period of abstinence from 
each treatment prior to a MCh challenge. 
 
PART 4: PARTICIPANT RECRUITMENT 
4.1 How many participants will be enrolled in the project: GN 4.1  Globally? 0  Locally? 30 
4.2 Describe who will be selected (target population) and the criteria for their inclusion. GN 4.2 Individuals may 
participate if they are 18 years of age or older. Eligible asthmatic participants must be diagnosed with mild-
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to-moderate asthma, must have a MCh PC20 less than or equal to 8mg/mL, and must have a baseline lung 
function (% predicted FEV1) greater than or equal to 65%. If they have not previously undergone testing in 
the Asthma Research Lab, these criteria will be confirmed during their first study visit with baseline testing. 
Eligible nonasthmatic participants must have a negative MCh PC20 (greater than 16mg/mL). 
4.3 Describe who will be excluded from participation. GN 4.3 Individuals may not participate if they have taken any 
anticholinergic agent, any long-acting beta agonist, or any combination therapy within 30 days prior to 
beginning the study. Due to contraindications for MCT, pregnant and/or nursing mothers, and those with 
cardiovascular problems will be excluded. Due to contraindications for the study treatments, individuals with 
a prostate, kidney or urinary retention problem, hypokalemia, diabetes, or with glaucoma will be excluded. 
Eligible participants cannot have suffered from a respiratory infection or an asthma attack from allergen 
exposure within 4 weeks prior to beginning the study.  
4.4 Provide a detailed description of the method of recruitment. GN 4.4  
a) How will prospective participants be identified? Non-asthmatic candidates will be recruited through PAWS (i.e. 
no other form of advertisement will be used to recruit them). We do not have current clinic research 
records of non-asthmatics. Asthmatics will first be recruited from our research records (i.e. participants 
from previous studies that match the inclusion criteria) and, if enrolment is slow, a PAWS 
announcement will be made to recruit asthmatic participants.  
b) Who will contact prospective participants? Any of the named study staff/student 
c) How will this be done? (Ensure that any letters of initial contact or other recruitment materials are attached to this 
submission (e.g. advertisements, flyers, verbal or telephone script, etc.).  Communication will likely occur by 
email and if not, then phone contact will be made. If recruitment is slow, an REB-approved ad will be 
placed on PAWS. 
 
PART 5: CONSENT PROCESS 
5.1 Describe the consent process. GN 5.1 
a) Who will ask for consent? Dr. Davis or the student researcher (provided that Dr. Davis is present) 
b) Where, and under what circumstances? Signing of the consent form will occur in Room 346 Ellis Hall 
c) Describe any situation in which the renewal of consent for this research might be appropriate and how this would take 
place (e.g. Participant turns 18 or emergency situation).  No such situation is anticipated. It is understood that 
re-consent will be required if such a situation presents itself. 
5.2 How long will the participant have to decide whether or not to participate? If less than twenty-four hours, provide an 
explanation. GN 5.2  Participants will be allowed as much time as they need to make a decision. Knowledgeable 
participants will be allowed to consent in less than 24 hours. Knowledgeable participants are those who 
have conducted several methacholine challenge studies in our lab in the past. Such participants are 
therefore well acquainted with the procedures performed and the risks involved. These participants will still 
be given the option of reviewing the consent form over at least 24 hours prior to enrolling if they so desire. 
The anticipated condensed timeframe would be less than one hour for such participants. Following a 
discussion of the study purpose and procedure during the first testing visit (which is standard procedure in 
our lab with each participant for every study), knowledgeable participants will still be able to reschedule if 
they wish to take more time to consider the study and consent.  
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5.3 Will all participants be able to consent on their own behalf? GN 5.3 
 Yes  No 
If No, explain why: 
 
 
a)     If a participant is unable to consent, who will consent on his/her behalf?  
b)     Will the participant be able to assent to participate? 
 Yes  No 
If yes, explain how assent will be sought:  
5.4 If monetary compensation or reimbursements for expenses will be offered to the participants please provide the 
details. GN 5.4 The participants will be reimbursed $25 per MCh challenge performed. 
5.5 Describe your plans for providing project results to the participant?  GN 5.5 Participants will be instructed to 
contact the lab following the completion of the study and the breaking of the randomization code to obtain 
personal results. They may request a summary of the results and/or provision of any research article 
regarding the study when (if) available. The appropriate correspondance email to make such requests is 
provided in the consent form. 
 
PART 6:  PROCEDURES AND RISKS 
6.1 Identify those procedures that are different from the current standard of care (i.e. unique to the research project). 
GN 6.1  Typically, MCT is performed until a concentration of MCh produces a 20% fall in FEV1. This study 
proposes performing this procedure until a 40% fall in FEV1 is experienced in order to observe the 
formation of a plateau in response to the study medications. This is not uncommon for this type of 
investigation; previous studies that have examined the influence of anti-asthma medications on the MCh 
DRC have followed participants to a 40-60% fall in FEV1.  
6.2 What are the known risks associated with the procedures outlined in Section 6.1? Also include any risks 
associated with the placebo or wash out periods, if applicable. GN 6.2  MCT may cause wheezing, coughing, mild 
shortness of breath, dizziness, and/or headaches. However, most people do not experience any symptoms. 
The washout period (at least ten days between treatment administrations) is sufficient in duration to 
prevent any reaction between test drugs. 
6.3 What strategies will be put in place to minimize and/or manage the potential risk(s) to participants and other 
affected individuals? GN 6.3  The lab has standard procedures to help minimize/manage risks (e.g. salbutamol 
is kept on hand to counteract MCh if the need arises, as the effects of MCh can be quickly reversed with this 
bronchodilator). The student researcher will have expert guidance available at all times (i.e. Dr. Davis 
and/or Dr. Cockcroft will be available to help during testing, in case the need arises). 
6.4 For double blind projects, describe the provisions made to break the code in an emergency situation [24 hour 
availability], and indicate who has the code.  If it is clearly articulated in the clinical protocol, it is acceptable to append 
the information or provide the protocol page reference. The randomization code will be maintained in a sealed 
envelope in the lab until all testing is complete. Should an emergency occur where the code must be 
broken, the envelope will be opened and the treatment administered identified.  
 N/A, not a double blind project 
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PART 7: DATA SECURITY AND STORAGE  GN 7.1   
The Saskatchewan Health Information Protection Act (HIPA) requires an assessment of the risks to privacy and how the 
risks will be minimized.  Accessing existing patient information, such as Health Records, requires consent of the 
individual which must be addressed in the consent form. 
7.1 Indicate from which sources personal and health information data will be collected: GN 7.1   
 Participant data collected prospectively for the purpose of this project (e.g. case report form) 
 Family physician record 
 Heath Region – please specify Region, Site & Dept. if applicable:  
 
  
 SK Ministry of Health 
 SK Cancer Agency 
 Other – please specify:  
 Not applicable (No personal or health information to be collected).  Proceed to Section 8. 
7.2 How will the confidentiality of participants and their health information be protected? GN 7.2  Subject data will be 
de-identified by use of study codes (i.e. DRC01 for participant 1, etc.). However, no full guarantee can be 
made that their confidentiality will be protected. 
7.3 Describe the storage arrangements and final disposition of the project data collected. GN 7.3  All data will be stored 
in Room 346 Ellis Hall (which has keyed entry) for five years following the publication of the manuscript and 
thesis stemming from this study. All data will be shredded after this time. 
7.4 List the project personnel who have access to any identifiable personal health information and who will have 
access to any list that links participant names to their project ID number, consent form, enrolment log, etc. GN 7.4 
Dr. Cockcroft, Dr. Davis, Christianne Blais, a summer student researcher (Yifan Han, until 08/31/2016) and 
an undergraduate honours student (Samuel Simonson). The latter two students have access in the sense 
that they can access the lab, but there is no foreseeable need for either to access the study files or view 
participant information.  
7.5 Check all applicable boxes below to provide an assessment of the potential privacy risks and the 
safeguards/solutions that you will put in place to mitigate the risks. GN 7.5 
Potential Privacy Risks Possible Safeguards/Solutions (check all that you will use) 
 Unauthorized external or internal access to identifying 
     information through active use or transmission  
 Project personnel screening/agreements   
 Access authorization procedures    
 Designated systems administrator    
 Passwords/screen timeouts     
 System access audits/disclosure logs    
 Secure mail/transport     
 Firewall/virus protect     
 Encrypted transmission 
 Identification through publication or release  Aggregation levels      
 Alternate identifiers   
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 Identification through data-matching  Use of non-linkable elements or identifiers 
 Loss of data control outside jurisdiction  Confidentiality and security agreements for out-of- 
     province recipients or storage providers 
 
 
 
 
 
 
 
PART 8: CONFLICT OF INTEREST 
8.1 Is there any real or perceived conflict of interest (any personal or financial interest in the conduct or outcome of 
this project)? GN 8.1   Will any of the researcher(s), members of the research team and/or their immediate family 
members: 
• Receive personal benefits in connection with this project over and above the direct costs of conducting the project, 
such as remuneration or employment? 
 Yes  No 
• Receive significant payments of other sorts from the sponsor such as grants, compensation in the form of 
equipment or supplies or retainers for ongoing consultation and honoraria? 
 Yes  No 
• Have a non-financial relationship with a sponsor (such as unpaid consultant, board membership, advisor or other 
non-financial interest? 
 Yes  No 
• Have any direct involvement with the sponsor such as stock ownership, stock options or board membership. 
 Yes  No 
• Hold patents, trademarks, copyrights, licensing agreements or intellectual property rights linked in any way to this 
project or the sponsor? 
 Yes  No 
• Have any other relationship, financial or non-financial, that if not disclosed, could be construed as a conflict of 
interest? 
 Yes  No 
If yes, please describe the personal benefits or relationship. 
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PART 9: DECLARATION BY PRINCIPAL INVESTIGATOR GN 9.1 
(OR SUPERVISOR FOR STUDENT PROJECTS) 
Project Title: 
The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve 
• I confirm that the information provided in this application is complete and correct. 
• I accept responsibility for the ethical conduct of this project and for the protection of the rights and welfare of the human 
participants who are directly or indirectly involved in this project.  
• I will comply with all policies and guidelines of the University and Health Region/affiliated institutions where this project will 
be conducted, as well as with all applicable federal and provincial laws regarding the protection of human participants in 
research.  
• I will ensure that project personnel are qualified, appropriately trained and will adhere to the provisions of the REB-
approved application.  
• I will ensure that any significant changes to the project, including the proposed method, consent process or recruitment 
procedures, will be reported to the Research Ethics Board for consideration in advance of its implementation.  
• I will ensure that a status report will be submitted to the Research Ethics Board for consideration within one month of the 
current expiry date each year the project remains open, and upon project completion.  
• If personal health information is requested, I assure that it is the minimum necessary to meet the research objective and 
will not be reused or disclosed to any parties other than those described in the REB-approved application, except as 
required by law.  
• I confirm that adequate resources to protect participants (i.e., personnel, funding, time, equipment and space) are in place 
before implementing the research project, and that the research will stop if adequate resources become unavailable. 
• I understand that if the contract or grant related to this research project is being reviewed by the University or Health 
Region, a copy of the ethics application inclusive of the consent document(s), may be forwarded to the person responsible 
for the review of the contract or grant. 
• I understand that if the project involves Health Region resources or facilities, a copy of the ethics application may be 
forwarded to the Health Region research coordinator to facilitate operational approval.  
 
 
_______________________________   
 
                                                   
Signature of Principal Investigator   Printed Name of Principal Investigator  Date (MM/DD/YY) 
 
 
 
 
Department Head:  The signature/approval of the Department/Administrative Unit acknowledges that he/she is aware of and 
supports the research activity described in the proposal.  
 
 
_______________________________                                                      
Signature of Department Head    Printed Name of Department Head   Date (MM/DD/YY) 
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PART 11: ATTACHMENTS  
Provide a full and accurate listing of all documents submitted with this application.  
All projects requiring the use of RQHR resources must complete this section.  
Document Included? Comments 
Certificate of Approval from another REB  Yes  N/A 
 
 
Peer Review reports  Yes  N/A  
Participant Consent Form  Yes  N/A Two consent forms are attached, 
one for asthmatic participants and 
one for non-asthmatic participants 
Control Participant Consent Form  Yes  N/A  
Assent Form  Yes  N/A  
Tissue/Blood Banking Consent Form  Yes  N/A  
Letter of Initial Contact  Yes  N/A  
Advertisement to Recruit Participants  Yes  N/A  
Questionnaires, tests, interview scripts, 
etc. 
 Yes  N/A  
Other- please specify:  Study Protocol  Yes  N/A  
Other- please specify:    Yes  N/A  
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6.8 Appendix H: LAMA/uLABA Study Asthmatic Participants Consent Form 
 
 
Asthmatic Participant Information and Consent Form 
 
Title of Study: The effect of glycopyrronium and indacaterol, as monotherapy and in 
combination, on the methacholine dose-response curve 
Principal Investigator: Dr. Donald Cockcroft MD FRCP 
    Department of Medicine 
    Division of Respirology, Critical Care and Sleep 
Medicine 
    University of Saskatchewan 
    306-844-1446     
 
Sub-Investigators:  Dr. Beth Davis, PhD 
    Department of Medicine 
    Division of Respirology, Critical Care and Sleep  
Medicine 
    University of Saskatchewan 
    306-844-1444  
 
Master’s Student   Christianne Blais, B.Sc. hon.  
Researcher:    Department of Physiology 
    University of Saskatchewan 
    306-480-8983    cmb831@mail.usask.ca    
24-Hour Emergency Contact: In the event of an emergency (i.e. serious side effects), seek 
immediate medical attention (which will be provided at no additional cost to you). When able to 
do so, please notify the study staff of the incident (Christianne Blais at 306-480-8983). If you 
need to cancel or reschedule a lab visit, please call, text, or email Christianne 
(cmb831@mail.usask.ca). 
Introduction: You are invited to participate in this research study, as your asthma diagnosis 
(mild-to-moderate asthma), age (at least 18 years of age) and health status (controlled, stable 
asthma) make you a suitable representative of the population of interest. 
Your participation is entirely voluntary and you may withdraw from the study at any time 
without providing a reason for doing so. If you do not wish to participate or if you choose to 
withdraw from the study, your current health care and/or academic status (if you are a student at 
the U of S) will not be impacted. 
Please take time to read the following information carefully. You may direct any questions or 
concerns to the study staff prior to and at any time during the study. Please feel free to discuss 
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the study and your potential participation with friends, family, and/or your personal healthcare 
provider. 
Agencies Contributing Funds and Resources to the Study: The study will be internally 
funded (i.e. the asthma research lab will be managing the cost of the study without financial aid 
from a third party organization). Novartis Pharmaceuticals Inc. will be providing the active drugs 
Seebri® and Onbrez®, matching placebos, and the Breezhaler® inhalation devices. The 
researchers and the University of Saskatchewan are not being paid to conduct this study. 
Purpose of Study: Bronchodilators are medications that can improve breathing in those who are 
experiencing difficulty (e.g. an individual with asthma). Ventolin® is an example of a 
bronchodilator/inhaler that is commonly used. There are other bronchodilator drugs that act 
through different mechanisms to open the airways and provide relief from asthma symptoms. 
Three medications are being tested in this study: indacaterol (Onbrez®, an ultra long-acting beta 
agonist), glycopyrronium (Seebri®, a long-acting muscarinic antagonist), and a combination of 
indacaterol and glycopyrronium. Indacaterol acts directly on beta-2 receptors in the airways to 
relax the airway smooth muscle, which facilitates breathing. Glycopyrronium works differently 
as it blocks airway muscarinic receptors, which when activated produce airway constriction and 
difficulty breathing. 
In order to observe the effects of these medications on the airways as well as how long these 
effects last, methacholine challenge testing can be performed. Methacholine challenge testing 
(MCT) is a common diagnostic test performed in patients showing symptoms of asthma in order 
to rule in/out the condition. It is routinely performed in clinics and in research labs, such as our 
Asthma Research Lab here at the University of Saskatchewan. A detailed explanation of the 
procedure can be found later in this document.  
The influence of each of the three study drugs has not yet been demonstrated through the 
generation of a dose-response curve to methacholine (MCh). These dose-response curves will be 
useful for investigating how each medication affects the airways. Dose-response curves are 
graphical representations of how the response of interest (in this case airway constriction) 
changes with increasing concentrations of a stimulus (in this case MCh). In the normal or non-
asthmatic airway, the target response to MCh is not achieved and the curve develops a plateau. In 
the asthmatic airway, less stimulation is needed to generate the response of interest and a plateau 
does not usually form. The specific factors causing these differences in the dose-response curves 
of asthmatics versus non-asthmatics have been identified and so, these curves can be used to 
assess which airway abnormalities may be causing the asthma. Curves generated following 
medication use will then allow for the observation of the drug’s effects on these airway 
abnormalities. We plan to recruit fifteen asthmatic and fifteen non-asthmatic participants within 
Saskatoon. We will then be able to compare the MCh dose-response curves of asthmatics to non-
asthmatics in order to better understand how the improvement in breathing among asthmatic 
participants in response to the study medications resembles regular breathing in healthy controls. 
Eligible Participants: To be eligible to participate, you must be 18 years of age or older, have 
been diagnosed with mild-to-moderate asthma, and have sufficient baseline lung function. For 
this study, the amount of air you can forcefully exhale during the first second of exhalation 
(FEV1) must be at least 65% of what is predicted for your age, gender and height. In addition, 
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your current MCh PC20 (concentration of MCh causing a 20% reduction in your FEV1) must be 
8mg/mL or less. If you have not previously participated in a study with the Asthma Research 
Lab, these criteria will be determined during your first visit to the lab.  
You may not participate in this study if you have taken long-acting bronchodilators (e.g. Oxeze®, 
Serevent®) or long–acting anticholinergics (e.g. Spiriva®) within 30 days prior to beginning the 
study. You may not participate if you are pregnant, nursing, or suffer from cardiovascular 
problems.  Due to potential negative interactions with the study treatments, individuals with 
prostate, kidney or urinary retention problems, hypokalemia, diabetes or glaucoma are not 
eligible to participate. In addition, you may not participate if you have suffered from a 
respiratory infection or an asthma attack from an allergy exposure within 4 weeks prior to 
beginning the study. 
Inhaled corticosteroids (e.g. Flovent®, Pulmicort®) are allowed provided that you have been 
taking this medication regularly (daily for at least 30 days). Short-acting bronchodilator therapy 
(e.g. Ventolin®, Bricanyl®, Airomir®) is allowed but must be withheld for at least six hours prior 
to all lab visits and short-acting anticholinergics (e.g. Atrovent®) must be withheld for 12 hours. 
Study Overview: You will be required to attend the laboratory nine times over a minimum time 
frame of four weeks. Three treatments are being tested: glycopyrronium, indacaterol, and 
combination glycopyrronium/indacaterol. The order in which you will receive the treatments will 
be randomized (i.e. assigned by chance) and will be unknown to you and to the study staff. 
However, we can determine the order if we need to for your safety. A summary of the study 
schedule can be found on the next page. On day 1, we will discuss the study procedure and 
requirements, and information regarding your asthma symptoms, severity, triggers, and 
medication use will be collected. Basic demographic information such as your age, height, 
weight, and smoking status will also be collected. You will then be required to undergo a MCh 
challenge (the procedure is described below) to assess your lung function when un-medicated. If 
your lung function parameters as found through the MCh challenge do not meet the study 
criteria, you will be deemed ineligible to continue participating and you will be provided with an 
honorarium for your time. Provided that your lung function parameters meet the study criteria, 
we will proceed with treatment 1 administration. You will be provided with two Breezhaler® 
inhalers from which you will inhale twice. If you are being administered one of the study 
treatments, then one inhaler will contain glycopyrronium or indacaterol while the other inhaler 
will contain a placebo (i.e. no active medication, a substance without therapeutic effect). If you 
are being administered the combination of both study treatments, each inhaler will contain an 
active drug. You will then wait for one hour before undergoing a second MCh challenge. 
Overall, this visit will take approximately 3 hours. 
You will then be required to return to the lab at the same time once per day for two consecutive 
days (days 2 and 3). On each day, you will undergo a single MCh challenge, which will take 1-
1.5 hours. Following a minimum of 10 days between each drug administration, you will be 
required to follow the same schedule with the other two treatments.  
The order in which you receive each of the three treatments will be random (i.e. assigned by 
chance using a computer program). The data collected will then allow for comparison of each 
treatment’s dose-response curve as well as their respective duration and degree of effect. 
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Methacholine Challenge: MCT involves the inhalation of aerosolized MCh, a known 
bronchoconstrictor that may cause your airway to constrict. You will inhale MCh through a 
loose-fitting mask for a period of two minutes. During the inhalation period, your nose will be 
plugged with a nose clip and you will be asked to breathe normally. Following inhalation of 
MCh, you will be required to inhale sharply and exhale as forcefully as you can into a 
spirometer, which is a handheld device connected to a computer that allows for the measurement 
of your lung capacity. This is referred to as spirometry or lung function testing.  
We will then repeat this procedure with increasing concentrations of MCh until you no longer 
show a response to MCh [i.e. the amount of air you can forcefully exhale (FEV1) only decreases 
by up to 5% after three consecutive MCh concentrations], your FEV1 is decreased by 40%, or the 
maximal concentration of MCh (128mg/mL) is inhaled. If you feel too uncomfortable at any 
time and/or do not wish to continue, the test will be stopped and you will be given salbutamol 
(i.e. a rescue bronchodilator that opens up the airways, such as Ventolin®). You will be given 
salbutamol following each MCh challenge, except after the “baseline” or un-medicated MCh 
challenge prior to each treatment administration*; Following these ‘baseline’ MCh challenges, 
you will be given one of the study medications instead. 
Breakdown of study visits: 
Visit 1  
(≈3 hrs.) 
§ Breakdown of study procedure and requirements 
§ Signing of the consent form 
§ Baseline MCh challenge* (no salbutamol inhalation post-MCh 
challenge) 
§ Treatment 1 inhalation (provided participant meets study criteria) 
§ MCh challenge at 1 hr. post-treatment 
Visit 2 
(≈1-1.5 hrs.) 
§ MCh challenge at 24 hrs. post-treatment 
Visit 3 
(≈1-1.5 hrs.) 
§ MCh challenge at 48 hrs. post-treatment 
Washout 1 (minimum 10 days between treatment administrations) 
Visit 4 
(≈3 hrs.) 
§ Baseline MCh challenge* (no salbutamol inhalation post-MCh 
challenge) 
§ Treatment 2 inhalation  
§ MCh challenge at 1 hr. post-treatment 
Visit 5 
(≈1-1.5 hrs.) 
§ MCh challenge at 24 hrs. post-treatment 
Visit 6 
(≈1-1.5 hrs.) 
§ MCh challenge at 48 hrs. post-treatment 
Washout 2 (minimum 10 days between treatment administrations) 
Visit 7 § Baseline MCh challenge* (no salbutamol inhalation post-MCh 
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(≈3 hrs.) challenge) 
§ Treatment 3 inhalation  
§ MCh challenge at 1 hr. post-treatment 
Visit 8 
(≈1-1.5 hrs.) 
§ MCh challenge at 24 hrs. post-treatment 
Visit 9 
(≈1-1.5 hrs.) 
§ MCh challenge at 48 hrs. post-treatment 
Responsibilities of The Participant: As a participant of this study, you will be expected to (1) 
follow the directions of the researchers, (2) report all medications (prescribed, over-the-counter, 
and herbal products) being used or that you plan on taking prior to and throughout the duration 
of the study, and (3) report any changes in your health to the study staff. These steps are 
important both for your own safety as well as for accurate interpretation of the test results. The 
study investigator may remove you from the study early in the event of non-compliance with the 
above responsibilities or if significant side effects are experienced.  
Your health and wellbeing are more important than this study and so, if a situation arises where 
you must use a medication that will interfere with the study, we ask that you take the medication 
and contact us to reschedule your appointment. 
Benefits of Participating in This Study: If you choose to participate in this study, there will be 
no benefit for you personally. However, your participation will help increase knowledge on three 
respiratory disease medications and their impact on MCT, where data is currently lacking.  
Honorarium: If you choose to participate in this study, you will not be charged for any 
research-related materials or procedures. Although you will not be paid for your participation, 
you will be provided with an honorarium in the amount of $25 per MCh challenge ($300 total) to 
cover your time and out-of-pocket expenses (e.g. parking, meals). Should you choose to 
withdraw early from this study, you will be compensated according to the number of MCh 
challenge tests you completed. The University of Saskatchewan will require your social 
insurance number and will send you a T4A slip at the appropriate time. 
Potential Risks and Discomforts: MCT may cause the following symptoms: wheezing (10%), 
coughing (25%), mild shortness of breath (21%), dizziness (6%), and/or headaches (2%). The 
effects of MCh are short-lasting and should subside untreated. Nonetheless, you will be given 
salbutamol following each challenge (except when you will be given one of the study drugs) to 
ensure complete and prompt recovery from any airway constriction. 
Some common side effects (1-10% of patients) of Seebri® are: dry mouth, cold-like symptoms 
(e.g. cough, sore throat), insomnia, headache, urinary tract infection, and stomach flu. 
Some common side effects (1-10% of patients) of Onbrez® are: nausea, upper respiratory tract 
infection, muscle spasms, headache, and cold-like symptoms 
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Voluntary Withdrawal: Your participation in this study is voluntary and as such, you may 
withdraw from the study at any time. No reason needs to be given for your withdrawal, and your 
current health care and/or academic status (if you are a student at the U of S) will not be 
impacted in any way. The data collected about you until the point of withdrawal will be retained 
for analysis. You will be notified if new information regarding the procedure or treatments 
involved becomes available during the course of the study that may affect your willingness to 
continue to participate. Early withdrawal from the study bears no safety concerns, as the study 
medications are each only used once and will naturally wear off. 
Study-Related Injury: In the unlikely event of an adverse effect arising related to the study 
procedures, trained staff will be available throughout the conduct of the study who can respond 
immediately. Necessary medical treatment will be made available at no additional cost to you. 
By signing this document, you do not waive any of your legal rights against the investigators or 
anyone else. 
Confidentiality: In Saskatchewan, the Health Information Protection Act (HIPA) defines how 
the privacy of your personal health information must be maintained so that your privacy will be 
respected. Your name will not be attached to any information nor mentioned in any study report, 
nor be made available to anyone except the research team (i.e. non-identifying codes will be used 
for your data e.g. if you are participant 1, your code will be DRC01). Any identifying 
information collected from you will remain under lock and key at the lab. However, no guarantee 
can be made for complete confidentiality. For quality assurance and/or monitoring purposes, the 
University of Saskatchewan Biomedical Research Ethics Board reserves the right to inspect 
research records and medical records that may identify you in the presence of the Investigator or 
his or her designate. It is the intention of the research team to publish results of this research in 
scientific journals and to present the findings at related conferences and workshops, but your 
identity will not be revealed. 
Your study records will be kept for at least 5 years in a secured area. After storage, your study 
records will be shredded in a confidential manner. 
Contact Regarding Any Questions/Concerns About The Study: If you have any questions or 
concerns regarding this study before or during participation, you may contact Christianne at 
cmb831@mail.usask.ca, Dr. Cockcroft at 306-844-1446 or Dr. Davis at 306-844-1444.  
If you have any concerns about your rights as a research participant and/or your experiences 
while participating in this study, contact the Chair of the University of Saskatchewan Research 
Ethics Board, at 306-966-2975 (out of town calls 1-888-966-2975). The Research Ethics Board 
is a group of individuals (scientists, physicians, ethicists, lawyers and members of the 
community) that provide an independent review of human research studies. This study has been 
reviewed and approved on ethical grounds by the University of Saskatchewan Research Ethics 
Board (Bio#16-205). 
Following the completion of the study, you may contact the study staff (i.e. student researcher at 
cmb831@mail.usask.ca) if interested in obtaining a summary of the results and/or provision of 
any research article regarding the study when (if) available. 
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Consent: 
Study: The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the 
methacholine dose-response curve 
 
o I have read the information in this consent form. 
o I understand the purpose, procedure and possible risks of the study. 
o I was given sufficient time to think about it. 
o I have had the opportunity to ask questions and have received satisfactory answers. 
o I am free to withdraw from this study at any time for any reason and the decision to stop 
taking part will not affect my future medical care or academic status. 
o I agree to follow the study staff’s instructions and will tell the study staff at once if I feel 
I have had any unexpected or unusual symptoms. 
o I give permission for the use and disclosure of my de-identified personal health 
information collected for the research purposes described in this form. 
o I understand that by signing this document, I do not waive any of my legal rights. 
o I will be given a signed and dated copy of this consent form. 
I agree to participate in this study: 
 
 
 
Printed name of participant     Date 
 
 
 
Signature of participant     Phone Number 
 
 
________________________________________________________________________ 
Participant Mailing Address     Social Insurance Number 
 
 
 
Printed name of person obtaining consent   Date 
 
 
 
Signature of person obtaining consent    		
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6.9 Appendix I: LAMA/uLABA Study Non-Asthmatic Participants Consent Form 
 
Non-Asthmatic Participant Information and Consent Form 
 
Title of Study: The effect of glycopyrronium and indacaterol, as monotherapy and in 
combination, on the methacholine dose-response curve 
Principal Investigator: Dr. Donald Cockcroft MD FRCP 
    Department of Medicine 
    Division of Respirology, Critical Care and Sleep 
Medicine 
    University of Saskatchewan 
    306-844-1446     
 
Sub-Investigators:  Dr. Beth Davis, PhD 
    Department of Medicine 
    Division of Respirology, Critical Care and Sleep  
Medicine 
    University of Saskatchewan 
    306-844-1444  
 
Master’s Student   Christianne Blais, B.Sc. hon.  
Researcher:    Department of Physiology 
    University of Saskatchewan 
    306-480-8983    cmb831@mail.usask.ca  
24-Hour Emergency Contact: In the event of a last minute schedule change, please call or text 
Christianne Blais (306-480-8983) or email (cmb831@mail.usask.ca). In the event that you feel 
serious side effects from the methacholine challenge, seek immediate medical attention (which 
will be provided at no additional cost to you) and, when possible, please notify Christianne. 
Introduction: You are invited to participate in this research study, as your age (i.e. at least 18 
years of age) and health status (i.e. no asthma or other lung disease) make you a suitable 
representative of the non-asthmatic population of interest. 
Your participation is entirely voluntary and you may withdraw from the study at any time 
without providing a reason for doing so. If you do not wish to participate or if you choose to 
withdraw from the study, your current health care and/or academic status (if you are a student at 
the U of S) will not be impacted. 
Please take time to read the following information carefully. You may direct any questions or 
concerns to the study staff prior to and at any time during the study. Please feel free to discuss 
the study and your potential participation with friends, family, and/or your personal healthcare 
provider. 
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Agencies Contributing Funds and Resources to the Study: The asthma research lab will be 
managing the cost of the study without financial aid from a third party organization. Novartis 
Pharmaceuticals Inc. will be donating the drugs and devices (which will only be used with the 
asthmatic participant group). The researchers and the University of Saskatchewan are not being 
paid to conduct this study. 
Purpose of Study: Bronchodilators are medications that can improve breathing in those who are 
experiencing difficulty (e.g. an individual with asthma). Ventolin® is an example of a 
bronchodilator/inhaler that is commonly used to treat respiratory disorders like asthma. There are 
other bronchodilator drugs that act through different mechanisms to produce bronchodilation and 
relief of asthma symptoms. Three medications are being tested in this study: indacaterol 
(Onbrez®, an ultra long-acting beta agonist), glycopyrronium (Seebri®, a long-acting muscarinic 
antagonist), and a combination indacaterol/glycopyrronium. Indacaterol acts directly on beta-2 
receptors in the airways to relax the airway smooth muscle, which facilitates breathing. 
Glycopyrronium works differently as it blocks airway muscarinic receptors, which when 
activated produce airway constriction and difficulty breathing. 
In order to observe the effects of these medications on the airways as well as how long these 
effects last, methacholine challenge testing can be performed. Methacholine challenge testing 
(MCT) is a common diagnostic test performed in patients showing symptoms of asthma in order 
to rule in/out the condition. It is routinely performed in clinics and in research labs, such as our 
Asthma Research Lab here at the University of Saskatchewan. A detailed explanation of the 
procedure can be found later in this document.  
The influence in asthmatics of each of the three study drugs has not yet been demonstrated 
through the generation of a dose-response curve to methacholine (MCh). These dose-response 
curves will be useful for investigating how each medication affects the airways. Dose-response 
curves are graphical representations of how the response of interest (in this case airway 
constriction) changes with increasing concentrations of a stimulus (in this case MCh). In the 
normal or non-asthmatic airway, the target response to MCh is not achieved and the curve 
develops a plateau. We are seeking your participation to generate dose-response curves to MCh 
in the non-asthmatic airway to use as a comparator to the dose-response curves in unmedicated 
asthmatic airways and in asthmatic airways following each of the three treatments. The specific 
factors causing these differences in the dose-response curves of asthmatics versus non-asthmatics 
have been identified and so, these curves can be used to assess which airway abnormalities may 
be causing the asthma. Curves generated following medication use will then allow for the 
observation of the drug’s effects on these airway abnormalities. We plan to recruit fifteen 
asthmatic and fifteen non-asthmatic participants within Saskatoon. We will then be able to better 
understand how the improvement in breathing among asthmatic participants in response to the 
study medications resembles regular breathing in healthy controls. 
Eligible Participants: To be eligible to participate, you must be 18 years of age or older and 
must meet a specific lung function criterion. This criterion will be determined through 
spirometry and a MCh challenge, the procedures of which are outlined in the next section. The 
specific lung function parameter required is a negative (>16mg/mL) MCh PC20 [the 
concentration of MCh bronchoconstrictor that reduces the amount of air you can forcefully 
exhale during the first second of exhalation (FEV1) by 20%]. Having a negative MCh PC20 
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simply means that you do not in fact have current asthma. If the result from the MCh challenge is 
positive, we will discuss with you the implications of a positive test result and provide you with 
information on how to follow up a positive test result with your family physician. If such an 
event occurs, please note that you will not be able to enroll in the study as an asthmatic without a 
physician diagnosis of asthma. 
Due to some potential effects of MCT, you may not participate if you are pregnant, nursing, or 
suffer from cardiovascular problems. In addition, you may not participate if you have suffered 
from an upper respiratory tract infection 4 weeks prior to beginning the study. 
Study Overview/Visit: You will be required to attend the laboratory on one occasion, lasting 
between 1-1.5 hours. First, information on your respiratory health (i.e. lack of asthma 
symptoms), age, height, and weight will be collected. Next, you will undergo one MCh challenge 
(the procedure is described below). This information will allow for comparison of the MCh dose-
response curve in asthmatics versus non-asthmatics. 
Methacholine Challenge: MCT involves the inhalation of aerosolized MCh, a known 
bronchoconstrictor that may cause your airway to narrow. You will inhale MCh through a loose-
fitting mask for a period of two minutes. During the inhalation period, your nose will be plugged 
with a nose clip and you will be asked to breathe normally. Following inhalation of MCh, you 
will be required to inhale sharply and exhale as forcefully as you can into a spirometer, which is 
a handheld device connected to a computer that allows for the measurement of your lung 
capacity. This is referred to as spirometry or lung function testing.  
We will then repeat this procedure with increasing concentrations of MCh until you no longer 
show a response to MCh [i.e. the amount of air you can forcefully exhale (FEV1) only decreases 
by up to 5% after three consecutive MCh concentrations], your FEV1 is decreased by 40%, or the 
maximal concentration of MCh (128mg/mL) is inhaled. If you feel too uncomfortable at any 
time, the test will be stopped and you will be given the option of taking salbutamol (a rapid-
acting bronchodilator that opens up the airways) to quickly reverse any effects of MCh.  
Responsibilities of The Participant: As a participant of this study, you will be expected to (1) 
follow the directions of the investigators and researchers, and (2) report all medications 
(prescribed, over-the-counter, and herbal products) being used. These steps are important both 
for your own safety as well as for accurate interpretation of the test results. The study 
investigator may remove you from the study early in the event of non-compliance with the above 
responsibilities 
Benefits of Participating in This Study: If you choose to participate in this study, there will be 
no benefit for you personally. However, your participation will help increase knowledge on the 
difference in the MCh dose-response curve between asthmatics and non-asthmatics. This could 
then help to form a better understanding of the airway changes that occur in asthma.  
Honorarium: If you choose to participate in this study, you will not be charged for any 
research-related materials or procedures. Although you will not be paid for your participation, 
you will be provided with an honorarium in the amount of $25 to cover your time and out-of-
pocket expenses (e.g. parking, meal). 
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Potential Risks and Discomforts: MCT may cause the following symptoms: wheezing (10%), 
coughing (25%), mild shortness of breath (21%), dizziness (6%), and/or headaches (2%). These 
effects are short-lasting and should subside untreated. If you do respond to MCh, you will be 
given the option of receiving salbutamol following the MCh challenge to ensure complete and 
prompt recovery from any airway constriction. 
Voluntary Withdrawal: Your participation in this study is voluntary and as such, you may 
withdraw from the study at any time. No reason needs to be given for your withdrawal, and your 
current health care and/or academic status (if you are a student at the U of S) will not be 
impacted in any way. The data collected about you until the point of withdrawal may be retained 
for analysis. You will be notified if new information regarding the procedure involved becomes 
available during the course of the study that may affect your willingness to participate. Early 
withdrawal from the study poses no safety concerns. 
Study-Related Injury: In the unlikely event of an adverse effect arising related to the study 
procedures, trained staff will be available throughout the conduct of the study who can respond 
immediately. Necessary medical treatment will be made available at no additional cost to you. 
By signing this document, you do not waive any of your legal rights against the investigators or 
anyone else. 
Confidentiality: In Saskatchewan, the Health Information Protection Act (HIPA) defines how 
the privacy of your personal health information must be maintained so that your privacy will be 
respected. Your name will not be attached to any information, nor mentioned in any study report, 
nor be made available to anyone except the research team (i.e. non-identifying codes will be used 
for your data e.g. if you are healthy participant 1, your code will be HDRC01). Any identifying 
information collected from you will remain under lock and key at the lab. However, no guarantee 
can be made for complete confidentiality. For quality assurance and/or monitoring purposes, the 
University of Saskatchewan Biomedical Research Ethics Board reserves the right to inspect 
research records and medical records that may identify you in the presence of the investigator or 
his or her designate. It is the intention of the research team to publish results of this research in 
scientific journals and to present the findings at related conferences and workshops, but your 
identity will not be revealed. 
Your study records will be kept for at least 5 years in a secured area. After storage, your study 
records will be shredded in a confidential manner. 
Contact Regarding Any Questions/Concerns About The Study: If you have any questions or 
concerns regarding this study before or during participation, you may contact Christianne at 
cmb831@mail.usask.ca, Dr. Cockcroft at 306-844-1446 or Dr. Davis at 306-844-1444.  
If you have any concerns about your rights as a research participant and/or your experiences 
while participating in this study, contact the Chair of the University of Saskatchewan Research 
Ethics Board, at 306-966-2975 (out of town calls 1-888-966-2975). The Research Ethics Board 
is a group of individuals (scientists, physicians, ethicists, lawyers and members of the 
community) that provide an independent review of human research studies. This study has been 
reviewed and approved on ethical grounds by the University of Saskatchewan Research Ethics 
Board. 
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Following the completion of the study, you may contact the study staff (i.e. student researcher at 
cmb831@mail.usask.ca) if interested in obtaining a summary of the results and/or provision of 
any research article regarding the study when (if) available. 
 
Consent: 
Study: The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the 
methacholine dose-response curve 
 
o I have read the information in this consent form. 
o I understand the purpose, procedure and possible risks of the study. 
o I was given sufficient time to think about it. 
o I have had the opportunity to ask questions and have received satisfactory answers. 
o I am free to withdraw from this study at any time for any reason and the decision to stop 
taking part will not affect my future medical care or academic status. 
o I agree to follow the study staff’s instructions and will tell the study staff at once if I feel 
I have had any unexpected or unusual symptoms. 
o I give permission for the use and disclosure of my de-identified personal health 
information collected for the research purposes described in this form. 
o I understand that by signing this document, I do not waive any of my legal rights. 
o I will be given a signed and dated copy of this consent form. 
I agree to participate in this study: 
 
 
 
Printed name of participant     Date 
 
 
 
Signature of participant     Phone Number 
 
 
 
Printed name of person obtaining consent   Date 
 
 
 
Signature of person obtaining consent    	
 
